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Procollagen III amino-terminal propeptide (P-III-NP), a biomarker for detecting growth 
hormone administration, is currently measured by immunoassays in the absence of 
international reference material. The main aim of this research is to demonstrate 
whether liquid chromatography tandem mass spectrometry (LC-MS) can be used to 
quantify P-III-NP in blood. 
Low serum concentration (1-5 ng/mL, 25-125 pM) and medium protein size of P-III-NP 
(~42 kDa) complicates method development, in that there is a requirement for very 
sensitive LC-MS methods. To meet this, a digest approach with trypsin has been 
adopted. By LC-HRAMS (high resolution accurate MS in tandem mode) analysis of 
digested bovine P-III-NP material, post translational modifications (PTMs) of some 
amino acid residues have been identified through the partial de novo sequencing of 
peptides. Once assessed for stability, peptides T1 and T5 were synthesized and used 
to develop sensitive nano- and micro-flow LC-MS methods on a highly sensitive triple 
quadrupole MS. By both approaches, adequate sensitivity of peptides (with no matrix) 
has been achieved to accommodate analysis of P-III-NP at basal levels. 
However, despite the sensitivity of these developed methods, the presence of albumin 
(HSA, 35-50 mg/mL, 5.3-7.75 x 10-1 mM) in the sample matrix prevents analysis by 
LC-MS. Through investigation, it has been determined that HSA concentrations 
> 20 µg/mL results in the complete ion suppression of P-III-NP peptides (100 pM) in the 
MS. Hence, HSA depletion ≥ 99.6 % is necessary to produce samples suitable for 
LC-MS. Investigations into common proteomic HSA depletion methods have shown 
that double depletion methods, i.e. protein precipitation (ppt) then molecular weight cut 
off (MWCO) filters or double MWCO, should be effective in depleting HSA sufficiently 
from serum. However, further investigations have highlighted that the co-precipitation 
of P-III-NP with HSA and the poor reproducibility of P-III-NP recovery from MWCO limit 
the application of these approaches for preparing our serum samples for LC-MS. 
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With the recent (limited) release of an ELISA immunoassay kit targeting P-III-NP, 
immunocapture of serum P-III-NP prior to trypsin digestion and LC-MS has enabled the 
identification of peptides from endogenous sources. Using the T5 peptide, the 
hP-III-NP concentration in a normal human serum sample was semi-quantitatively 
determined as ~2 ng/mL. For absolute quantification, however, suitable internal 
standards are needed. Isotopically heavy labelled hT1 and T5 peptide variants have 
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Chapter 1 : General Introduction 
Human growth hormone (hGH), due to its anabolic and lipolytic properties is misused in 
sport, despite it being prohibited by the World Anti-Doping Agency (WADA) [1]. 
Intended for use for the therapeutic treatment of GH-related hypopituitarism, access to 
hGH is tightly controlled. Nevertheless, athletes have been able to obtain hGH for 
doping, in either its recombinant human (rhGH) or pituitary-derived "cadaveric" form 
(both have identical amino acid (aa) sequences), through the black market. Abuse 
among athletes is significant, especially in the bodybuilding and strength athletic 
community [2]. Besides its ergogenic effects and aid in injury recovery, athletes chose 
this drug for doping over others that give a similar effect due to the difficulties 
associated with detection of hGH by analytical testing methods [3]. Aware of this, the 
anti-doping community has been engaged in research before 2000 to develop an 
appropriate approach to detect hGH administration [4, 5]. Resulting from their efforts, 
several testing methods have been developed for hGH, however, research is on-going 
to further develop these approaches to improve discrimination between synthetic 
(rhGH, 22 kDa GH) and pseudo-endogenous (cadaveric GH, identical isoform 
distribution as endogenous hGH) from natural hGH, in the hopeful attempt of 
eliminating GH abuse in sport. 
1.1 Growth hormone 
GH (also known as somatotropin) is a protein hormone that stimulates growth and 
cellular reproduction and regeneration in humans and increases muscle mass and 
strength whilst reducing body fat. Only human GH is bioactive in humans, as this 
hormone shows species specificity [6]. The majority of the circulating hGH is made up 
of the 22 kDa isoform (70 %), which has a half-life of 15-20 minutes. Due to RNA 
(ribonucleic acid) splicing, 20 kDA (5-10 %) and 17 kDA (4%) bioactive isoforms as well 
as others in smaller amount exist that have longer half lives than the 22 kDA variant [7-
9]. Also, through the formation of oligomers, post-translational modification (PTM, e.g. 
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acetylation, deamidation or phosphorylation) and peptide fragmentation of the 
aforementioned isomers, less abundant variants exist in circulation [8, 10]. 
The main source of circulating hGH is through the pulsative secretion of the 
somatotrope cells in the anterior pituitary. During pregnancy, females secrete additional 
hGH in the placenta [11]. In humans the basal range of pituitary GH is between 
0.01-1 ng/mL, however after a secretary pulse this range increases to 1-100 ng/mL [3]. 
These wide hGH reference ranges are associated with the combined effects of age, 
gender, nutritional state, sleep, body composition, stress, various hormones and 
physical exercise on GH release. Age is a significant modulator of GH, in that 
concentrations decrease by ~14 % per decade after age 40 [12]. This is not surprising 
as a number of physiological age related conditions (e.g. reduced muscle mass, 
strength and energy) are similar to that of GH deficient (GHD) adults. 
The amount of GH secreted in each pulse is physiologically regulated by the peptidyl 
agonist and antagonistic actions of three peptides: GH releasing hormone (GHRH), 
somatostatin and GH releasing peptide (GHRP, Ghrelin) [13]. In the brain, GHRH from 
the hypothalamus stimulates GH production and secretion, and somatostatin inhibits 
release without affecting synthesis [14, 15]. GHRP, which is expressed in the stomach, 
anterior pituitary and hypothalamus, increases the secretion of GH through an 
associated receptor [12, 16]. GHRP plays a minor role in GH secretion in that, although 
capable of direct stimulation, it predominantly works synergistically to GHRH [17]. 
Additional secretion can be achieved through a series of compounds called GH 
secretagogues, that act as agonists of either GHRH or GHRP to increase GH release. 
GH pulses occur every 2-3 h, at varying amplitudes, with the largest pulses normally 
occurring at night during the slow wave stage of the sleep cycle [18, 19]. Once 
released, GH interacts with two receptors at different binding sites to start a signalling 
cascade that results in the generation of insulin-like growth factor-I (IGF-I) [14]. GH 
inhibits its own secretion, either directly or indirectly, through IGF-I, using a negative 
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Figure 1.1-1: The GH-IGF-I axis showing the inhibitory (-) and stimulatory (+) actions that 
regulate hormone secretion. The dashed line indicates that GH has a direct effect on growth 
and anabolism. In response to GH release, tissues produce IGF-I and the collagen markers, 
with IGF-I playing a significant role in GH regulation (Image taken from [3] with permission). 
On the basis of its lipophilic and anabolic properties, GH is considered to be a powerful 
metabolic hormone. Through the anabolic actions of GH an increase in protein 
anabolism and decrease in catabolism in the skeletal muscles occurs, this results in the 
increase of hypertrophic and hyperplasic growth in muscles, strength and exercise 
performance [20, 21]. GH also stimulates the formation of bone in excess of its 
resorption, to lead to a build-up of peak bone mass. These anabolic properties are 
primarily mediated by circulating IGF-I [21], although GH is also a direct stimulus 
(shown in Figure 1-1). Both indirectly (through the actions of IGF-I) and directly, GH 
stimulates lypolysis to increase the concentration of circulating free fatty acids for 




1.1.1 GH deficiency and treatment 
Continued production of GH by the anterior pituitary glands is needed or GHD results. 
GHD shows different symptoms with age. In infants and children growth failure is the 
major symptom. Whilst in adults, although rare, the features of GHD include diminished 
lean body mass, poor bone density, increased body fat (especially abdominal visceral 
fat) and increased risk of cerebro- and cardiovascular disease [17]. Hormone 
replacement treatment in children reverses the symptoms of GHD [23]. In adults, some 
reversal properties of hypopituitarism have been noted where changes in vigour, 
ambition and sense of wellbeing have been noted upon drug administration [24]. There 
has been considerable debate over the performance enhancement properties of GH 
[25-27]. However, studies have indicated that GH exerts performance benefit to 
abstinent anabolic steroid users [28, 29]. 
First extracted and purified (from the pituitary glands) in 1956 [23], cadaveric hGH was 
used to treat GHD until, in 1985, it was identified as one of the causes of the prion 
induced Creutzfeldt-Jakob disease and was removed from the market. Being pituitary 
derived, cadaveric hGH is identical to endogenous circulating hGH, containing the full 
range of isoforms. Using recombinant DNA technology, a recombinant hGH (rhGH), 
identical to the 22 kDA GH isoform, was developed for therapeutic use to replace the 
extinct cadaveric hGH [30, 31]. 
1.2 Measurement of hGH 
The clearance of hGH in urine is not proportional to that of plasma hGH; as only 
0.1-1 % of the blood concentration is reflected in urine [32]. As such hGH is measured 
in blood. The direct measurement of hGH is complicated due to the combinational 
effects of the proteins pulsatile release into circulation, short half-life and the 
heterogenous nature of its isoforms. Despite this, to detect hGH administration for anti-
doping tests direct as well as indirect (biomarker) approaches are used. 
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1.2.1 Direct approach 
In response to the negative feedback regulation of GH, exogenous administration of 
hGH suppresses the endogenous release of the hormone in the body. If rhGH 
(recombinant form of 22 kDa GH) is administered, down regulation of the hGH is 
observed, which offsets the natural 22 kDa/pituitary GH isoform ratio to provide a 
measurable parameter for the determination of drug administration. This aspect is 
utilised in anti-doping testing approaches, where immunoassay serum measurements 
of the 22 kDa, 20 kDa [33], and total hGH are used to detect anomalies in the 22:20 
kDa or 22 kDa: total hGH ratios. These measurements are unaffected by sex, age, 
sport discipline or pathological state [34]. Exercise however can have an effect on 
measurements, where if done in excess endogenous release of GH is promoted and 
can normalise the isoform ratios to mask exogenous rhGH administration [35]. 
The main disadvantage of this approach to measuring the GH isoform ratios is the 
short detection window associated to the half-life of GH. Even rhGH when injected is 
cleared rapidly (half lives for subcutaneous, intramuscular and intravenous injections 
are 4-6 h, 3h, 18 min, respectively), and is often undetectable the morning after 
injection [36]. Thus, if an athlete stops administration a day before testing, this 
approach is ineffective in detecting doping. If pituitary-derived GH is administered 
detection by isoform ratio is not possible, as this exogenous material has identical 
heterogeneity to endogenous GH. Also, other methods of promoting the effects of GH 
used by athletes (e.g. IGF-I and GH secretagogoues) are undetectable by measuring 
GH isoform ratios. 
1.2.2 Biomarker approach 
Alternatively hGH administration can be detected through the measurement of GH 
responsive biomarker proteins that have longer half-lives and have more stable serum 
concentrations. Regardless of the source of hGH or the promoter of its effects, by this 
approach administration is detectable. Placebo controlled studies in recreational 
athletes have shown an increase in the serum concentrations of the IGF axis proteins 
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(IGF-I, IGF binding proteins (IGFBP-1, -2 and -3) and acid labile subunit (ALS)) and 
specific collagen proteins (osteocalcin, procollagen I and III amino-terminal propeptides 
(P-I-NP and P-III-NP) and procollagen I carboxyl-terminal propeptide (ICTP)) as a 
result of hGH administration [37-40]. These studies demonstrate the potential of these 
proteins as biomarkers for exogenous hGH misuse. Differences in the 
pharmacodynamic profile of the biomarker proteins result in their considerably longer 
half-lives (90-500 h) compared to hGH (15-20 min, detailed in Figure 1-2 below) [41]; 
thus facilitating an extension to the window of detection of hGH administration with this 
approach. 
To associate selectivity to the detection of hGH, the combined monitoring of one 
marker from each marker group is suggested. As the most responsive markers to hGH, 
IGF-I and P-III-NP are co-monitored in doping control tests [39, 42]. Both proteins have 
little diurnal variation and are largely unaffected by exercise relative to hGH intake [43]. 
Body mass index (BMI) and race contribute little to the variability of these markers [43-
45]. Age affects the natural levels of both IGF-I and P-III-NP, in that they are inversely 
proportional, with maximum levels being observed during pubertal years. For P-III-NP 
slightly higher concentrations exist in men (average concentration 5.4 ±2.3 ng/mL) 
compared to women (average concentration 5.1 ±1.5 ng/mL); where the opposite is 
true for IGF-I [44]. 
The compliance of an athlete's sample is assessed using a calculated GH-2000 score, 
based on the natural logarithm of IGF-I and P-III-NP concentrations that are combined 
in a sex-specific and age discriminant function [46, 47]. The formulae used for 
calculation (shown below in Equation 1-1 and Equation 1-2) were constructed based on 
normative data collected from elite athletes (n=314), for which their results are specific 
to the reagents and assays used to measure the biomarkers [43, 48]. Hence, for each 




Equation 1-1: GH-2000 Biomarker score for males [47] 
−6.584 + 2.905 × ln(𝑃𝑃 − 𝐼𝐼𝐼𝐼𝐼𝐼 − 𝑁𝑁𝑃𝑃) +  2.100 × ln(𝐼𝐼𝐼𝐼𝐼𝐼 − 𝐼𝐼) − 101.737/𝑎𝑎𝑎𝑎𝑎𝑎 
Equation 1-2: GH-2000 Biomarker score for females [47] 
−8.459 + 2.454 × ln(𝑃𝑃-− 𝐼𝐼𝐼𝐼𝐼𝐼 − 𝑁𝑁𝑃𝑃) + 2.195 × ln(𝐼𝐼𝐼𝐼𝐼𝐼 − 𝐼𝐼) − 73.666/𝑎𝑎𝑎𝑎𝑎𝑎 
 
 
Figure 1.2-1: GH direct (isoform) and indirect (marker) approaches to measurement. 
Endogenous hGH, secreted by the anterior pituitary, circulates as heterogenous mixture of 
different isoforms. In the direct measurement approach, differences in the change of hGH ratios 
caused by the administration of rhGH (containing the 22 kDa isoform) are measured. Whereas 
in the indirect biomarker approach, measurement of the change in hGH responsive IGF axis 
proteins and collagen markers are measured. The half-lives for hGH (min) and its responsive 
biomarkers (h) are shown in bold. (Image modified from [49] with permission). 
 
IGF-I and P-III-NP were successfully used to detect hGH administration by the Drug 
Control Centre (King’s College London), whilst conducting the anti-doping tests for the 
London 2012 Paralympic Games. Two Russian power lifters were caught cheating with 
hGH based on the anomalous findings of the biomarker test, although they passed the 
isofom test. Both athletes admitted to doping and were disqualified from the Games. 
These results demonstrate the advantages of the extended window of detection 
provided by this approach, which allows for the detection of hGH-related doping days 




IGF-I is a 7.6 kDa protein that is synthesized in the liver and consists of 70 amino 
acids, six of which are cysteine that form three intra-molecular disulphide bridges [50]. 
Clinically, serum IGF-I concentration is significant in the diagnosis and treatment of GH 
disorders. A number of assays exist for IGF-I, which include radioimmunoassays (RIA), 
enzyme-linked immunosorbance (ELISA), immunochemiluminescence, immuno-
functional, and kinase receptor activation [51]. These assays use different antibodies, 
sample extraction methods (to remove high-affinity binding proteins) and approaches to 
calibration that have led to a lack in the harmonisation of inter-laboratory results [52, 
53]. The typical concentration of serum IGF-I has been shown to be within the 
magnitude of several hundred nanograms per millilitre (ng/mL) [52], however, ~98 % of 
the protein is bound to binding protein in serum. Therefore enrichment or serum 
depletion is necessary before quantification, in order to achieve adequate sensitivity. 
Methods for the quantification of intact [54-56] and trypsin digested IGF-I [57] by mass 
spectrometry (MS) have been developed; these complement the existing 
immunoassays and provide better inter-laboratory agreement of measurements [57]. 
1.4 P-III-NP 
Type III collagen is the second most prominent protein present in most normal tissues 
and plays a major role during growth and tissue repair after injury [58, 59]. Like all 
collagens, type III is made up of three α chains containing a predominant Gly-X-Y 
sequence repeat (X and Y represent any amino acid). Several cells possess the ability 
to synthesise collagen III, however under normal conditions this is done by the 
fibroblasts using the code of the COL3A gene. Type III collagen is expressed as a 
procollagen precursor, which in addition to collagen III has two extension propeptides 




Procollagen synthesis involves several specific enzymes that coil the individual proα1-
chains to form intra-chain bonds to result in a helix. During, or after secretion from the 
collagen producing cell the carboxyl-terminal is lost, leaving pN-collagen. In the extra-
cellular space, these collagen molecules form covalent intra- and inter-molecular cross-
links to produce collagen fibrils. During the formation of these fibrils P-III-NP is 
sequentially cleaved from the surface to establish stability in the intra-molecular cross-
links and allow for attachment of a new pN-collagen, as shown in Figure 1-3 below [58]. 
Hence, pN-collagen remains on the surface of the fibril and is only released into 
circulation during the growth or degradation of the type III collagen fibril. It has been 
suggested that both P-III-NP (also in a truncated Col 1 form) and P-III-CP regulate the 
biosynthesis of collagen III using negative feedback mechanisms [61, 62]. 
 
 
Figure 1.4-1: Synthesis of type III collagen. Secretion of procollagen from the cell leads to the 
removal of P-III-CP, leaving type III pN-collagen (P-III-NP and collagen). As pN-collagen is 
attached to the collagen fibril, P-III-NP from the surface is released into the blood stream. 
(Modified from [59]). 
 
Like collagen, P-III-NP consists of three identical pro α1-chains that are covalently 
linked by inter-molecular disulphide bonds in the carboxyl-terminal region to form a 
42 kDa protein [63].Isolated from pN-collagen with bacterial collagenase, P-III-NP 
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separates to form three distinct domains, Col 1, 2 and 3, that show different mobility 
(based on molecular weight (MW)) and can be separated by gel electophoresis [64]. 
The heaviest fraction, Col 1, can be found at the amino-terminal of the propeptide, and 
contains three identical peptide chains with 85 amino acids each. This domain is rich in 
acidic amino acids and cysteine, and is characterised by five intra-molecular covalent 
disulphide bonds in each chain, which results in the folding of this domain into several 
loops to form a globular domain [64-66]. At the carboxyl-terminal of the Col 1 is Col 3, 
the tropocollagen or "collagen-like" domain. Similar to collagen, Col 3 has a tri-peptidic 
Gly-X-Y repeat, with a high Gly and Pro content that allows the three pro α1-chains in 
this region to twist into a left-handed super helix [64, 65]. The remainder of P-III-NP is 
the Col 2 domain, which protrudes from the tropocollagen Col 3. Unlike the prior 
domain, the amino acids in this region are fully extended; a conformation that facilitates 
the formation of inter-molecular disulphide bonds between the three chains, which are 
important for the cross-linking of the Col 3 triple helical domain [66]. In the bacterial 
collagenase fraction, Col 2 domain overlaps with collagen, to contain seventeen non-
P-III-NP amino acid residues from the amino-terminal of type III collagen [65, 67]. 
Physiologically, the telopeptide region is cleaved during protein maturation by 
proteolysis at P-130 by type III procollagen N-proteinase to leave three linked 130 aa 
Col 1-3 pro α1-chains known as P-III-NP [65]. 
1.4.1 Protein sequence 
Prior to the use of mass spectrometry (MS), protein aa sequences were obtained by 
Edman degradation of peptide fragments (ideally 30 aa in length). In this sequencing 
approach the amino-terminus residue is sequentially labelled and cleaved from the 
peptide by reacting with phenyl isothiocyanate, as shown in Figure 1-4 below. As 
residues are removed their phenylthiohydantoin derivatives are analysed by 
chromatography or electrophoresis, for identification relative to known standards. 
However, if the amino-terminal residue is chemically modified (e.g. by acetylation or 
pyroglutamation) the sequencing of the peptide is blocked, as the five-membered ring 
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intermediate cannot be formed. For P-III-NP, after removal of the first amino acid 
residue (Q), Edman degradation was used to sequence the extended Col 1-3 of bovine 
P-III-NP [65, 67]; that with aa substitutions inferred from the cDNA of the procollagen III 
α1 human [68] give the aa sequence shown in Figure 1-5. 
 
 
Figure 1.4-2: Showing the Edman degradation mechanism where phenyl isothiocyanate reacts 
with an uncharged amino group at pH 8 to form a five-membered cyclical phenylthiocarbamoyl 
derivative that is later cleaved from the peptide under acidic conditions as a thiazoline 
derivative. The thiazolinone is then treated with acid to form a phenylthiohydantoin (PTH)- 
amino acid derivative that can be identified by chromatography or electrophoresis. (Mechanism 





Figure 1.4-3: Schematic illustration of P-III-NP showing the amino acid (aa) sequence of one of 
the three identical pro α1-chains. The bars represent disulphide bonds in the Col 1 and Col 2 
domains. The Col 3 domain is highlighted in bold to show the dominant Gly-X-Pro repeat, 
where X represents any aa. The italicised residues (at the carboxyl-terminus)show the extended 
Col 2 domain (17 additional aa), retrieved after cleavage from procollagen with bacterial 
collagenase. (Image modified from [70] with permission). 
 
1.4.2 Circulating P-III-NP 
It has been suggested that the main antigenic site for P-III-NP is located between aa 20 
and 83 of the Col 1 domain [71, 72], although some antigenic properties have been 
associated with Col 3 or the amino-terminal end of Col 2 [58]. For antigenic activity to 
occur, the tertiary conformation of the Col 1 domain or the intact P-III-NP protein is 
necessary [70]. Using the available radioactive immunoassays (RIA), several studies 
[58, 70, 72-75] have separated (from different body fluids ) four antigenic P-III-NP 
fractions (assigned A-D) by gelfiltration, these are shown in Figure 1-6 below. 
In serum (and other body fluids except bronchiolar lavage fluid), main antigenic 
response was obtained from fraction D, which has a smaller molecular weight than 
intact P-III-NP, and correlates with the mass of Col 1 [70, 74]. Fraction C corresponds 
to intact P-III-NP, which interestingly was found in all body fluids except urine [59]. 
Fraction B (found is serum, wound and synovial fluid) has a MW twice that of P-III-NP 
and is believed to be a dimer, formed by the covalent cross-linking of propeptide 
1QQEAVEGGCSHLGQSYADRDVWKPEPCQICVCDSGSVLCDDIICDDQELDCPNPEIPFGECCAVCPQPPAPTRPPN
GQGPQGPK86GDPGPPGIPGRNGDPGIPGQPGSPGSPGPPGICESCPTGPQNYSP131QYEAYDVKSGVAGGGIA147 
Human P-III-NP sequence (UniProt accession no. P02461):
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molecules [58, 76]. Fraction A, corresponding to a higher MW than B, is thought to be 
complexes of P-III-NP and plasma proteins suspected to have formed during 
circulation, as it is not found in wound or synovial fluid. 
 
 
Figure 1.4-4: Elution profile according to Jensen et al.[77]obtained from the antigenic fractions 
of serum P-III-NP after chromatographic separation using a Sephacryl S-300 column. The solid 
line show profiles obtained from P-III-NP RIA and the dotted line represent that obtained using a 
P-III-NP fab RIA kit. The suspected P-III-NP structure for each obtained fraction is represented. 
(Image taken from [77] with permission). 
 
1.5 Existing methods of analysing P-III-NP in biological samples 
Like IGF-I, P-III-NP is clinically significant in that it is used to monitor chronic active 
hepatitis, liver fibrosis and cirrhosis [78-81]. As mentioned earlier, P-III-NP is monitored 







tests [82, 83]. For both clinical and anti-doping purposes, quantification of P-III-NP is 
only achievable by immunoassay approaches. For decades, P-III-NP measurements 
have been reliant on the use of two radioactive immunoassays, P-III-NP RIA-gnost® 
(CisBio Bioassays, Codolet, France) and UniQ® P-III-NP RIA (Orion Diagnostica, 
Espoo, Finland). However, more recently two ELISA methods, Advia Centaur® 
immunoassay platform (Siemens Healthcare Diagnostics Inc., New York, USA) and 
P-3NP-EL-US (CisBio Bioassays, Codolet, France) have become available. For all 
these assays P-III-NP concentrations are expressed as ng/mL, except for the RIA-
gnost, which measures in units/mL. 
1.5.1 P-III-NP antibodies 
Traditionally antibody-based assays (immunoassays), such as ELISA and RIA, were 
used for the targeted quantification of proteins. Although allowing for high-throughput 
and sensitive analysis of proteins, the accuracy and precision of these measurements 
heavily rely on the specificity of the antibodies used. The development of highly specific 
antibodies can be expensive, time-consuming and resource intensive [84]. Irrespective 
of the quality of the antibody some cross-reactivity for closely related isoforms or 
interferents exist. The binding of these non-targeted molecules to the assay antibodies 
can produce erroneous results. 
For immunoassays antibodies can be either polyclonal or monoclonal. Polyclonal 
antibodies are less specific as they recognise multiple epitopes on the target antigen, 
whereas monoclonal antibodies recognise only one epitope. Polyclonal antibodies are 
useful in maximising sensitivity for low abundant antigens, however they are more 
prone to erroneous measurements. Hence for quantitative immunoassays monoclonal 
antibodies are preferentially employed, as they show a higher degree of affinity and 
specificity towards their target analyte.  
The antibodies used in the P-III-NP assays are all monoclonal and are raised against 
purified material from either human or bovine sources [85]. However, the binding 
epitope of these antibodies are not well characterised and cross-reactivity for different 
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P-III-NP species is observed [59]. In the absence of authentic human P-III-NP 
(hP-III-NP) material, all the immunoassays use bovine P-III-NP (bP-III-NP), which 
shares 97 % sequence homology with hP-III-NP, as the assay quality control sample 
[71, 85, 86]. 
1.5.2 Limitations 
For the RIAs, the use of radioactive material as the signal-generating label associate 
drawbacks to methods. Radioactive materials are health hazards, thus special 
licensing is needed for handling such material and handlers need to be properly 
trained. The storage of kits are limited by the short half-lives of the isotopes used, 
including iodine-125 (59.49 days ± 0.13) that are used in P-III-NP RIA kits [87]. Also 
specific instruments are required for radioactive counting. 
For the Advia Centaur® immunoassay, a specific platform is needed. In order to 
measure P-III-NP samples, the Advia Centaur® is reliant on instrument calibration using 
the manufacturer provided low and high quality controls, for which the components and 
their concentrations are undisclosed. As the most recent assay to be released, the 
P3NP-EL-US is still awaiting validation by anti-doping laboratories, before it can be 
considered for use in sports testing. All the other assays listed above have been 
validated and approved by WADA for determining P-III-NP concentrations, to be used 
in the detection of GH administration. A lack of commutability exists with the P-III-NP 
measurements produced the available assays, where measurements for the same 
sample using each assay gives a different result. As a consequence of this, different 
GH-2000 score calculations are employed for the different P-III-NP and IGF-I assay 
pairs used to measure analyte concentration. 
The quality of immunoassay measurements is heavily reliant on the antibodies used. 
Due to the difficulty and cost associated with antibody manufacture, immunoassay kits 
are prone to change or withdrawal from the market. If and when these changes occur, 
validation and re-assignment of GH-2000 score decision limits become necessary. To 
overcome these and other limitations, analytical methods based on the mass 
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spectrometric measurement of P-III-NP are desirable [3]. However, as a result of its 
size (42 kDa) and the sub-nanomolar serum concentration (25-125 pM), the 
development of such methods for P-III-NP is difficult, especially with the lack of 
reference material. 
1.6 Protein mass spectrometry 
Significant advances to mass spectrometry (MS) over the last few decades have 
resulted in the use of MS-based assays for protein quantification as an alternative to 
immunoassay approaches. High specificity and selectivity are associated with MS-
based assays, especially where unique selected reaction monitoring (SRM) methods 
are used to target the specified protein. The proteins targeted in these bio-analyses are 
commonly found in complex biological matrices such as serum. Prior separation of 
these analytes from other matrix proteins is necessary in order to obtain sensitive and 
reproducible results from MS methods. This can be achieved with appropriate sample 
preparation and chromatographic separation techniques, which are usually developed 
in parallel to MS methods so as to produce complete bioassays. 
1.6.1 Sample preparation 
A wide dynamic range of protein concentrations exist in biological matrices such as 
serum and blood. The complexity of these matrices negatively affect the detection (and 
quantification) of low-abundant proteins (LAPs) such as P-III-NP by MS. This is due to 
the presence of high-abundant proteins (HAPs), like albumin and IgG, which mask the 
detection of the LAPs by causing ion suppression in the mass spectrometer. Thus 
simplification of the sample matrix is necessary. In proteomics, this is achieved through 
the fractionation of the biological sample by depletion or enrichment approaches. 
Due to the wide variance of physical and chemical characteristics associated with 
proteins (as a result of different aa compositions), there is no model for sample 
preparation for this class of compound. Successful methods that have been used to 
deplete HAPs in proteomic studies include affinity chromatography, ultrafiltration, 
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dialysis and protein precipitation [88-91]. These techniques vary in mechanism and 
efficiency, thus they should be individually assessed for applicability to each intended 
bioassay. Although these techniques are targeted towards the depletion of HAPs, 
losses of LAPs may occur if they are bound to HAPs as protein complexes. Disruption 
of the binding within these complexes can be achieved by changing the sample pH 
through the addition of organic acids (e.g. acetic, formic and trifluoroacetic acid), mild 
bases (e.g. ammonium hydroxide) or denaturing agents (e.g. urea). 
As a more targeted and selective approach to sample preparation, the enrichment of 
LAPs is recommended. This approach utilises unique properties of target proteins such 
as their aa sequence, post-translational modification (PTMs) (e.g. glycosylation) or 
antibody epitope to capture and separate them from the sample matrix [92-94]. For 
antibody-based capture the availability of specific antibodies is a limiting factor of this 
application. However, unlike immunoassays, polyclonal antibodies are appropriate for 
quantification methods as antibodies are only used as capture tools and are not 
involved in detection. 
In addition to separating proteins from matrix, peptide handling and storage need to be 
considered. Non-specific adsorption loss to surfaces such as pipette tips, sample 
vessels and instrument tubing is commonly observed in protein analysis, especially at 
low concentrations. It is thought that these losses can be minimised with changing the 
protein (or peptide) environment through the adjustment of solvent composition, pH 
and temperature [95]. However, some level of caution should be exercised when 
altering the protein environment so that its chemical stability (e.g. to oxidation, 
reduction, and deamidation) and physical stability (e.g. to denaturation and 
aggregation) is maintained. As an alternative approach to reduce non-specific surface 
loss, the incorporation of excess amounts of surrogate molecules, which do not 
interfere with analytical methods and will preferentially bind to non-specific sites in 
preference to target analytes, is incorporated in the sample preparation protocols. 
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Although the complexity of samples are reduced using these sample preparation 
approaches, the probability of complete analyte isolation is small. Residual HAPs and 
non-targeted LAPs will remain in the fractionated matrix along with the target peptide, 
however, their concentration ranges should be of the same order of magnitude. For MS 
based approaches further separation of the sample is required and, to achieve this, 
liquid chromatography is often used. 
1.6.2 Liquid chromatography 
For additional separation of the separated sample matrix, which contains some residual 
HAPs and untargeted LAPs, liquid chromatography (LC) is often used prior to MS for 
protein analyses [96]. In LC further separation of the sample components is achieved 
based on their differences in distribution between an immiscible mobile and stationary 
phase. Reversed-phase LC (RPLC) is commonly used for protein and peptide 
quantification, where the stationary phase is non-polar and the mobile phase is polar. 
Using silica based particles as solid support, alkane hydrocarbons (C4 -C18) are 
tethered to the column, through which the mobile phase is pumped to elute separated 
analytes. The mobile phase is generally a binary mixture of water and a miscible polar 
organic solvent (e.g. methanol or acetonitrile). Non-polar analytes will interact with the 
stationary phase and be retained, however the degree of interaction of each analyte is 
dependent on its hydrophobicity. By manipulating the composition of the mobile phase 
(i.e. polar: non-polar ratio), elution of analytes from the column stationary phase can be 
controlled to effectively separate the sample mixture. Alternative phases such as 
normal-phase or hydrophobic interaction LC (HILIC) have been applied to protein 
analysis [95, 97]. 
1.6.3 Mass spectrometry 
Prior to 1990, the use of MS was limited to the analysis of small volatile molecules 
(< 1000 Da) for which gas-phase charged ions (measured as mass to charge (m/z) in 
the MS) could be formed using electron ionisation (EI), a hard ionisation technique. The 
high energy transferred in EI makes it inappropriate for the analysis of large molecules, 
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like proteins, nucleotides and carbohydrates, as they would be completely destroyed or 
degraded during ionisation. However with the invention of soft ionisation techniques 
(i.e. electrospray ionisation (ESI) and matrix assisted laser desorption ionisation 
(MALDI)) and the potential coupling of MS to LC, the analysis of these large molecules 
by MS was made possible. Interfaced with LC, ESI is the most appropriate ionisation 
mode. This is because ESI forms gas phase ions from solvated sample (described 
below in section 1.6.3.1), whereas MALDI does this using a solid state (section 
1.6.3.2). 
1.6.3.1 Electrospray ionisation 
In ESI, solutions eluted from LC are infused under atmospheric pressure into the 
ionisation source through a capillary, where they are nebulised with a high electric 
voltage (3-4 kV) to form an electrospray containing highly charged droplets. Once 
formed these droplets are electrically driven towards the entrance of the mass 
spectrometer with the aid of warm neutral gas (usually nitrogen). Two mechanisms for 
the formation of gas phase ions from these charged droplets have been proposed; 
these are the ion evaporation and charge residual ionisation models [98, 99]. Using the 
ion evaporation model, LC solvent is evaporated and the droplets break down to 
continually reduce in size. Eventually the repulsive force of the ions on the surface of 
the shrinking droplet becomes high enough to exceed the surface tension of the 
solvent, thereby producing ions that are in the gas phase [100]. Alternatively gas phase 
ions are produced using the charge residue model, where the continuous evaporation 
of the solvent accompanies droplet fragmentation to leave a single ion (completely 
devoid of solvent) at the end of the process [98]. Figure 1-7 shows the differences of 
these processes. ESI tends to produce multiply-charged ions from biomolecules such 
as proteins and peptides; by doing this the theoretical mass limit of the MS is extended. 
Thus large molecules will appear with a lower m/z despite their mass being beyond the 




Figure 1.6-1: Schematic of ESI , showing the ion evaporation and charge residual theories for 
the formation of gas phase ions. Solvated sample is passed through a capillary to form charged 
droplets, which are reduced to single ions by columbic explosion (ion evaporation model) or 
solvent evaporation (charge residual model). The scheme represents positively charged ions, 
however, the same mechanism applies in negative ion mode. (Image taken from [101] with 
permission). 
 
1.6.3.2 Matrix assisted laser desorption ionisation 
In MALDI, the sample is mixed with an appropriate solid matrix and an ultraviolet laser 
beam (usually a nitrogen laser at 337 nM) is used to transfer energy to the matrix and 
then the analyte to result in their subsequent ionisation and desorption from the 
surface. With MALDI, ions are mostly generated as single charged species. The 
process of ion formation is shown in Figure 1-8. Unlike ESI, the mechanism of ion 
formation for MALDI is not fully understood, and the matrix used is mainly experimental 




Figure 1.6-2: MALDI ionisation process, where matrix-analyte crystals are excited with a laser 
beam to result in the ionisation and desorption of the analyte from the surface. (Image taken 
from [101] with permission). 
 
1.6.4 Mass analysers 
The four main mass analysers used in proteomics are linear quadrupoles, time of flight 
(TOF), trapping quadrupoles and the Orbitrap [103]. MS which combine these 
analysers (e.g. quadrupole-TOF) are also commonly used. 
1.6.4.1 Quadrupoles- linear and ion trap 
Linear quadrupoles consists of four equally spaced and shaped rods to which a specific 
radiofrequency (RF) and direct current (DC) is applied. Manipulation of these voltages 
allows for the selection of ions with a specific m/z based on the stability of the trajectory 
of the ions [104]. Ion trap quadruopoles (QIT) use an oscillating field to store ions of 
multiple m/z values, based on the RF of a quadrupolar field in a concentric three-
dimensional orbital. The 3D QIT has two end cap electrodes that are electrically 
isolated from either side of a ring electrode. Here ions of all masses are trapped and 
form different trajectories around the central electrode, where an RF is applied that 
causes the ions to oscillate with a specific radius based on their m/z. By altering the 
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amplitude of the RF applied to the electrodes, ion trajectories are eventually 
destabilised to result in the expulsion of ions from the trap (according to mass) [104]. 
Quadrupoles have a limited mass range (usually < 4000 Da) and are considered to be 
low resolution instruments as they have unit mass resolution, however they give good 




Figure 1.6-3: Schematic of a linear quadrupole mass analyser showing the four parallel 
electrical rods to which differing direct current and radio-frequencies allow for separation of 
charged ions based on their trajectory. The solid line show ions with the "right trajectory" which 
reach the detector, and the dotted line show ions with the "wrong" trajectory which collide with 
the rods and are ejected. (Image taken from [101] with permission). 
 
 
Figure 1.6-4: Schematic of a 3D ion trap mass analyser showing the ring and end-capped 
electrodes, where alternating and direct potentials are applied to eject the trapped ions 




1.6.4.2 Time of flight 
Separation of ionised species using ToF relies on differences in the analyte’s free flight 
(associated with mass) while travelling in a field free tube (1-2 m) to reach the detector. 
With this approach all formed ions will reach the detector, unlike quadrupoles that filters 
ions. The mass range of a ToF is theoretically limitless, although the resolving power is 
dependent on tube linearity and length [107]. However, the use of a reflectron-type 
mass analyser with an electrostatic ion mirror (shown in Figure 1-11) can extend the 
flight path of ions with higher kinetic energy, which penetrate deeper into the mirror, 




Figure 1.6-5: Schematic of flight path of charged ions in a conventional ToF (A) and reflectron-
type ToF (B) mass analysers. (Image taken from [101] with permission). 
 
1.6.4.3 Orbitrap 
Orbitraps have two end cap electrodes enclosing a central electrode, which unlike 
quadrupoles, uses a static electrostatic field to sustain ion trapping following a 
specialized dynamic injection pulse. As the ions enter the Orbitrap they oscillate around 
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the central electrode. Here each ion has a characteristic frequency that is converted to 
a m/z by Fourier transformation to produce a spectrum with accurate mass 
measurements (accuracy < 5 ppm) and high resolution (> 140,000 FWHM) [86]. Like 
ToFs, all the ions that enter the MS will reach the detector; thus this instrument is only 
capable of full scan experiments unless coupled with a quadrupole mass analyser. 
 
 
Figure 1.6-6: Cut-away model of an Orbitrap mass analyser, showing the oscillation path of ions 
around the central electrode(a) and outer electrode (b) (which is split in half by an insulating 
ceramic ring, (c)). (Image taken from [108] with permission). 
 
1.6.4.4 Ion cyclotron resonance 
Ion cyclotron resonance (ICR) is related to the movements of ions in a magnetic field. 
Where ions in a cyclotron at the same frequency as the electromagnetic wave adsorb 
energy to increase the radius of its trajectory to 1 cm, at which point they strike a 
perpendicular to create a measurable "image current" [109]. The frequencies appear as 
a complicated waveform consisting of an overlay of the individual frequencies and 
amplitudes that can be converted by Fourier transformation as an infinite series of sine 
and cosine functions that are expressed as a mass spectrum [104]. 
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1.6.5 Tandem MS 
So far the analysers as described are only capable of single MS analysis (e.g. full scan 
or single ion monitoring (SIM)) that can be used for molecular ion determination. 
However if quadrupoles are placed in tandem with each analyser (i.e. quadrupole-
quadrupole (QqQ), quadrupole-ToF (Q-ToF) and quadrupole-Orbitrap), MS/MS 
experiments for a target precursor can be conducted. In this set up the quadrupole is 
used to isolate target ions that can be fragmented in a collision cell before entering the 
second analyser for m/z separation (schematic shown in Figure 1-13 below). 
 
 
Figure 1.6-7: Comparison of single (top) and tandem (bottom) MS analysers. In single MS , ions 
that enter the MS are separated in the analyser before reaching the detector. In tandem MS, 
specific ions can be selected in MS1 and fragmented, fragments are then separated in a second 
analyser (MS2) and detected. (Image taken from [101] with permission). 
 
For the purpose of this project, peptide characterisation was performed using a 
Q-Exactive® (quadrupole coupled to an Orbitrap) system, which produces untargeted 
high resolution measurements (to 4 decimal places) from full and product ion scan 
acquisitions. In full scan, samples are analysed directly by the Orbitrap using HRAMS 
(high resolution accurate MS). For product ion scanning, analytes of a specific mass 
range are filtered by the quadrupole MS into a collision cell, where fragmentation 
occurs prior to HRAM analysis in the Orbitrap. However in developing targeted 
quantitative methods, triple quadrupole (QqQ) instruments are employed to optimise 
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the sensitivity of analysis by increasing signal to noise ratios through the mass filtering 
capabilities provided in SIM. Here multiple unique fragment reactions are monitored in 
selected reaction monitoring (SRM) mode to increase the selectivity of MS analysis. 
1.6.5.1 Protein fragmentation 
Soft ionisation of peptides by ESI limit in-source fragmentation and produce [M+xH]x+  
(where x= 1, 2, 3...) in positive mode. In ESI where mild acidic conditions are used for 
protonation, multiply charged ions can be produced from proteins, which have multiple 
protonation sites. Higher charge states (i.e. x ≥ 2) are common in peptides ≥ 15 aa, or 
that contain multiple basic residues (Arg, Lys and His). Under MS/MS conditions 
protonated peptides fragment at Cα-C, C-N or N-Cα by rearrangement-type reactions 
or direct bond cleavage to produce 6 typical fragment ions [110]; for which their 
standardised Roepstroff-Fohlmann-Biemann [111, 112] nomenclature is presented in 
Figure 1-14 below. 
 
Figure 1.6-8: Nomenclature of the common peptide fragment patterns observed in tandem mass 
spectrometry [111]. 
 
The most comprehensive model to describe the peptide dissociation by re-arrangement 
is the "mobile proton" model where upon excitation added proton(s) migrate around the 
peptide to various sites prior to the cleavage of weakened and thermodynamically less 
stable peptide bonds [113]. Protons that are sequestered by side chains of basic 
residues are unable to direct fragmentation by this model. Lower energy is required for 
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re-arrangement type reactions than is needed for direct bond cleavage, making the 
latter mode of fragmentation uncommon in ESI-MS [110]. 
1.6.6 Quantification of proteins using MS 
With this application of MS to protein analysis accurate protein mass measurements 
are now obtainable that has aided the accurate determination of protein (and peptide) 
sequences and facilitated the identification of post-translational modifications (PTMs). 
However for MS, proteins need to be within the upper m/z range of instruments 
(currently around 4000-5000 m/z), or only require a small amount of multiple charging 
to achieve a detectable m/z of reasonable abundance. Therefore for large proteins, 
smaller peptides can be obtained by protein digestion (incorporated in the sample 
preparation step of analysis), which are analysed in place of the intact protein to reduce 
the spread of the MS signal seen with multiple charging and improve the signal 
intensity. When taking this approach however, surrogate peptides need to be selective 
and specific to their precursor protein to ensure MS measurements are of the target 
protein and not a contaminant. 
For quantitative analyses internal standard(s) (ISTD) should be incorporated in the 
bioassay. The ideal ISTD should have similar physical and chemical characteristics to 
the target analyte, in order to control any assay variability associated with sample 
preparation, LC and ionisation efficiencies (associated with matrix effects or drift in ion 
current). In most MS assays, isotopic analogues of the target analyte are used (most 
likely containing 13C and/or 15N), as these compounds share chemical properties with 
the analyte but have different masses, so that they can be separated in the MS 
analyser to produce separate MS signals [114]. A mass difference of at least 3-4 Da is 
preferable to minimise errors associated with isotopic overlap [95]. Where digest 
peptides are targeted in the MS for quantification, isotope labelled peptides can be 
used in place of the isotope labelled protein standard. Although the peptide has similar 
chemical and physical properties in LC and MS, in sample preparation where the intact 
protein is the analyte, these standards cannot compensate for variance. 
53 
 
1.6.7 Protein and peptide standards for P-III-NP 
As a low abundant protein whose expression is age dependent, natural sources of 
hP-III-NP are limited. By recombinant approaches, procollagen III has been produced 
for application to tissue engineering in the medical field [115-117]. It is important to 
ensure the occurrence of PTM events (e.g. specific Cys-Cys disulphide bonds and Pro 
hydroxylation), which affect the cross-linking of the protein; these processes are 
dependent on the age and physiology of the tissue used for maturation during 
recombination [118]. On the basis of yield (20 % increase) for the target type III 
collagen, the recombinant production of procollagen III without P-III-NP has 
predominated in this field [118]. Hence, although possible to produce by recombinant 
technologies a source to rhP-III-NP is not available. 
Similar to the in vivo production of proteins, peptides and proteins can be chemically 
synthesised through the gradual elongation of the aa units in its sequence via coupling 
reactions. Like the recombinant production, PTM and cross-linking is important to 
protein synthesis and need to be incorporated into the synthesis process. This 
complicates synthesis, and potentially produces a combination of products of varying 
and irreproducible yield. Peptide synthesis is a simpler process, where although PTMs 
are essential for association with the endogenous protein, cross-links are not as 
essential, especially where they are removed before LC-MS. Synthetic synthesis of 
peptides can be achieved by solution or solid phase mechanisms, where the latter is 
practical for research applications based on the quantity of material used [119]. 
1.6.7.1 Peptide standards - synthesis 
For solid phase synthesis, peptides are synthesised from the carboxyl- to amino-
terminus of the peptide. To start the peptide synthesis the first aa (carboxyl-terminus aa 
in the sequence) is coupled onto an activated linker on the surface of the solid-phase 
resin. This is an important step in synthesis, in that the efficiency of this coupling 
defines the yield and scale of SPPS. Once attached the protecting molecule from the 
α-amino group is selectively removed to provide a free amino group, able to react with 
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the chemically activated α-carboxyl group of the subsequent aa for coupling. Peptides 
are elongated with the repetitive coupling and de-protection of aa residues until the 
sequence is complete. After this the synthesised peptide is removed from the resin 
along with any additional reactive side chain to yield the desired product. The 
generalised scheme of SPPS is shown in Figure 1-15 below. 
 
 
Figure 1.6-9: Generalised approach to solid phase peptide synthesis, where peptides are 
synthesised on a solid support resin from their carboxyl- to amino- terminus. During their 
synthesis peptides are elongated through by the sequential addition of aa using a repetitive 
coupling and de-protection mechanism. To dictate the location of amide bonds, aa residues with 
reversible-protected side groups (e.g. Fmoc, Boc and Trt) are used.  
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1.7 Aims and objectives of this PhD 
The overall aim of this PhD is to demonstrate that LC-MS is capable of quantification of 
serum hP-III-NP using a digest MS approach and to complement the existing 
immunoassays, as a part of the evidence towards determining hGH administration in 
sport doping tests. 
1.7.1 Objective 1: To evaluate the yield of digest peptides from P-III-NP 
In the absence of international reference material for P-III-NP, partial characterisation 
of the protein is undertaken by enzymatic digestion using the aa sequence (obtained 
from genomic databases) and a sample of bP-III-NP (sharing 97 % sequence 
homology with hP-III-NP). Following evaluation for selectivity and MS sensitivity, 
surrogate peptides were selected for developing target LC-MS methods for hP-III-NP. 
These methods are covered in Chapter 2.  
1.7.2 Objective 2: To develop sensitive and selective LC-MS methods 
targeting P-III-NP 
Using the selected peptides, targeted LC-MS methods were developed to achieve the 
optimum sensitivity for P-III-NP, so as to enable analysis at the reported serum level 
(1-5 ng/mL, 25-125 pM). To achieve this, conventional, micro- and nano-flow 
technologies are investigated in Chapter 3. 
1.7.3 Objective 3: To develop a suitable sample preparation procedure for 
serum P-III-NP analysis 
Present within complex matrices (i.e. blood and serum) at very low concentrations the 
direct analysis of P-III-NP by MS is not possible without sample preparation. In Chapter 
4 is a description of some of the common techniques used in proteomics that have 
been investigated to assess their efficiency and applicability for separating P-III-NP 
from serum for MS analysis. 
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1.7.4 Objective 4: To develop an approach to obtaining peptide standards 
for the quantification of P-III-NP  
Once suitable methods for P-III-NP analysis in serum have been developed, 
appropriate standards for the quantification of P-III-NP need to be obtained. Initial 
synthesis of labelled and unlabelled peptide standards are presented in Chapter 5. 
With successful development of these standards, quantification of serum hP-III-NP by 
LC-MS should be achieved.  
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Chapter 2 : In silico and in vivo digestion of P-III-NP 
2.1 Overview 
This chapter details the in silico and in vivo digestions of procollagen III amino terminal 
propeptide (P-III-NP) to predict peptides to target for quantitative mass spectrometry 
(MS). P-III-NP was in silico digested with five endoproteases (trypsin, Asp-N, Glu-C, 
chymotrypsin and Lys-C) to identify the best digest approach to support development 
of a selective quantitative LC-MS method. Bovine P-III-NP was digested with trypsin 
prior to partial de novo peptide sequencing using liquid chromatography tandem mass 
spectrometry (LC-MS). Deviations from the peptide masses determined by in silico 
digests were observed in experimental products, due to the presence of post 
translational modifications (PTM) in some amino acid (aa) residues. The uniqueness, 
stability and MS response of the digested peptides generated by both in silico and in 
vivo methods were assessed to target surrogate peptides for possible quantification of 
P-III-NP by LC-MS. 
2.2 Introduction 
Mass spectrometry (MS) has become the bioanalytical method of choice for sensitivity 
and selectivity [97]; with recent advances in MS and chromatography, tandem 
techniques can now be used to measure small amounts of protein in complex matrices 
with greater throughput and improved accuracy and precision. Liquid chromatography 
(LC) is used to separate the many components present in complex biological mixtures 
(e.g. serum), whilst MS detection allows for the accurate and precise mass 
measurement of targeted (and untargeted) analytes. Unpredictability of the associated 
molecular weight of proteins resulting from amino acid (aa) post- translational 
modification (PTM) across the peptide backbone can complicate MS data 
interpretation. Hence, protein characterisation (sequencing) is undertaken in the first 
stages of method development. 
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2.2.1 Procollagen III amino terminal propeptide  
Procollagen III amino terminal propeptide (P-III-NP) is a 42 kDa trimeric protein [64] 
consisting of three identical pro α1- chains covalently linked by disulphide bonds [59]. 
Bacterial collagenase digested P-III-NP separates on diethylaminoethyl (DEAE) 
cellulose to reveal three conformational distinct domains. Carboxyl- to amino-terminus; 
these are the globular (Col 1), triple helical or "collagen-like" (Col 3) and telopeptide 
precursor (Col 2) domains [64, 66]. In conjunction with the aa sequence of P-III-NP, the 
topology of these domains help predict possible P-III-NP post-translation modifications 
that affect protein mass, structure and stability of the protein. 
2.2.1.1 Deamidation 
Glutamine (Gln) and asparagine (Asn) residues in peptides and proteins are inherently 
unstable under physiological solvent conditions and are often deamidated to glutamic 
acid (Glu) or pyroglutamate (pyroE) and aspartic acid (Asp) respectively; in a wide 
variety of proteins [120]. Deamidation of Gln is much slower than Asn; except for 
amino-terminus Gln, where deamidation occurs rapidly to form a pyroE [121]. 
2.2.1.1.1 Asparagine 
Deamidation of Asn is not uncommon in proteins where it is amino-terminal to glycine 
(Gly) and to a lesser extent to serine (Ser) [122]. This process can take place slowly in 
intact proteins, however the rate of reaction increases dramatically after proteolytic 
digestion; where residues are left more exposed [123]. Rates of deamidation are 
dependent on pH, ionic strength, temperature and solvent conditions as well as the 
structure of the peptide or protein near the residue [120]. A typical conversion of 
70-80 % of Asn-Gly → Asp-Gly and ~10 % for Asn-Ser → Asp-Ser has been observed 
in the commonly used overnight trypsin digestion of proteins [122]. 
2.2.1.1.2 Glutamine 
PyroE is formed enzymatically in the presence of glutaminyl cyclase, but can also 
occur spontaneously from amino-terminus Gln or Glu through the deamidation or 
dehydration of respective residues [124]. The reaction rate for Gln is faster than that for 
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Glu in both the catalysed and spontaneous reactions [125]. Cyclised pyroE makes 
proteins resistant to aminopeptidase degradation thus slowing physiological turnover. 
Furthermore, it blocks peptide sequencing by Edman degradation, where phenyl 
isothiocyanate requires a free primary amino group to react. Hence, it is not surprising 
that early Edman sequencing of P-III-NP (calf) required prior removal of the first aa with 
pyroglutamate aminopeptidase, thus, providing evidence for this modification [65]. 
Amino-terminus pyroE has also been identified in calf type I [126] and sheep type I 
[127] procollagen peptides. 
2.2.1.2 Hydroxylation 
Col 3 P-III-NP is commonly referred to as the “collagen-like” domain owing to its 
similarity with collagen in topology and basic aa structure. Collagen has a basic triple 
helical conformation consisting of three supercoiled poly-proline (Pro) helices that 
require a Gly residue at every third position to obtain a predominant Gly-Pro-Pro repeat 
[128]. Hydroxyproline (hydroxyP) is formed by the enzymatic hydroxylation of Pro by 
prolyl hydroxylase [129], and is stereo and site specific in that it occurs only at Pro 
residues in the third position to give a Gly-Pro-hydroxyP repeat. This Pro hydroxylation 
adds stability to collagenous regions by enabling covalent bonding between the 
hydroxyl group and water molecules to form a tropocollagen [128, 130], as shown in 
Figure 2-2. 
2.2.1.3 Glycosylation 
Glycosylation, one of the more complex PTMs, is a common covalent modification in 
eukaryotic cells [131]. Greater than 50 % of human proteins are glycosylated [132] 
where the attached glycans are either nitrogen (N-) or oxygen (O-) linked [131]. 
2.2.1.3.1 Nitrogen linked glycosylation 
N-linked glycosylation can occur at the side chain amide nitrogen of Asn where a 
Asn-X-Ser/Thr sequon exists; X represents any aa residue except Pro. These glycans 
are added en bloc to the protein in the lumen of the endoplasmic reticulum usually as 
pre-synthesized core units of 14 saccharides [133] often involving GlcNac 
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(N-acetylglucosamine) [134, 135]. Among its many functions, N-linked glycosylation 
helps to stabilise proteins against denaturation and proteolysis, enhance solubility, 
facilitate orientation of proteins relative to a membrane, confer structural rigidity and 
regulate protein turnover [134]. 
2.2.1.3.2 Oxygen linked glycosylation 
O-linked glycosylation takes place in the Golgi apparatus where linkage occurs by the 
transfer of GalNac (N-acetylgalactosamine) to Ser/Thr by N-acetyl galactosaminyl 
transferase. After attachment of the first GalNac residue, gradual elongation and 
modification of the core structure can occur [136]. O-linked glycosylation sites are not 
easy to predict, as sugars are often clustered in short peptide regions rich in Ser and 
Thr. O-linked glycosylation can modulate aggregation, maintain stability of and confer 
protease and heat resistance to proteins [133]. 
2.2.2 Protein digestion 
Successful characterisation of P-III-NP PTMs will allow for the correct calculation of the 
protein's molecular weight. In general the MS sensitivity of proteins is less than that for 
peptides. As most MS instruments have a typical mass cut-off m/z 3000, proteins need 
to be multiply charged for analysis; thus, the peak intensity is shared between these 
multiple charges to effectively reduce the overall MS sensitivity. Ideal sequencing data 
is obtained from peptides ≤ 20 aa long [103]. As a low abundant serum protein, MS 
sensitivity for P-III-NP can be maximised by analysing smaller surrogate peptides 
obtained from endoprotease protein digestion. 
Digestion of proteins with trypsin is a standard step in proteomics. Trypsin owes this 
position to its high efficiency, cleavage site-specificity [137], and suitability of fragments 
for MS [138]. The cleavage-site specificity of trypsin is due to its highly conserved 
catalytic triad (Ser-195, Asp-102, His-57, shown in Figure 2-1 below) and the specificity 
of the binding pocket for basic residues arginine (Arg) and lysine (Lys) [139]. The 
frequency of trypsin cleavage in proteins generally yield peptides 7-35 aa long with a 
mass range of 600-4000 Da [140]. Most tryptic peptides have a carboxyl-terminus 
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Arg/Lys that enhances positive ionization and leads to favourable fragmentation of 
peptides potentially dominant in y-ions [138]. Trypsin “missed cleavage” can occur 
where seemingly cleavable sites are skipped. Extensive analysis of these “missed 
cleavages” has been studied by Keil [141], for which the most common are 
summarised in Table 2-1. 
These tryptic missed cleavages, as well as the frequency of Arg/Lys residues in a 
protein, can sometimes make this mode of digestion unsuitable for producing peptides 
that are suitable for MS, or give poor protein sequence coverage. In these cases, 
digestion with alternative endoproteases should be investigated. Table 2-2 summarises 
some common endoproteases and their cleavage conditions. Once peptides with 
unique aa sequences are selected, the suitability of MS characteristics (e.g. sensitivity 
and stability) are considered, so as to ensure the best selection of surrogate peptides 
for LC-MS methods. 
 
Table 2-1: Likely trypsin missed cleavage sites as defined by Keil [141]. Where P1 represents 
the primary binding site (specific for Arg (R) or Lys(K)), P1’-P3’ and P2-P4 represent the 
carboxyl-and amino-terminal secondary binding site carboxyl-terminal to P1, respectively. 
P4 P3 P2 P1 P1’ P2’ P3’ 
   [RK] [P]   
   [RK] [RK]   
  [DE] [RK]    
   [RK] [DE]   
   [RK]  [DE] [DE] 
[DE] [DE]  [RK]    





Figure 2.2-1: Showing the specificity of the Asp-189 residue at the S1 (P1) binding pocket of 
trypsin for Arg and Lys. Through nucleophillic attack from trypsin's Ser-195 to the carboxyl-
terminal amide bond of the bound Arg/Lys, a catalytic cascade involving His-57 and Asp-102 
and water forms an acyl-enzyme intermediate to result in the hydrolysis of the peptide bond. 
(Image taken with permission from [142]). 
 
Table 2-2: Common digestion endoproteases used in proteomics and their cleavage 
specificities 
Endoprotease Cleavage Specificity Optimal 
pH 
Examples of use 
Trypsin carboxyl-terminal of R and K 7.8-8.7 Most commonly used 
Lys-C carboxyl-terminal of K 7.0-9.0 
Produce larger peptides than 
trypsin; however sometimes 
used with trypsin to reduce K 
"missed cleavage" 
Glu-C 
carboxyl-terminal of E 
and to a lesser degree 
D 
4.0-9.0 
Used as an alternative to trypsin 
to produce different peptides and 
expand protein coverage. 
Cleavage sites are buffer 
specific. 
Asp-N amino-terminal of D 4.0-9.0 
Sometimes used to complement 
Glu-C digests to produce similar 
peptides (1 aa longer) 
Chymotrypsin 




Digestion of hydrophobic 
proteins (e.g. membrane 






Figure 2.2-2: Illustration of P-III-NP highlighting PTMs determined from the topology and aa sequence. Where the shapes represent the location of modification in 
the protein structure. 
Amino-terminus Gln pyroglutamation Glycosylation




2.3 Materials and Methods 
All water used was purified using an Elgastat Pure Lab Option water purification unit 
and had ~18 MΩ cm resistivity. Analar NormaPur. Formic acid (99-100 %) was 
purchased from VWR Chemicals (Fontenay-sous-Bois, France). Ammonium 
bicarbonate (≥99 %, Reagent Plus®), Substance P acetate salt hydrate (≥95%, HPLC 
grade), and albumin solution human (HSA, 30 % in 0.85 % sodium chloride, protease 
free), were purchased from Sigma Aldrich (St. Louis, MO, USA). 
2.3.1 In silico digestion of human P-III-NP 
Theoretical (in silico) digestion of human P-III-NP (UniProtKB entry E7ENY8) with 
trypsin, LysC, Chymotrypsin, Asp-N, and Glu-C was performed using ExPasy Peptide 
Cutter [143] and USCF Protein prospector [144], where zero missed cleavage was 
allowed for each digestion. To assess the uniqueness of in silico derived peptides 
(> 500 Da and > 5 aa), sequences were searched against the UniProtKB database 
using the Basic Local Alignment Search Tool (BLAST) with an expectation value (E) 
threshold of 10. 
2.3.2 P-III-NP in silico derived peptides  
In the absence of international reference material for human P-III-NP, five in silico 
proteolytic derived P-III-NP peptides (Table 2-3 below) were synthesized by Fisher 
Scientific (Offenbach, Germany) for the purpose of developing LC-MS methods to 
target P-III-NP. 
At the time of synthesis, it was unclear as to whether the highlighted amino acids in 
Tyr_6 (NGDPGIPGQPGSPGSPGPPGICESCPTGPQNYSP) were included in 
circulating P-III-NP (personal communication (Prof. Cowan (supervisor) and Dr. L 




2.3.2.1 Sample Preparation of peptides for LC-MS 
Sample preparation for LC-MS analysis was dictated by the presence of Cys (C) 
residues in the peptide amino acid sequence. 













2.3.2.1.1 Preparation of peptide standards 
For Tyr_5, the only peptide not containing a Cys residue, pure peptide standards (1, 7, 
14, 70, 140 and 210 nM) were prepared in formic acid (0.3 %) and acetonitrile (5 % ) 
solution. By LC-MS/HRAMS, standards were used to develop a product scan method 
for Tyr_5, and establish the limit of detection (LOD) for the peptide as detailed in 
section 2.3.3. 
2.3.2.1.2 Preparation of peptide standards (C derivatisation) 
For all other peptides (containing Cys residues within the peptide sequence) 
spontaneous coupling of thiol residues to form inter- and intra-covalently linked 
disulphide bonds was expected. These bonds complicate LC-MS analysis, requiring 
the use of deconvolution software to interpret data. To avoid this step, disulphide bonds 
were reduced from our peptide standards using dithitohreitol (DTT. Bio-Rad 
Laboratories, Herts, UK) and later blocking by alkylation with iodoacetamide (IDA. 
Sigma Aldrich, St. Louis, MO, USA) to carbamidomethylate the C residue. Pure 
standards (1, 7, 14, 70, 140 and 210 nM) for each peptide were prepared in ammonium 
bicarbonate (100 mM) and derivatised using the following protocol: 
1. In a 1.5 mL Lobind Eppendorf tube (Sigma Aldrich, Hamburg, Germany), DTT 
(100 mM in 100 mM NH4HCO3, 5 μL) was added to the sample (100 µL)and 
66 
 
vortexed (2-3 sec), prior to mixing at 900 rpm in a Thermomixer® for 10 min at 
60 ˚C. 
2. Samples were left to stand for a further 50 min at 60˚C in the Thermomixer®, 
before cooling to room temperature and centrifuging at 500 rpm for 5 min to 
collect condensate. 
3. IDA (250 mM in 100 mM ammonium bicarbonate, 5 μL) was then added to the 
sample which was incubated in the dark for 30 min at room temperature. 
Once derivatised, standards were prepared for LC-MS/HRAMS analysis by adding 
formic acid (2 %, 10 µL) to the sample. As with Tyr_5, standards were again used to 
develop product ion scans and establish LODs. 
2.3.3 Liquid chromatography coupled mass spectrometry-high resolution 
mass spectrometry (LC-MS/HRAMS) 
2.3.3.1 Liquid chromatography 
A simple gradient LC method using a Thermo Fisher™ Dionex™ UltiMate™ 3000 
UHPLC (ultra high performance liquid chromatography) system was developed  to 
allow for sufficient separation of the in silico derived peptides (from a postulated 
P-III-NP digest) from potential matrix peptides. Using the settings detailed in Table 2-4 
below, separation of sample (10 µL) was achieved using a Waters Acquity® UPLC® 
BEH 130Å column (C18, 1.7 µm, 2.1 x 50 mm), with mobile phases A (0.3 % formic 
acid in water) and B (0.3 % formic acid in acetonitrile) over 10 min. 
Table 2-4: LC gradient conditions used to achieve separation of P-III-NP peptides by UHPLC 
Time(min) Flow(mL/min) % A % B 
0.00 0.3 95 5 
3.00 0.3 95 5 
8.00 0.3 10 90 




2.3.4 Mass spectrometry 
2.3.4.1 MS tune conditions 
To optimise MS source conditions suitable for analysing our peptides, substance P 
(1347 Da), a readily available but similar sized peptide was used. By infusing 
substance P (500 ng/mL, 371 nM) at 5 µL/min on a Thermo Fisher Scientific 
Q-Exactive with HESI II ionisation source in positive mode (using N2 as source and 
collision gas), the following instrument parameters were established: 
• sheath, auxiliary and sweep gas: 70, 13 and 0 arbitrary units 
• capillary and heater temperature: 300 ˚C and 325 ˚C 
• spray voltage: 3.75 kV 
2.3.4.2 MS/HRAMS product scan methods 
To select an appropriate precursor ion for each of the in silico derived P-III-NP 
peptides, a full scan spectrum was collected using high resolution accurate mass 
spectrometry (HRAMS) over the m/z scan range 200 - 3000. In HRAMS mode the 
resolving power was set to 140,000 FWHM, with an AGC target of 1 x 106 and a 
maximum injection time of 100 ms. 
Using the full scan spectrum, singly-, doubly- and triply-charged ions (m/z) (refer to 
Table 2-5 below) for each peptide were extracted to identify the most abundant 
precursor. The selected precursor (± 1 amu) was used to trigger product ion scans in 
MS/HRAMS mode using normalised collision energies (nCE) 15, 20, 25 and 30 (%, 
arbitrary units) to select the best spectrum. Where complete or insufficient 
fragmentation of the precursor was observed (within the selected range), the nCE was 
appropriately adjusted.  
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Table 2-5: Peptide m/z values (singly-, doubly- and triply-charged ions) for in silico derived 
P-III-NP (human) peptides; where C represents carbamidomethylated (C2H3NO, +57.0215 Da) 
Cys residues. 







Tyr_1 QQEAVEGGCSHLGQSYADR 2091.9149 1046.4611 697.9765 
Glu-C_2 GGCSHLGQSYAD 1251.5059 626.2566 417.8401 
Glu-C_10 CCAVCPQPPTAPTRPPNGQGPQGPKGD 2844.2974 1422.6524 948.7707 
Tyr_5 GDPGPPGIPGR 1019.5268 510.2670 340.5138 
Tyr_6 NGDPGIPGQPGSPGSPGPPGICESCPTGP 2743.2087 1372.1080 915.0744 
 
2.3.4.3 Data-dependent mass spectrometry 
To generate untargeted MS/HRAMS a product ion spectrum for the P-III-NP trypsin 
digest, the resolving power for the initial full (survey) scan by HRAMS was reduced to a 
resolution of 70,000 FWHM, to allow for the collection of more data points. Using a top 
50 method and a precursor isolation window of ±1 amu, data dependent MS/HRAMS 
spectrum were collected across m/z 200-3000, with a resolving power of 17,500 
FWHM, nCE 30, AGC target set to 5 x 104 and maximum injection time of 50 ms. 
For data analysis, collected spectra were checked using the Matrix Science Mascot 
server (version 2.2.06) searching against all taxonomic entries in 
UniProtKB_sprot_130200. A peptide and fragment tolerance of 5 ppm and ±0.50 Da 
with a maximum of three missed cleavages was allowed, with a peptide charge 1+, 2+ 
and 3+ and above. Carbamidomethyl (C) was entered as a fixed modification, whilst 
Q-> pyroE (N-term Q), Oxidation (P) and Deamidated (NQ) were entered as variable 
modifications. Data was also checked with Carbamidomethyl (C) as a variable 
modification. Samples were analysed with and without the error tolerance tool. 
2.3.5 In vivo trypsin digestion of bovine P-III-NP 
To evaluate the yield of the synthesized in silico derived tryptic peptides from P-III-NP, 
an in vivo digestion of bovine P-III-NP (97 % homology with human, Institute of 
Bioanalytics, L.L.C (Branford, USA)) was evaluated by LC-MS. Using our developed 
methods full scan (HRAMS), product scan (MS/HRAMS targeting trypsin peptides) and 
data dependent MS/HRAMS spectrum were collected. Trypsin digestion of a P-III-NP 
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positive control (~100 µg/mL in 0.1 % human serum albumin (HSA)) and HSA negative 
control (0.1%) was performed as follows: 
1. Using the protocol described in Section 2.3.2.1 above, each control (100 µL) 
was derivatised, to remove disulphide bonds. 
2. Trypsin (100 µg, sequencing grade modified (Promega, Wisconsin USA)) was 
reconstituted by adding acetonitrile (50 mM, 20 µL) and then ammonium 
bicarbonate (100 mM, 480 µL) before repeatedly pipetting up and down (~6 
times), to make a stock solution. 
3. To each control, trypsin stock solution (2 µg, 10 µL) was added and vortexed 
before incubating overnight (min 8 h) at 37 ˚C whilst mixing at 1,400 rpm in a 
Thermomixer®. 
4. To end trypsin digestion, formic acid (2 %, 10 µL) was added to each control 
and vortexed (2-3 sec) before evaporating at 45 ˚C in a Speedvac® (~3.5 h). 
5. The controls were reconstituted in formic acid (0.3 %) and acetonitrile 5 % 




2.4 Results and Discussion 
2.4.1 In silico digestion of human P-III-NP 
 
Figure 2.4-1: Map of cleavage sites after P-III-NP (human UniProtKB entry E7ENY8, monomeric) tryptic and chymotryptic digestion. The cleavage specificity 





Table 2-6: Showing the in silico digestion products for P-III-NP (human) for five endoproteases (trypsin, Lys-C, Chymotrypsin, Asp-N and Glu-C) with no missed 
cleavage allowed. Only fragments with > 5 aa and > 500 Da are shown. Peptide sequences highlighted in bold are unique to P-III-NP (all species) according to 






































































































































In general, peptides < 500 Da and 5 aa in length were not unique to P-III-NP when 
searched with BLAST against UniProtKB. Hence, these peptides were excluded from 
the peptide list presented in Table 2-6 above. Of the endoproteases used to digest 
P-III-NP all the peptides produced by trypsin and LysC were found to be unique. 
2.4.1.1 Trypsin 
For trypsin, basic cleavage principles dictate hydrolysis of the amide bond carboxyl-
terminal to Arg (R)/Lys (K) -X (where X ≠ Pro) to give four digest peptides for P-III-NP 
(Table 2-6). Being the most commonly used endoprotease to digest proteins, trypsin 
activity for all applicable amino acid tri-peptidic combinations has been documented by 
Keil [141], allowing the prediction of cleavage probability for P-III-NP as shown in 
Figure 2-3. 
Considering trypsin's preference for Arg residues (compared to K), the 64 % probability 
predicted at the first cleave site, 19R, is considerably low. This is attributed to secondary 
specificity of neighbouring negatively charged Asp (D) residues in positions P2 and P1' 
at the cleavage site, which can form salt bridges with Arg, thus, competes with 189D in 
the trypsin S1 pocket and potentially inhibits enzyme activity. Although the probability 
of cleavage is lower than expected, extensive exposure to the enzyme should increase 
the yield of Tyr_1 from P-III-NP, hence we considered this peptide for developing 
LC-MS methods.  
Amongst the in silico derived peptides, Tyr_2-4 (66 aa with mass 7021 Da) is the 
heaviest; this is an atypical product for trypsin which normally produces peptides of 
7-35 aa (600-4000 Da) [140]. The size of the peptides is attributed to the presence of 
two "missed cleavage" sites at 21V-W-K-P-E and 81P-T-R-P-P within the aa sequence; 
although "zero missed cleavage" were permitted for in silico digest. 
It is interesting to note that for the Tyr_2-4 "missed cleavage" site, 21V-W-K-P-E, 
advanced cleavage specific data for trypsin [141] predict hydrolysis of this bond with a 
probability of 100 % (see Figure 2-3). This is due to trypsin's strong preference for 
cleavage at W-K-X bonds, including X=Pro. The initial "missed cleavage" predicted at 
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this site is dependent on the Pro residue in position P1', which is expected to hinder 
attachment of the protein to the specificity pocket, however, in this case the effect of 
Pro is secondary to that of Typ (W). Trypsin will therefore cleave Tyr_2-4 to two 
peptides 20DVWK (Tyr_2) and 24PEPCQICVCDSGSVLCDDIICDDQELDCPNPEIPFGE 
CCAVCPQPPTAPTRPPNGQGPQGPK (Tyr_3-4). Unfortunately Tyr_2 is not unique to 
P-III-NP and does not improve peptide yield. 
For the second "missed cleavage" site, 81P-T-R-P-P, using the advanced data set the 
probability of cleavage is 0.0001%. The Arg residue is neighboured by Pro residues in 
positions P3, P1' and P2'. The combined conformational rigidity of Pro at these 
positions will twist the peptide backbone and restrict the protein entering the trypsin 
specificity pocket to result in a "no cleavage" site. The remaining peptide, Tyr_3-4 
(62 aa with mass 6492 Da), is still large for analysis using current MS instruments 
(maximum m/z 2000), which to observe would require a charge state ≥ 4, hence it is 
not considered as a surrogate peptide for method development. 
The probability of cleavage for the other peptides, Tyr_5 and Tyr_6 is > 90 %, which is 
sufficient for good repeatability of peptide yield. Both are unique to P-III-NP, and 
although the Tyr_6 is larger than that expected for trypsin peptide (3218 Da), both are 
considered for developing LC-MS methods. 
2.4.1.2 Lys-C 
Lys-C cleaves carboxyl-terminal Lys(K)-X (X= any aa) bonds to give three unique 
peptides from P-III-NP. Unlike trypsin, Lys-C has high specificity for Lys-Pro, Lys-Arg or 
Lys surrounded by Asp/Glu in the P4-P2 and P1’-P3’ of the cleavage site. Hence, to 
decrease Lys-affiliated trypsin "missed cleavages", a Lys-C digest can be included to 
increase peptide yield [145]. Besides 22W-K-P, which already has a high affinity for 
hydrolysis by trypsin, none of these bonds exist in P-III-NP. 
Lys-C generated peptides are potentially more basic than those produced by trypsin as 
they may contain R residues in addition to terminal Lys. This can facilitate higher 
charge states that can be beneficial for MS analysis. This is the case for Lys-C_1, a 
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fairly sized peptide (23 aa with mass 2563 Da) only requiring a charge state ≥ 2 to be 
visualised by conventional MS, which is easily achieved by one basic residue. 
Lys-C_2 and Lys-C_3 are large peptides (>4000 Da) identical to Tyr_3+4 and 
combined Tyr_5 and Tyr_6, respectively. Lys-C_2 was earlier disregarded as a 
surrogate for P-III-NP and will be discussed no further. Lys-C_3 requires a charge state 
≥ 3 for MS analysis which may be difficult to achieve with one basic residue at 96R, 
hence it is also not considered for developing LC-MS methods. 
2.4.1.3 Chymotrypsin 
Chymotrypsin cleaves carboxyl-terminal Trp (W), Tyr (Y) and Phe (F) with high 
specificity and to a lesser extent at Leu (L), Met (M) and His (H) (in preferential order) 
[141] to give two unique P-III-NP peptides. Due to the frequency of cleavage sites, 
chymotrypsin derived peptides are typically small (i.e. < 5 aa). Hence it is interesting to 
observe Chym_7 (70 aa with a mass 6703 Da) amongst the products for this 
endoprotease. The size of this peptide may be attributed to the predominant tri-peptidic 
Gly-Pro-Pro repeat within the Col_3 domain of P-III-NP, from which the majority of the 
peptide originates. 
The frequency of chymotrypsin cleavage for polypeptidic substrates has been studied 
in great detail [141] indicating additional low specificity chymotrypsin cleavage sites in 
P-III-NP at Gly (Q), Ala (A), Gly (G), Cys (C), Arg (R), Ile (I), Val (V) and Asn (N) 
residues as shown in Figure 2-3. For Chym_1, occurrence at these low specific sites 
could produce peptides: 1Q, 2QEA, 5VEG, 8GC, 10SH and 12L, which would no longer be 
unique to P-III-NP. Likewise, additional cleavage of Chym_7 can occur to produce two 
unique peptides 87PGPPGIPGR and 105QPGSPGSPGPPG. 
The low selectivity of chymotrypsin for P-III-NP, could lead to a yield of 41 peptides. 
However, because of the typical low cleavage probability for most sites (only three sites 
> 90 %) (Figure 2-3) numerous missed cleavage are expected, which will affect the 
reproducibility of peptide yield from a digest. It is for this reason that chymotryptic 




Asp-N cleaves amino-terminal Asp (D) to produce four unique peptides from P-III-NP. 
At high concentration additional amino-terminal cleavage of Glu (E) can be expected 
[146]. Occurrence of cleavage at these low specific sites affects the stability of Asp-N 
derived peptides, to potentially observe these additional peptides from: 
Asp-N_1: 1QQ and 3EAVEGGCSHLGQSYA, 
Asp-N_9: 50DCPNP, 55EIPFG and 60ECCAVCPQPPTAPTRPPNGQGPQGPKG 
Asp-N_11: DPGIPGQPGSPGSPGPPGIC and ESCPTGPQNYSP. 
These additional cleavage sites will affect the reproducibility of peptide products from 
Asp-N digests, hence they are not considered further for method development. 
2.4.1.5 Glu-C 
In phosphate buffer, Glu-C will cleave amino-terminal Glu (E) and Asp (D) [147] to 
produce two unique peptides from P-III-NP. Cleavage probability is decreased with Pro 
residue in positions P3, P1' or P2'. This is evident for Glu-C_10-12, which has two 
missed cleavage sites at 85K-G-D-P-G. and 97N-G-D-P-G. Unlike trypsin and 
chymotrypsin, the nature of this endoprotease is not as well defined, hence the 
likelihood of occurrence of these Pro defined "missed cleavages". If we assume that full 
cleavage of the protein will occur, from Glu-C_10-12 we obtain additional unique 
peptides: 
Glu-C_10: CCAVCPQPPTAPTRPPNGQGPQGPKGD (2672.2257 Da) 
Glu-C_11: PGPPGIPGRNGD (1132.5625 Da) 
Glu-C_12: PGIPGQPGSPGSPGPPGICE (1799.8512 Da) 
The reproducibility of these peptides will be decreased because of the effect of Pro, 
however, we investigated Glu-C_10 as a possible surrogate peptide for P-III-NP 
because it provides additional sequence information to previously selected peptides 
Tyr_1, Tyr_5 and Tyr_6. It is ideal to have at least two peptides from digestion for 
LC-MS analysis, hence, Glu-C_2 was also investigated. 
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2.4.2 MS-HRAMS of in silico derived peptides 
2.4.2.1 Trypsin in silico derived peptides 
The doubly- and triply-charged peptides ion for Tyr_1 were observed in full scan mode, 
with the triply charged ion being the most abundant. Using a normalised collision 
energy of 18 a product ion scan spectrum for the [M+3H]3+ ion (m/z 697.98 ±0.2 amu) 
was obtained (Figure 2-4 below). The most abundant peptide fragment in the product 
ion scan was the deamidated derivative of the precursor ion, [M-NH3+3H]3+. Under low 
energy MS/MS conditions, deamidated peptides can result from charge directed 
ammonia loss from the side chain of Gln, Glu, Arg or Lys residues. For Tyr_1,the 
presence of bz-NH3 series (especially b2-NH3) suggests the site of ammonia loss is the 
amino-terminus Gln. It can be argued that in-solution spontaneous pyroglutamation of 
Gln can also produce these fragments, however, full scan Tyr_1 spectrum show the 
deamidated [M+3H]3+ derivative is < 10 % of its unmodified precursor. 
For Tyr_5 all the precursor ions were observed in full scan, with the doubly-charged ion 
being the most abundant. Using a normalised collision energy of 18, a product ion scan 
of the [M+2H]2+ ion (510.57 ± 0.2 amu) was obtained (Figure 2-5 below). The most 
abundant peptide in the product scan was y92+, resulting from the cleavage of the 2D-3P 
amide bond, which is unusually labile at acidic pH [148]. The higher proton affinity of 
Pro to Asp, allows the y- fragment to retain the "mobile" proton to give the observed 
double charge. In source production of this peptide was investigated in full scan mode, 




Figure 2.4-2: Extracted ion chromatogram at m/z 697.9765 ±5 ppm and corresponding product 
scan spectrum of the fragmented carbamidomethylated Tyr_1 triply charged peptide using a 
normalised collision energy of 18. The most abundant b- and y-ions are annotated, where no 
charged is indicated the ions are singly-charged. 
 
A prominent y- series is observed for Tyr_5, resulting from proton sequestering at the 
carboxyl-terminus Arg. Cleavage of the Pro amide bonds appear to dictate the peptide 
fragments observed in the product ion scan spectrum (Figure 2-5) for Tyr_5, where 
y92+, y7+ and y3+ ions are the most abundant ions. This is to be expected, as Pro 
residues have been shown to have a bias for amino-terminal fragmentation due to the 
structural hindrance imposed on the aa for nucleophillic attack of the amino-terminal 
carbonyl [149]. 
Where a doubly-charged y- ion is observed, both the sequestered and "mobile" protons 
are retained by the truncated y-peptide ion. For singly-charged y- ions, the "mobile" 
proton is likely to be retained by the leaving b- ion. Low abundance of b- ions in the 
spectrum indicate instability of the ions formed which are further internally fragmented 




Figure 2.4-3: Extracted ion chromatogram at m/z 510.2671 ±5 ppm and corresponding product 
scan spectrum of the fragmented Tyr_5 doubly-charged peptide ion using a normalised collision 
energy of 18. The most abundant b- and y-ions are annotated, where no charged is indicated 
the ions are singly-charged. 
 
Figure 2.4-4: Extracted ion chromatogram at m/z 915.0744 ±5 ppm and corresponding product 
scan spectrum of the fragmented carbamidomethylated Tyr_6 triply charged peptide ionusing a 
normalised collision energy of 12. The most abundant b- and y-ions are annotated, where no 




For Tyr_6, the doubly- and triply-charged peptide ions were observed in full scan, with 
the triply charged ion being the most dominant. Using a normalised collision energy of 
12, a product scan spectrum of [M+3H]3+ (m/z 915.07 ± 0.2 amu) was obtained (Figure 
2-6 above), where the most abundant peptide fragment was b6+. Unlike the other two 
tryptic peptides, Tyr_6 does not have a terminal basic group, so it is not surprising that 
there is not a dominant y- series for this peptide. The b- ions seem to be more stable 
for this peptide, as they extend closer to the carboxyl-terminus thus providing greater 
peptide coverage (e.g. b21-NH3+). Like Tyr_5 fragmentation of Tyr_6 is biased to the 
amino-terminus of Pro residues (e.g. b6+, b9+, y14+ and y4+). It is not surprising to 
observe mostly singly-charged peptides in the product scan spectrum for Tyr_6 as 
there are not highly basic aa in the peptide sequence that can sequester the available 
protons. 
2.4.2.2 Glu-C in silico derived peptides 
 
Figure 2.4-5: Extracted ion chromatogram at m/z 626.2566 ±5 ppm and corresponding product 
scan spectrum of the fragmented carbamidomethylated Glu-C_2 doubly-charged peptide ion 
using a normalised collision energy of 22. The most abundant b- and y-ions are annotated, 




The doubly- and singly-charged peptide ions for Glu-C_2 were observed in full scan for 
which the doubly-charged ion was most dominant. Using a normalised collision energy 
of 22 a product scan spectrum of the [M+2H]2+ (m/z 626.26 ± 0.2 amu) was obtained 
(Figure 2-7 above). Unlike the tryptic peptides, a predominant b- series is observed 
with full peptide coverage. Lack of a carboxyl-terminus basic group accounts for the 
low representation of y- ions in the spectrum. There is a basic His residue incorporated 
in most of the fragments, suggesting a possible site for proton sequestering, especially 
where doubly-charged fragment ions are observed (b102+ and b92+). Instability of b9 and 
b10 ions is evident as additional internal fragmentation and loss of neutrals is observed 
in the spectrum with the presence of [b9-H20]+, a9, [b10-H20]+, a102+ and [a10-NH3]2+. 
 
Figure 2.4-6: Extracted ion chromatogram at m/z 948.7707 ±5 ppm and corresponding product 
scan spectrum of the fragmented carbamidomethylated Glu-C_10 triply charged peptide ion 
using a normalised collision energy of 29. The most abundant b- and y-ions are annotated, 
where no charged is indicated the ions are singly-charged. 
 
For Glu-C_10, the doubly- and triply-charged peptide ions were observed in full scan 
for which the triply charged ion was most dominant. Using a normalised collision 
energy of 29, a product ion scan of [M+3H]3+ (m/z 948.7707 ±0.2 amu) was obtained 
(Figure 2-8 above). A poor quality spectrum was obtained for this peptide, which 
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required a relatively high energy (compared to the other peptides) for fragmentation. 
Glu-C_10 contains two basic residues within its aa peptide sequence, which can 
sequester available protons to yield multiple charged peptide fragments. At m/z 
945.4936, 1098.5490 and 1178.5639 the more abundant isomers of y202+ (m/z 
984.997), y222+ (m/z 1097.5536) and y232+ (m/ 1177.5689) are displayed. 
2.4.2.3 Limit of detection  
Table 2-7: Tentative limit of detection for in silico derived P-III-NP peptides (10 µL, determined 




Tentative Limit of Detection 
(LOD)/nM 
Trypsin Tyr_1 7 
Tyr_5 7 
Tyr_10 7 
Glu-C Glu-C_2 7 
Glu-C_10 14 
 
As potential surrogate peptides for P-III-NP, determination of instrument sensitivity for 
each in silico derived peptide, by defining the limit of detection is necessary to 
determine the applicability for bioanalysis. Basal serum concentrations P-III-NP are 
1-5ng/mL (23-117 pM, 100 µL) [52]. Using the developed product ion scan methods 
and the LOD determined (Table 2-7) a minimum P-III-NP concentration of 300 ng/mL 
(Tyr_1, Tyr_5, Tyr_6 and Glu-C_2) and 600 ng/mL (Glu-C_10) can be analysed. 
Combined trypsin produces more sensitive peptides for LC-MS, hence we perform in 
vivo digestion on P-III-NP to verify the production of in silico derived peptides from 
bovine foetal material. Sharing 97 % sequence homology to human P-III-NP, the 
following aa substitutions (highlighted in red) were made for bovine (UniProt_TrEMBL 
entry Q08E14) methods: 
Tyr_1: QQEAVDGGCSHLGQSYADR 
Tyr_6: NGDPGPPGSPGSPGSPGPPGICESCPTGGQNYSP 
2.4.3 Partial characterisation of bovine P-III-NP by in vivo trypsin digestion 
Using the developed LC-MS product ion scans targeting Tyr_1 (bovine), Tyr_5 and 
Tyr_6 (bovine), the digest products of a trypsin bovine digest was analysed, for which 
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none of the peptides were found. Research into the possible P-III-NP post-translational 
aa modifications (PTM) that would alter the observed mass of the targeted peptides 
was undertaken. 
2.4.3.1 Bovine Tyr_1 peptide 
Deamidation of the exposed amino-terminus Gln to form an acidic pyroE (Q-NH3, 
Gln-NH3) derivative is possible; resulting in a -17.0265 Da shift in the mass of the target 
peptide. Being enzymatic and spontaneously driven, this modification is expected to be 
extensive or even complete for serum P-III-NP. Hence, it is not surprising to observe in 
the full scan MS data of the digest P-III-NP products doubly- and triply-charged ions 
corresponding to the pyroE_T1 (see Table 2-8 for reference values) peptide. Unlike 
Tyr_1, the doubly-charged peptide ion was the most abundant; this suggests that for 
Tyr_1 the amino-terminus Gln is an important protonation site. 
Using a normalised collision energy of 30 a product ion scan spectrum of the 
carbamido-methylated [M+2H]2+ PTM peptide (1030.94 ±0.2 amu) was obtained (see 
Figure 2-9 below). Evidence of Gln-NH3 is observed in the mass of the b- ions; which 
are identical to the b-NH3 ions for the in silico derived Tyr_1 peptide (Figure 2-4 above). 
Full peptide coverage for the PyroE_T1 peptide was observed with overlapping y- 
(83 %) and b- (70 %) ions (Table 2-9). The y7+ (GQSYADR) peptide fragment at 
m/z 796.3566 (theoretical m/z 796.3584) is the most prominent in the spectrum. The 
largest peptide fragment to be observed is b18+ (Q-NH3QEAVDGGCSHLGQSYA) at 
m/z 1886.7677 (theoretical m/z 1866.7610) and the smallest is b2+ (Q-NH3Q) at m/z 
240.0977 (theoretical m/z 240.0979). 
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Table 2-8: Bovine P-III-NP trypsin digestion products selected for MS analysis. The sequences shown are the modified in silico derived peptides and the expected 
products based on a priori knowledge of PTMs (highlighted in bold). For T1, deamidation of the amino-terminus Gln (Q) to Q-NH3 results loss of 17.0265 Da to the 
PTM peptide. For the T5 and T6 peptide, hydroxylation of Pro in the Gly-X-Pro results in the addition of 15.9949 Da for every P-OH residue. For the T6, deamidation 
of the susceptible Amino-terminal Asn (N)-Gly to Asp (D)-G results in further addition of 0.984 Da to the PTM peptide. The theoretical singly-, doubly- and triply-
charged ions (m/z) for each peptide is presented. 
Peptide Amino acid sequence 
Peptide ion (m/z values) 
[M+H]+ [M+2H]2+ [M+3H]3+ 
     
Tyr_1 
In silico 1QQEAVDGGCSHLGQSYADR19 2020.8777 1010.9425 674.2974 
Carbamidomethylated 1QQEAVDGGCSHLGQSYADR19 2077.8992 1039.4532 693.3046 
Carbamidomethylated 
PTM 1Q-NH3QEAVDGGCSHLGQSYADR19 2060.8727 1030.9400 687.6291 
      
Tyr_5 
In silico 86GDPGPPGIPGR96 1019.5269 510.2671 340.5138 
PTM 86GDP-OHGPP-OHGIP-OHGR96 1067.5116 534.2594 356.5087 
      
Tyr_6 
In silico 97NGDPGPPGSPGSPGSPGPPGICESCPTGGQNYSP130 3121.3262 1561.1667 1041.1136 








Figure 2.4-7: Extracted ion chromatogram at m/z 1030.9400 ±5 ppm and corresponding product ion spectrum of the fragmented post translational modified 
carbamidomethylated bovine pyroE_T1 doubly-charged peptide ion using a normalised collision energy of 30. The most abundant b- and y-ions are annotated, 
where no charged is indicated the ions are singly-charged (Refer to Table 2-9 below for theoretical m/z values). 
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Table 2-9: Possible b- and y-ions of in vivo tryptic bovine P-III-NP carbamidomethylated 
pyroE_T1 peptide, showing the fragment ions observed (in bold) from the extracted ion 
chromatogram shown in Figure 2-9 above and sequence coverage in green. 















- - 1 Q-NH3 19 - - 
240.0979 - 2 Q 18 1949.8406 975.4240 
369.1405 - 3 E 17 1821.7821 911.3947 
440.1776 - 4 A 16 1692.7395 846.8734 
539.2460 - 5 V 15 1621.7023 811.3548 
654.2729 - 6 D 14 1522.6339 761.8206 
711.2944 - 7 G 13 1407.6070 704.3071 
768.3159 - 8 G 12 1350.5855 675.7964 




11 1293.5641 647.2857 
1015.3786 - 10 S 10 1133.5334 567.2703 
1152.4375 576.7224 11 H 9 1046.5014 523.7543 
1265.5212 633.2644 12 L 8 909.4425 455.2249 
1322.5430 661.7751 13 G 7 796.3584 398.6828 
1450.6016 725.8044 14 Q 6 739.3369 370.1721 
1537.6336 769.3204 15 S 5 611.2784 306.1428 
1700.6969 850.8521 16 Y 4 524.2463 262.6268 
1771.7340 886.3707 17 A 3 361.1830 181.0951 
1886.7610 943.8841 18 D 2 290.1459 145.5766 
- - 19 R 1 175.1190 88.0631 
 
2.4.3.2 Tyr_5 peptide 
For Tyr_5 which originates from the collagen-like, Col 3, domain of P-III-NP, 
post-translational hydroxylation at the second P in the G-P-P repeat is expected; this 
will result in a +47.9847 Da shift in the mass of the target peptide. In full scan, the 
singly- and doubly-charged hydroxyP_T5 peptide ions were observed, for which the 
doubly-charged peptide was more abundant (see Table 2-8 for reference values). 
Using a normalised collision energy of 20, a product scan spectrum of the [M+2H]2+ 




Figure 2.4-8: Extracted ion chromatogram at m/z 534.2594 ±5 ppm and corresponding product ion spectrum of the fragmented bovine P-III-NP post translational 
modified hydroxyP_T5 doubly-charged peptide ion using a normalised collision energy of 20. The most abundant b- and y-ions are annotated, where no charged is 
indicated the ions are singly-charged (Refer to Table 2-9 below for theoretical m/z values). 
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The observed mass of y6+ (P+OHGIP+OHGR) at m/z 628.3407 (theoretical m/z 628.3413) 
and y7+ (PP+OHGIP+OHGR) at m/z 725.3934 (theoretical m/z 725.3941) support the 
stereo and site specificity of hydroxylation for which we observe a mass difference of 
97.0528 Da, which is equivalent to P. Full peptide coverage for hydroxyP_T5 was 
observed with 100 % y- ions and 80 % b- ions across the peptide sequence (Figure 
2-10). The fragmentation pattern is similar to that of Tyr_5 (Figure 2-5) where y92+ 
(P+OHGPP+OHGIHP+OHGR) at m/z 448.2350 (m/z 448.2352) is the most prominent in the 
spectrum, followed by y72+ (PP+OH GIP+OH GR) at m/z 363.2003 (theoretical 
m/z 363.2007). All other peptide fragment ions were much less abundant. 
Table 2-10: Possible b- and y-ions of in vivo tryptic bovine P-III-NP hydroxyP_T5 peptide, 
showing the fragment ions observed (in bold) from the extracted ion chromatogram shown in 
Figure 2-10 above and sequence coverage in green. 















- - 1 G 11 - - 
173.0557 - 2 D 10 1010.4901 505.7487 
286.1034 - 3 P+OH 9 895.4632 448.2352 
343.1248 - 4 G 8 782.4155 391.7114 
440.1776 - 5 P 7 725.3941 363.2007 
553.2253 - 6 P+OH 6 628.3413 314.6743 
610.2467 - 7 G 5 515.2936 258.1504 
723.3308 - 8 I 4 458.2722 229.6397 
836.3785 - 9 P+OH 3 345.1881 173.0977 
893.3999 - 10 G 2 232.1404 116.5738 
- - 11 R 1 175.1190 88.0631 
 
2.4.3.3 Bovine Tyr_6 peptide 
Among the trypsin peptides for P-III-NP; Tyr_6 is most susceptible to post translation 
modification. The first expected PTM is hydroxylation of Pro in the region of the peptide 
originating from Col 3, resulting in a +15.9949 Da mass shift for each modified P in the 
peptide. An additional -17.0265 Da mass shift for Tyr_6 can occur where spontaneous 
deamidation of the amino-terminus Asn to Asp is possible. With these modifications the 




Potential N-linked and O-linked glycosylation at 126Q-N-Y, 108S, 111S, 120S, 123T and129S 
have been identified within the peptide sequence for Tyr_6. However, lack of 
characterization of the oligosaccharide(s) and the number of occupied sites they 
occupy, makes it difficult to predict the adjusted peptide mass for Tyr_6. Cleaving these 
probable oligosaccharides from P-III-NP prior to trypsin digestion, would eliminate this 
unknown. However this step would complicate sample preparation procedures and 
increases peptide loss and is therefore not ideal. 
A very small amount of non-glycosylated triply charged PTM_T6 peptide was observed 
at m/z 1111.4458 (theoretical m/z 1111.4457) from a digest of concentrated bovine 
P-III-NP (~ 100 µg/mL, 100 µL). Using a normalised collision energy of 20, a product 
scan of 1111.45 ± 2 amu was generated, for which 12 % b- ions and 9 % y- ions were 
observed (refer to Table 2-11 for details). Besides obtaining a poor quality spectrum for 
this peptide, the insufficient yield and unknown ratio of glycosylated and 
nonglycosylated peptide complicate quantification. This meant that PTM_T6 was no 
longer considered as a surrogate peptide for developing LC-MS methods.  
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Table 2-11: Possible b and y ions of in vivo tryptic bovine P-III-NP deamidated + hypdroxyP_T6 
peptide, showing the fragment ions observed (in bold) from the extracted ion chromatogram, 
and sequence coverage in green. 
b- fragment y- fragment 
m/z 
[M+H]+ fragment no. 
amino acid 
sequence fragment no. 
m/z 
[M+H]+ 
- 1 N-NH3 →D 34 - 
173.0557 2 G 33 3217.2957 
288.0826 3 D 32 3160.2742 
401.1303 4 P+OH 31 3045.2473 
458.1518 5 G 30 2932.1996 
555.2045 6 P 29 2875.1781 
668.2522 7 P+OH 28 2778.1254 
725.2737 8 G 27 2665.0777 
812.3057 9 S 26 2608.0562 
925.3534 10 P+OH 25 2521.0242 
982.3748 11 G 24 2407.9765 
1069.4069 12 S 23 2350.9551 
1182.4546 13 P+OH 22 2263.9230 
1239.4760 14 G 21 2150.8754 
1326.5080 15 S 20 2093.8539 
1439.5557 16 P+OH 19 2006.8219 
1496.5772 17 G 18 1893.7742 
1593.6300 18 P 17 1836.7527 
1706.6776 19 P+OH 16 1739.7000 
1763.6991 20 G 15 1626.6523 
1876.7832 21 I 14 1569.6308 
2036.8138 22 C (+C2H3NO, +57 Da) 13 1456.5468 
2165.8564 23 E 12 1296.5161 
2252.8884 24 S 11 1167.4735 
2412.9191 25 C (+C2H3NO, +57 Da)) 10 1080.4415 
2509.9718 26 P 9 920.4108 
2611.0195 27 T 8 823.3581 
2668.0414 28 G 7 722.3104 
2725.0624 29 G 6 665.2889 
2853.1210 30 Q 5 608.2675 
2967.1639 31 N 4 480.2089 
3130.2273 32 Y 3 366.1660 
3217.2593 33 S 2 203.1026 




2.4.3.4 Human serum albumin 
As the most likely matrix to source P-III-NP for bio-analysis, possible interference from 
human serum albumin (HSA) for P-III-NP peptides was investigated. Analysis of a HSA 
control solution  using PTM product ion scan methods for pyroE_T1 and hydroxyP_T5 
was negative for the peptides. Hence we conclude that the tryptic peptides produced 
by HSA are different in mass from those generated from P-III-NP. 
2.4.3.5 Data dependent analysis 
Untargeted and pyroE_T1 targeted data-dependent spectrum for the bovine tryptic 
digest products returned negative results for P-III-NP when searched using Mascot 
against UniprotKB. It was later discovered that, unlike the human P-III-NP (UniProtKB 
entry E7ENY8), bovine P-III-NP(UniProt_TrEMBL entry Q08E14) is unreviewed and 
would not be included in the UniProt_SwissProt database that was applied to our data. 
As such, the data was reprocessed with the error tolerance tool enabled to allow for the 
expected aa substitutions between bovine and human variant; however, no significant 
score for P-III-NP was obtained. 
2.5 Summary 
Of the five endoproteases used to in silico digest P-III-NP (human, UniProtKB entry 
E7ENY8), trypsin produced more unique peptides suitable for mass spectrometry. In 
the absence of human P-III-NP international reference material, bovine P-III-NP 
(sharing 97 % sequence homology with man) was in vivo digested with trypsin prior to 
LC-MS analysis, to enable the verification of the in silico derived peptides. Initial 
analysis of digest products gave insufficient response for P-III-NP peptides, however 
with the consideration of potential PTM aa (and their effect on the expected peptide 
mass) modified variants of tryptic peptide, Tyr_1 (pyroE_T1) and Tyr_5 (hydoxyP_T5), 
were identified with 100 % sequence coverage. Hence, these peptides were targeted 
as surrogates of the P-III-NP peptides. They are the focus of Chapter 3, where they are 
used to assist in the development of highly sensitive LC-MS methods capable of 
identifying P-III-NP at basal serum levels.  
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Chapter 3 : Analysis of P-III-NP to target two authentic derived 
peptides 
3.1 Overview of the chapter 
In the previous chapter, peptides from digested P-III-NP, pyroE_T1 and hydroxyP_T5, 
were identified as being the most stable for the subsequent development of quantitative 
LC-MS methods. Here, synthesized variants (human (h) and bovine (b)) of these 
peptides were used to develop MS/MS methods to achieve LODs < 100 pM; thus 
sufficiently accommodating the analysis of hP-III-NP at basal serum concentrations 
(1-5 ng/mL, 25-125 pM). Matrix effects of serum albumin on P-III-NP peptide analysis 
are investigated to define the basic requirements of sample preparation. Use of 
immunoassay (Orion Diagnostica P-IIII-NP assay), as an independent check on 
P-III-NP concentration throughout sample preparation, was also assessed. 
3.2 Introduction 
In doping control, measurements of P-III-NP have relied on the use of radioactive 
immunoassays (RIA), RIA-gnost® (CisBio Bioassays) and UniQ® P-III-NP RIA (Orion 
Diagnostica) and the non-radioactive Advia Centaur® immunoassay platform (Siemens 
Healthcare Diagnostics Inc.) [59, 150]. In the absence of international reference 
material for human P-III-NP, these immunoassays use bovine P-III-NP (97 % sequence 
homology with human) as reference; thus, relying on the cross- reactivity of epitopes 
for human and bovine material. More recently an enzyme linked immunosorbent assay 
(ELISA) (CisBio Bioassays) has been developed, however, it is still to be evaluated by 
anti-doping laboratories. 
For each immunoassay, the antibodies and exact epitope location on P-III-NP are 
unknown. The antibody used in the RIA gnost® assay is based on bovine collagenase 
digested collagen and has highest affinity (or activity) for the Col 1 domain of P-III-NP. 
The UniQ® P-III-NP RIA shows activity for the intact 42 kDa protein and 
immunoreactive molecules with higher molecular weights (e.g. P-III-NP aggregates and 
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dimers, see Chapter 1 for relevant antigens) [59]. The Centaur P-III-NP assay uses two 
monoclonal antibodies that bind to two different sites on P-III-NP; however specificity 
for antigenic form of P-III-NP is unknown [150]. 
According to immunoassay measurements, circulating P-III-NP has basal serum 
concentrations between 1-5 ng/mL (25-125 pM) in normal adults [52, 58]. In the 
absence of international reference material for hP-III-NP, immunoassays utilise the 
cross reactivity of antibodies for bovine and human epitopes [59]. Hence, to develop 
LC-MS methods targeting human serum P-III-NP, good sensitivity is required to allow 
for analysis at these small endogenous levels. 
3.2.1 Mass spectrometry 
Target quantification of proteins by MS can be performed using any tandem MS set up, 
however, to achieve optimal sensitivity triple quadrupole instruments are often 
employed [97]. When used for quantitative analysis triple quadrupoles are operated in 
their selected reaction monitoring (SRM) mode. In SRM mode the precursor analyte as 
charged ions (e.g. [hT1+nH]n+, and [T5+nH]n+; where n is any integer except 0) is 
filtered in the first quadrupole mass analyser (Q1) prior to bombardment with an inert 
gas to fragment the ion in a collision cell (q). Fragment (product) ions are then selected 
in the third quadrupole mass analyser (Q3) for detection. Triple quadrupoles are 
capable of producing scan data, however, due to its mass filtering capabilities more 
sensitive (greater signal-to-noise, S/N) measurements are achieved in SRM mode. 
Quadrupoles are considered to be low resolution instruments, resulting from their 
limited unit m/z resolution; as such nominally isobaric background contaminants may 
be incorporated in the mass filter. To improve selectivity and specificity of MS methods 
multiple SRMs can be monitored for each analyte. 
Peptides (and proteins) need to be present as ions (i.e. possessing a charge) for 
acceleration and separation through the mass spectrometer hence they are detected 
as m/z ions. Post LC separation, the volatilisation of the accompanying eluent is 
necessary for the formation of gaseous ions for MS. To achieve this and preserve aa 
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sequencing information, “soft ionisation” techniques like MALDI (matrix assisted laser 
desorption ionisation) or ESI (electrospray ionisation) are most frequently applied in 
protein MS [97]. Normally MALDI produces singly-charged peptides (proteins) ions, 
unlike ESI, that often produces multiple charged ions that are easily compatible with 
the limited m/z range (< 2000 m/z) of triple quadrupole instruments. 
In ESI, analytes separated by LC, are ionised during the formation of charged droplets 
by spraying through a capillary, at high voltage (2-5 kV) with a strong electric field, 
which is interfaced with the MS. As these charged droplets move towards the MS inlet, 
the eluent is evaporated to leave droplets containing highly charged analyte ions [151]. 
To improve sensitivity, micro- and nano-flow LC-MS techniques, which have reduced 
flow rates (see Table 3-1 below), have been applied to protein MS analyses [152-154]. 
By using a narrower LC column with reduced flow rates a greater concentration of 
analyte (relative to solvent) is observed during separation. Also, at these lower flow 
rates the diameter of the ESI tip can be decreased to result in the formation of smaller 
droplets, containing less analytes (which reduces clustering) and solvent (leading to 
rapid desolvation) to improve ionisation efficiency and increase sensitivity. 
Table 3-1: Comparison of flow rates and column internal diameters for various HPLC 
techniques according to Waters Ltd. guidelines [155]. 
HPLC technique Typical flow rate Column i.d. 
Conventional 50 µL/min - 2 mL/min 1 mm – 2.1 mm 
Micro 10 – 100 µL/min 500 µm – 1 mm 
Capillary 3 – 10 µL/min 150 – 300 µm 
Nano 100 nL/min – 1 µL/min 75 – 100 µm 
 
3.2.1.1 Micro-flow LC-MS 
Miniaturisation of the LC system to facilitate micro flow rates (10-100 µL) has resulted 
in the improved sensitivity of many proteins (peptides) [152, 156, 157]. However, 
reducing the internal diameter (i.d.) of the LC column limits the sample injection 
volumes that can counterbalance the theoretically improved sensitivity. To avoid peak 
broadening and maintain the separation of micro-LC columns, sample volumes < 30 % 
of the column peak capacity should be injected [153], dead volume is also to be 
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minimised by reducing the size of connecting tubing and the diameter of the ESI needle 
[158]. 
3.2.1.2 Nano-flow LC-MS 
Further reduction in the sample injection volume is needed for direct injection onto 
nano-LC columns; for which this compromise does not facilitate an increase in 
sensitivity. To overcome this, nano-systems use a column switching mechanism, where 
the sample (typically 5 µL) is loaded onto a short wider i.d. "trapping column" 
(18 µm x 20 mm) at a relatively high flow rate (using a mobile phase composition that 
will retain the analyte) before loading the analyte by mass onto the analytical column 
(75 µm x 150 mm). See Figure 3-2 for systematic diagram of valve switching 
mechanism that dictates LC flow. Once injected onto the nano-analytical column, 
separation is achieved using nano-LC flow rates. The i.d. of the ESI emitter of the 
nano- is also reduced (typical range 5-30 µm), and is normally made of fused silica or 
metal. With these i.d.'s much smaller droplet ions are formed at the end of the emitter, 
hence, nano-emitters are conveniently placed closer to the inlet of the MS, allowing for 
an in-line rather than orthogonal connection, which maximises the detection of the 
vaporised analytes, as shown in Figure 3-1. 
 
Figure 3.2-1: Illustration showing droplet formation at the ESI tip used in conventional and nano-
electrospray MS. Difference in size and position of the nanospray emitter tip to the MS inlet, 
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Figure 3.2-2: Schematic of the sample injection, trapping and separation process used for nano-
flow LC-MS, showing the valve position used during column switching. During sample loading 
an injection flow is directed to the trapping column only. Post trapping, the flow is directed to the 
analytical column through the trapping column; where the analytes are transferred and 




3.3 Materials and Methods 
The source of materials where unmentioned can be found in section 2.3. Authentic 
human and bovine P-III-NP peptides, pyroE_hT1 (human, hT1), pyroE_bT1 (bovine, 
bT1) and hydroxyP_T5 (T5), were synthesized by Fisher Scientific (Offenbach, 
Germany). The aa sequence of each peptide (500 fmoles) was verified by LC-MS using 
the HRMS methods described in section 2.3.3.2.2. 
3.3.1 Mass spectrometry 
Similar to the development of HRMS methods (section 2.3.3.2.1), Substance P 
(371 nM) was used to define initial source parameters for analysing P-III-NP peptides 
on a Waters Xevo® TQ-S MS triple quadrupole system. A flow of 10 µL/min was used 
for conventional ESI methods whilst flow rates of 8 µL/min and 0.4 µL/min were used 
for micro and nano ESI respectively. Analysis was carried out in positive ion mode 
using N2 as the auxiliary gas. Source parameters were retained for conventional ESI 
methods, however, for micro- and nano-ESI further optimisation, with synthesized 
peptides (500 nM), at their respective flow rates was required to establish the 
parameters detailed in Table 3-2 below. 
Table 3-2: Tune file parameters for each ESI set up on a Waters Xevo® TQS MS 
Instrument Parameter Conventional- ESI Micro- ESI Nano- ESI 
Capillary (kV) 2.78 2.22 1.75 
Cone (V) 26.00 22.00 45.00 
Source Offset (V) 27.0 27.0 30.0 
Source Temperature (˚C) 150 150 83 
Desolvation Temperature (˚C) 350 350 - 
Cone Gas Flow (L/Hr) 150 145 - 
Desolvation Gas Flow (L/h) 700 600 - 
Collision Gas Flow (mL/min) 0.34 0.17 0.15 
Nebuliser Gas Flow (Bar) 7.00 7.00 7.00 
LM 1 Resolution 2.3 2.3 3.2 
HM 1 Resolution 13.7 13.7 11.4 
Ion energy 1 1.2 1.2 0.8 
LM 2 Resolution 2.8 2.8 2.8 
HM2 Resolution 14.9 14.9 14.9 
Ion energy 2 0.6 0.6 0.6 




3.3.1.1 Selected reaction monitoring 
For each peptide (~500 nM), a full scan spectrum was collected with each ESI source 
by LC-MS to select appropriate precursors for SRM experiments. Using the most 
abundant precursor for each peptide, collision energy (CE) profiles between 5 - 50 eV 
were established from product ion scan data to select the MS-MS transitions to monitor 
in SRM using conventional ESI for hT1 and T5 and nano-ESI for bT1, listed in Table 
3-3 below. 
Table 3-3: Collision energies for SRM (selected reaction monitoring) transitions acquired for P-










692 768 10 
1038 240 50 
1038 440 40 
bT1 
688 539 20 
688 761 25 
1031 440 45 
T5 
534 363 20 
534 448 13 
534 628 27 
 
3.3.2 Liquid chromatography 
On a Waters Acquity® UPLC® coupled to a Xevo® TQ-S, the simple LC gradient 
conditions described in section 2.3.3.1 were used to approximate %B (0.3 % formic 
acid in acetonitrile) required to elute hT1 (and bT1) and T5 from an Acquity® UPLC® 
BEH 130 Å (C18, 1.7 µm, 2.1 x 50 mm) column. Dead time was established using the 
elution of unretained acetone (10 µL). As a basic model this was used to develop 
conventional-, micro- and nano-flow LC methods to enable at least 12 points per peak 
for each MS-MS transition acquired in SRM; whilst minimising any ion suppression that 
could be contributed from matrix (especially tryptic digest products of HSA). 
3.3.2.1 Conventional LC 
Conventional-flow LC-MS was performed on a Waters Acquity® UPLC® coupled to a 
Waters Xevo® TQ-S MS interfaced with a conventional ESI ion source. Gradient LC 
separation of each sample (10 µL) was achieved using an Acquity® UPLC® BEH 130 Å 
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(C18, 1.7 µm, 2.1 x 100 mm) column at 40 °C, with mobile phase A, 0.3 % formic acid 
in water, and B, 0.3 % formic acid in acetonitrile and a flow rate of 300 µL/min. Mobile 
phase B was held at 5 % for 3 min before increasing to 20 % in 17 min, then to 90 % in 
1 min and held for a further minute. Mobile Phase B was then immediately returned to 
5 % and held for 3 min to re-equilibrate the column. 
3.3.2.2 Micro LC 
Micro-flow LC-MS was performed on a Waters nanoAcquity® UPLC® coupled to a 
Waters Xevo® TQ-S MS interfaced with a narrow gauge ESI needle (60 µm i.d.) on a 
conventional ion source. A low dead volume fused silica capillary (25 µm i.d.) was used 
from the outlet of the column to the inlet of the ESI needle. Gradient LC separation of 
each sample (1 µL) was achieved on an Acquity® M - Class BEH 130 Å (C18, 1.7 µm, 
300 µm x 150 mm) column with mobile phase A, 0.3 % formic acid in water, and B, 
0.3 % formic acid in acetonitrile and a flow rate of 8 µL/min. Mobile phase B was 
increased from 5 % to 60 % over 20 min, then to 90 % in 1.5 min and held for 30 sec, 
after which it was immediately returned to 5 % and held for 3 min to re-equilibrate the 
column. 
3.3.2.3 Nano LC 
Nano-flow LC-MS was performed on a Waters nanoAcquity® UPLC® coupled to a 
Waters Xevo® TQ-S MS interfaced with a nano-ESI emitter (30 µm i.d.) using the 
Waters nano-spray source. Gradient LC separation was achieved using mobile phase 
A, 0.3 % formic acid in water, and B, 0.3 % formic acid in acetonitrile. Samples (5 µL) 
were trapped on an Acquity® UPLC® Symmetry C18 nanoAcquity® 10K 2GV/M trapping 
column (100 Å, 5 µm, 180 µm x 20 mm) for 5 min at flow 10 µL/min with 1 % mobile 
phase B. The trapped analytes were then loaded onto an Acquity® UPLC® M-Class 
Peptide BEH C18 column (130 Å, 1.7 µm, 75 µm x 150 mm) and separated by gradient 
elution. With a flow rate of 0.4 µL/min, mobile phase B was held at 5 % for 5 min, then 
increased to 9 % for 25 min and then 95 % for 2 min and held for 1 min. Mobile Phase 
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B was then immediately returned to 5 % and held for 27 min to re-equilibrate the 
column. 
3.3.3 Limit of detection and carryover 
Using pure peptides for hT1 and T5, peptide standards (500 nM) were prepared as 
described in section 2.3.2.1. In parallel, dilution standards (5, 10, 20, 50, 100, 200, 500, 
1,000 pM) were prepared from a sub-stock (1,000 pM) in mobile phase (0.3 % formic 
acid, 5 % acetonitrile in water) and analysed using the developed conventional-, micro- 
and nano- LC-MS methods in increasing concentration order (i.e. 5 pM to 10,000 pM). 
LOD was established where the S/N of the peptide was < 3:1. Mobile phase was 
injected before and after each injection in order to establish LOD of the peptides and 
assess carryover associated with LC method. 
3.3.4 Effect of matrix on P-III-NP LC-MS analysis 
Bovine P-III-NP 100 µg/mL (100 µL) and 10 µg/mL (100 µL) were separately spiked 
into a sample of HSA (100 mg/mL, 100 µL) and digested with trypsin (10 µg) using the 
protocol described in section 2.3.4. Once digested, samples were analysed by 
conventional LC-MS. 
3.3.4.1 HSA cut-off for P-III-NP peptide LC-MS analysis 
Duplicate HSA standards (0.1, 0.5, 1, 5, 10, 25, 50, and 100 µg) were digested with 
trypsin (2 µg) using the protocol described in section 2.3.4. One of each standard was 
reconstituted in formic acid (0.3 %) and acetonitrile (5 %) solution (50 µL) containing 
either P-III-NP hT1 and T5 peptides at 100 pM or at 500 pM; before transferring to an 
autosampler vial. The samples containing 500 pM hT1 and T5 were analysed by 
conventional-flow LC-MS whilst those containing 100 pM hT1 and T5 were analysed by 




3.3.5 Concentration of P-III-NP and synthesised peptides - Immunoassay 
The concentration of intact P-III-NP (~50 ng/mL) and equivalent concentrations of 
desalted P-III-NP fragments (single stranded monomeric P-III-NP, 
carbamidomethylated hT1 (and bT1) and T5) was measured using the Orion UniQ 
PIIINP radioactive immunoassay kit (Orion Diagnostica, Espoo, Finland) as follows. 
Whilst reagents, calibrators (0- 50 ng/mL), control (human serum) and samples were 
brought to room temperature (18-25 ˚C), test tubes were labelled for non-specific 
binding (NSB), calibrators, control, and samples. In duplicate, calibrators (200 µL), 
samples (100 µL) control (100 µL), and NSB (100 µL of any sample) were pipetted into 
appropriate tubes. To make up the volume of the sample, control and NSB tubes, HSA 
(0.1 %, 100 µL) was added. Tracer (200 µL) was added to all tubes. Antiserum 
(200 µL) was added to all tubes except the NSB, to which distilled water (200 µL) was 
added. All tubes were vortexed then covered with paraffin film and incubated for 2 h at 
37 ˚C. After mixing thoroughly by gently inverting, procollagen separation reagent 
(500 µL) was added to all tubes before vortexing and incubating for 30 min at room 
temperature. Tubes were centrifuged (2000 g) for 15 min at 4 °C before carefully 
decanting the supernatant (except the totals) by simultaneous inversion taking care not 
to disturb the precipitate. Using a gamma counter each tube was counted for at least 
1 min or until 10,000 counts/tube was accumulated. Using the mean count of 
calibrators, samples and controls the %B/B0 was calculated using Equation 3-1. On 
semi-log graph paper with %B/B0 values on the ordinate and P-III-NP concentration on 
the abscissa a calibration curve was drawn, from which the P-III-NP concentrations of 
samples and controls were determined. 
Equation 3-1:Calculation of %B/B0 for Orion P-III-NP RIA % 𝐵𝐵
𝐵𝐵0 = 𝑐𝑐𝑎𝑎𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑎𝑎𝑐𝑐𝑐𝑐𝑐𝑐 𝑐𝑐𝑐𝑐 𝑠𝑠𝑎𝑎𝑠𝑠𝑠𝑠𝑐𝑐𝑎𝑎 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 − 𝑁𝑁𝑁𝑁𝐵𝐵𝑐𝑐𝑎𝑎𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑎𝑎𝑐𝑐𝑐𝑐𝑐𝑐 0 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 − 𝑁𝑁𝑁𝑁𝐵𝐵 × 100 
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3.4 Results and Discussion 
3.4.1 LC- MS optimisation 
3.4.1.1 LC gradient 
 
Figure 3.4-1: Gradient elution of P-III-NP pyroE_T1 (T1) and hydroxyP_T5 (T5) peptides using 
simple LC conditions (described in section 2.3.3.1) on an Acquity® BEH C-18 column at 40 ˚C. 
The elution mobile phase composition (as % B, acetonitrile) of each peptide is shown. 
It is expected that T5, the less hydrophobic peptide would elute first during LC 
separation on a reversed phase column. Having only one hydrophobic aa (I-8) and 
several hydroxylated prolines (P-3, 6 and 9) resulting from PTM, T5 has limited 
interaction with the non-polar C-18 stationary phase of the column. Originating from the 
globular Col1 domain of P-III-NP, T1 contains more hydrophobic aa (A-4, V-5, L-12 and 
Y-16), thus increased column interaction is expected (and is observed) by this peptide. 
Despite a 5 % eluent composition difference between the P-III-NP peptides, using the 
simple LC conditions described in section2.3.3.1, the observed retention times of these 
peptides are similar (T5- 4 min and T1- 4.3 min). Thus, to maximise separation (and 
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within the peptide eluting region (% B 8 →12) is decreased in the developed LC-MS 
methods. 
For conventional-flow LC increasing the concentration of mobile phase B at a rate of 
0.88 % per min (flow 300 µL/min) will obtain a tR difference of 5 min between T5 and T1 
peptides. Optimal tR difference (~15 min) between peptides was achieved with 
nano-flow LC, where the concentration of mobile phase B was increased at a rate of 
0.16 % and then 44 % per min (flow 0.4 µL/min) in the peptide eluting region. For 
micro-LC, however, although utilising a nano-LC pump capable of very low flow rates, a 
relatively fast flow (8 µL/min) and gradient increase for mobile phase B (2.75 % per 
min) was used to improve the peak shape of T1. Thus a tR difference of only 1.2 min 
was observed between peptides for the micro-LC method. For all developed LC 
methods, baseline resolution of T5 and T1 was achieved. 
3.4.1.2 SRM - collision energies 
3.4.1.2.1 HydroxyP_T5 peptide (GDP+OHGPP+OHGIP+OHR) 
In full scan, the dominant T5 precursor, [M+2H]2+ (m/z 534) was observed. With 
application of argon and various collision energies, fragmentation of the peptide was 
achieved to produce sufficient diagnostic transitions for SRM methods (see Figure 3-4 
below). Within the CE profile the y92+ peptide (m/z 448) is the most abundant. This 
peptide is generated at a relatively low CE, (optimal 13 eV) as a result of the fragility of 
the 2D-3P+OH bond at the cleavage point within T5. Further increase in CE results in the 
reduction of this peptide, which is truncated through secondary fragmentation to 
produce smaller peptide fragments y72+ (m/z 363) and y6 (m/z 628). Typical to the 
product scan pattern, generated by MS-HRAMS (Chapter 2), the dominant peptide 
fragments terminate with a P (or P+OH) residue. These data suggest that the natural 
twist of P influences the MS peptide fragmentation pattern. It is interesting to note that 
peptide fragments (y92+ and y72+), which contain the 5P-6P+OH bond, retains both of the 
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available protons. At CE 27 eV, significant loss of peptide fragments was observed, 
thus further fragmentation was not investigated. 
 
Figure 3.4-2: Collision energy profile (10-27 eV) for P-III-NP T5 peptide (500 pM) obtained from 




Figure 3.4-3: Collision energy profile (10-50 eV) for P-III-NP hT1 peptide (500 pM) obtained 






















































Figure 3.4-4: Collision energy profile (10-30 eV) for P-III-NP hT1 peptide (500 pM) obtained 
from product scan spectra of [M+3H]3+ precursor (m/z 692 ±1 amu) using conventional ESI-MS 
conditions. 
 
3.4.1.2.2 PyroE_hT1 (Q-NH3QEAVEGGCSHLGQSYADR) 
For hT1, peptide fragments generated from the [M+2H]2+ (m/z 1038, Figure 3-5) and 
[M+3H]3+ (m/z 692, Figure 3-6) precursors were investigated. Fragmentation of the 
[M+2H]2+ precursor requires significantly higher collision energies (≥ 35 eV), when 
compared to T5. As a result, smaller less diagnostic peptide fragments were observed 
in the CE profile shown in Figure 3-5 above (e.g. y1+ (m/z 175), b2+ (m/z 240), b3+ 
(m/z 369) and b4+ (m/z 440)). For the [M+3H]3+ precursor, however, the presence of an 
additional "mobile proton" results in a decrease in the CE necessary for fragmentation, 
with complete fragmentation occurring when a CE ≥ 30 eV is applied. Similar to the 
[M+2H]2+ precursor, small peptides are generated, however, diagnostic peptide 
fragments y142+ (m/z 768) and y132+ (m/z 704) are also observed. Although significantly 
lower in abundance than the smaller peptide fragments generated by [M+2H]2+ 
precursor (m/z 1038), the [M+3H]3+ (m/z 692)→ y142+ (m/z 768) transition, is monitored 

























Figure 3.4-5: Collision energy profile (10-50 eV) for P-III-NP bT1 peptide (500 pM) obtained 
from product scan spectra of [M+2H]2+ (m/z 1031 ±1 amu) using nano ESI-MS conditions. 
 
 
Figure 3.4-6: Collision energy profile (10-30 eV) for P-III-NP bT1 peptide (500 pM) obtained 


















































m/z 688 m/z 761 m/z 539 m/z 440 m/z 608 m/z 704 m/z 240
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3.4.1.2.3 PyroE_bT1 (Q-NH3QEAVDGGCSHLGQSYADR) 
Similar to the CE profile produced by the [M+2H]2+ hT1 precursor, the bovine [M+2H]2+ 
peptide (bT1, m/z 1031, Figure 3-7) requires a high CE for fragmentation. Diagnostic 
ions y7+ (m/z 796) and y132+ (m/z 704) are observed in the peptide profile along with the 
less diagnostic y1+ (m/z 175), b2+ (m/z 240), b3+ (m/z 369) and b4+ (m/z 440) ions. The 
appearance of these ions may be attributed to the increased sensitivity provided by the 
nano-ESI source used to generate this profile, unlike the conventional-ESI used for the 
hT1 and T5 peptides. However, the abundance of the peptides produced by [M+2H]2+ 
(m/z 1031)→ y7+ (m/z 704) and [M+2H]2+ (m/z 1031)→ y132+ (m/z 704) is significantly 
lower than that generated from the [M+3H]3+ precursor (m/z 688), hence these 
transitions were excluded from SRM methods. For the [M+3H]3+ precursor, like hT1, 
peptide fragments are generated at lower CE with complete fragmentation occurring at 
CE ≥ 30 eV, with significant loss in abundance of the more diagnostic peptide 
fragments at CE 25 eV. 
3.4.2 Limit of detection, carryover and linearity 
In Chapter 2, the sensitivity achieved from LC-MS/HRMS methods for P-III-NP 
peptides was insufficient for analysis of serum P-III-NP at endogenous levels. To 
increase sensitivity, methods have been developed on a highly sensitive Waters Xevo® 
TQ-S triple quadrupole mass spectrometer utilising its mass filtering capabilities in 
selected reaction monitoring mode. Three ESI set-ups have been investigated on this 
instrument and are compared here. For conventional- and nano-flow LC methods, the 
injection volume (10 and 5 µL, respectively) was assigned based on the capacity of the 
sample loop on the system. For micro-flow LC, however, volumes ≥ 2 µL resulted in 
volume overload, so, an injection volume of 1 µL was selected for this method. For 
each peptide LOD was assigned at the lowest standard where all monitored SRMs had 
a signal to noise ratio > 3:1. For some set-ups (e.g. nano-flow LC-MS, see Figure 3-9 
below), almost complete elimination of noise was achieved; hence, LODs were 
determined at the limit of the mass signal detected by the MS. 
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3.4.2.1 PyroE_hT1 (Q-NH3QEAVEGGCSHLGQSYADR) 
For conventional-, micro- and nano-flow LC-MS the approximate LOD for hT1 was 
determined to be 100 pM (10 µL, 1 fmole), 100 pM (1µL, 100 amoles) and 5 pM (5 µL, 
25 amoles), respectively (see Figure 3-9). These LODs were obtained in the absence 
of matrix peptides, hence they represent instrumental LODs. The observed 
improvement in sensitivity for peptides is associated with decreased flow of the LC 
(and essentially the decrease in the volume of solvent accompanying the analyte), 
which improves ionization efficiency of the ESI. Despite the LOD (mass) of micro-flow 
LC-MS, the linearity of standards in producing a calibration line is very poor (R2 < 0.9) 
when compared with that obtained by conventional- and nano-flow methods for the 
same standards. For conventional- and micro-flow LC-MS methods, the area (and 
height) counts observed for hT1 are low (even at 1000 pM), further highlighting the 
inefficiency of ionisation of this peptide. Despite this, unlike the LOD achieved by 
LC-MS/HRMS (7 nM, see section 2.4.2.3), the established conventional-, micro- and 
nano-flow LODs are suitable for analysis of hT1 originating from serum P-III-NP at its 
highest expected basal level (5 ng/mL, 125 pM); with nano-flow LC-MS capable of 
analysis at the lower limit (1 ng/mL, 25 pM). 
Considering that hT1 and T5 peptides were analysed together using parallel dilution 
from the same sub-stock solution (1 nM hT1 and T5), the linearity of hT1 (R2 between 
0.873-0.992) was noticeably less than that achieved for T5 (R2 between 0.991-0.999, 
see section 3.4.2.2 below). It could be argued that the observed variance is due to a 
lack of homogeneity of hT1 in the stock, originating from the presence of oxidised and 
reduced forms of the hT1 due to incomplete carbamidomethylation during 
derivatisation. To investigate this, the carbamidomethylated hT1 stock (500 nM, 2 µL) 
was analysed by LC-MS/HRMS (see section 2.3.3 for details). A very small amount of 
reduced hT1 (0.24 % of carbamidomethylated hT1) at m/z 1009.4373 (± 5 ppm) was 
observed (see Figure 3-13). No oxidised hT1 (m/z 1008.9331) was observed, however, 
this could be due to the limited sensitivity of the Orbitrap instrument compared with the 
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triple quadrupole. Regardless, at these negligible concentrations, the presence of 
reduced and oxidised hT1 should not affect the linearity of the peptide. 
Carryover was not observed for the hT1 peptide, by any of the developed LC-MS 
methods. Hence, this could not affect the observed linearity. To improve the linearity, 
normalisation of the data with the addition of an internal heavy-labelled 





Figure 3.4-7: Chromatogram of P-III-NP peptides (hT1 and T5) near their LODs for conventional-, micro- and nano-flow LC-MS using optimised SRM methods. 
T5_100 pM








Figure 3.4-8: Linearity of synthesised P-III-NP hT1 peptide standards analysed by conventional-
flow LC-MS using absolute peak area and height. 
 
 
Figure 3.4-9: Linearity of synthesised P-III-NP hT1 peptide standards analysed by micro-flow 






























































Concentration of T1 (pM)
Concentration of
T1 (pM)
Peak area (conventional-flow LC-MS) Peak height (conventional-flow LC-MS)
m/z 1038 -> 440 m/z 1038 -> 240 m/z 692 -> 768 m/z 1038 -> 440 m/z 1038 -> 240 m/z 692 -> 768
100 6 11 9 25 40 36
200 7 20 6 31 77 27
500 74 96 90 303 389 388




















































Concentration of T1 (pM)
Concentration of
T1 (pM)
Peak area micro-flow LC-MS) Peak height (micro-flow LC-MS)
m/z 1038 -> 440 m/z 1038 -> 240 m/z 692 -> 768 m/z 1038 -> 440 m/z 1038 -> 240 m/z 692 -> 768
100 17 120 212 64 267 591
200 64 103 275 219 103 884
500 141 392 1684 466 875 5079




Figure 3.4-10: Linearity of synthesised P-III-NP hT1 peptide standards analysed by nano-flow 
LC-MS using absolute peak area and height. 
 
 
Figure 3.4-11: Extracted ion chromatogram at m/z 1009.4373 ±5 ppm (reduced hT1 [M+2H]2+ 
peptide) and m/z 1037.9478 ± 5ppm (carbamidomethylated hT1 [M+2H]2+ peptide) and 




Peak area (nano-flow LC-MS) Peak height (nano-flow LC-MS)
m/z 1038 -> 440 m/z 1038 -> 240 m/z 692 -> 768 m/z 1038 -> 440 m/z 1038 -> 240 m/z 692 -> 768
5 45 69 32 106 198 109
10 85 223 78 217 430 162
20 351 696 263 651 1411 677
50 1012 2144 1200 2004 4172 2353
100 2923 5627 3114 5567 10542 5971
200 6047 11682 6523 10934 20387 11457
500 20099 38783 23871 32305 61559 38583























































Concentration of T1 (pM)
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3.4.2.2 HydroxyP_T5 (GDP+OHGPP+OHGIP+OHR) 
For conventional-, micro- and nano-flow LC-MS the approximate instrumental LOD for 
T5 was 100 pM (10 µL, 1 fmole), 20 pM (1 µL, 20 amoles) and 5 pM (25 amoles), 
respectively (see Figure 3-9). Like hT1, with decreased flow a significant improvement 
in LOD was observed from conventional- to micro-flow methods. However, the LODs 
observed for nano- and micro-flow suggests that 20 amoles is the true detection limit 
for T5 on the Xevo® TQ-S triple quadrupole instrument. This suggests that optimum 
droplet size is achieved with micro-ESI using the narrow gauge needle (i.d. 60 µm). 
Despite the absence of an "internal standard" to normalise the data set, good linearity 
of the T5 standards was achieved. Compared to hT1, significantly greater sensitivity is 
observed for the T5 peptide, hence, this should be the preferred peptide for P-III-NP 
quantification. With the established LODs, serum P-III-NP at basal levels is possible, 
especially when micro- and nano-flow methods are used. Negligible carryover 
(< 0.005 %) is observed for T5 peptide (1000  pM) by nano-LC-MS. 
 
Figure 3.4-12: Linearity of synthesised P-III-NP T5 peptide standards analysed by conventional-

























































Concentration of T5 (pM)
Concentration of
T5 (pM)
Peak area (conventional-flow LC-MS) Peak height (conventional flow LC-MS)
m/z 534 -> 628 m/z 534 -> 448 m/z 534 -> 363 m/z 534 -> 628 m/z 534 -> 448 m/z 534 -> 363
100 36 253 150 124 703 525
200 88 512 391 305 1771 1315
500 190 1108 911 641 3518 3100




Figure 3.4-13: Linearity of synthesised P-III-NP T5 peptide standards analysed by micro-flow 
LC-MS using absolute peak area and height. 
 
 
Figure 3.4-14: Linearity of synthesised P-III-NP T5 peptide standards analysed by nano-flow 




















































Concentration of T5 (pM)
Concentration of
T5 (pM)
Peak area (micro-flow LC-MS) Peak height (micro-flow LC-MS)
m/z 534 -> 628 m/z 534 -> 448 m/z 534 -> 363 m/z 534 -> 628 m/z 534 -> 448 m/z 534 -> 363
20 86 688 394 249 2007 1384
50 128 1142 818 509 3703 2776
100 254 1729 1367 952 6154 5059
200 569 3989 3580 2030 11838 9605
500 1636 10765 8426 5883 37560 30148



























































Concentration of T5 (pM)
Concentration of
T5 (pM)
Peak area (nano-flow LC-MS) Peak height (nano-flow LC-MS)
m/z 534 -> 628 m/z 534 -> 448 m/z 534 -> 363 m/z 534 -> 628 m/z 534 -> 448 m/z 534 -> 363
5 539 2948 2690 1307 6900 6165
10 1093 6126 5540 2815 15524 13601
20 2792 15527 13819 6794 38912 34251
50 4604 25541 22746 4604 63863 56810
100 11436 63814 56589 28735 158157 142217
200 18671 111934 100152 46345 276534 246594
500 49826 289830 262599 125041 726076 662545
1000 103726 584880 524313 270923 1525148 1358857
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3.4.3 Effect of matrix on P-III-NP LC-MS analysis 
Despite the sensitivity of the conventional-flow LC-MS method, P-III-NP peptides 
originating from trypsin digested bovine P-III-NP (~100 µg/mL, 2.5 µM) in HSA 
(50 mg/mL, 757 µM) was not observed using conventional LC-MS methods. For the 
bT1 peptide, limited DTT and IDA may affect observance of peptide, however these 
reagents do not affect the yield of T5. A high concentration of trypsin (10 µg) was used 
to facilitate the digestion of P-III-NP and HSA, which were both present at relatively 
high concentrations. Thus, based on this observation, serum P-III-NP will need to be 
separated from albumin (and possibly other serum proteins) prior to trypsin digestion to 
enable LC-MS analysis. 
In serum, trypsin is not selective to digesting P-III-NP, hence, the LC-MS tolerance of 
P-III-NP peptides for HSA (the most abundant serum protein, basal conc. 
35-50 mg/mL) tryptic peptides was investigated. At the HSA peptide concentrations 
(0.1-100 µg) injected, P-III-NP peptides (100 pM) were not observed using 
conventional-flow LC-MS methods. For the samples analysed by nano-flow LC-MS, 
peptides (100 pM) were observed in 0.1 -1 µg HSA (2-20 µg/mL, 30-300 nM) peptide 
matrix (see Figure 3-17). Increasing the matrix concentration ≥ 5 µg/50 mL (100 µg/mL, 
1.5 µM) resulted in complete suppression of P-III-NP peptides in the MS. Hence, to 
analyse T5 and T1peptides originating from serum P-III-NP by the developed LC-MS 
methods, an HSA depletion efficiency > 99.6 % is necessary. 
3.4.4 Activity of immunoassay for P-III-NP peptides and protein 
Using the Orion P-III-NP assay, activity for intact bovine P-III-NP sample (~50 ng/mL) 
was 3 ng/mL against the standard curve. This is low, albeit not unexpected, as the 
P-III-NP in the original sample may have degraded due to age and storage conditions. 
For the monomeric single stranded protein and tryptic peptides (hT1, bT1 and T5) no 
activity was observed. These results would indicate that the P-III-NP antibody 
contained within the kit is specific for the trimeric intact protein. Hence, this assay 
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cannot be used as an independent quality control check for P-III-NP concentration 
throughout sample preparation for LC-MS. 
 
Figure 3.4-15:Extracted ion chromatograms of P-III-NP peptides (hT1 and T5, 100 pM) in HSA 
trypsin peptides in a) 1 µg/50 µL (300 nM) and b) 10µg/ 50 µL (3 µM) analysed by nano-flow 
LC-MS. The elution region of hT1 and T5 peptides are highlighted. 
 
3.5 Summary 
Sensitive methods capable of analysing P-III-NP at basal serum levels (1- 5 ng/mL, 
25-125 pM) have been developed using conventional-, micro- and nano-flow LC-MS 
set-ups on a highly sensitive triple quadrupole MS. However the presence of albumin 
(and other serum proteins) limit the capabilities of these methods. At concentrations 
> 20 µg/mL (300 nM) HSA, tryptic peptides completely suppress the signal of P-III-NP 
hT1
T5
b) hT1 and T5(100 pM) in 10 µg/ 50 mL HSA
a) hT1 and T5(100 pM) in 1 µg/ 50 mL HSA
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hT1 and T5 peptides (100 pM) in the MS. To overcome this P-III-NP needs to be 
separated from other serum proteins (especially albumin) prior to trypsin digestion, so 
as to enable LC-MS analysis. The antibody specificity of the Orion Diagnostica P-III-NP 
kit for intact P-III-NP limits the use of the assay as an independent concentration check 
for P-III-NP during sample preparation for LC-MS. In Chapter 4 methods to separate 
P-III-NP from HSA are investigated, so as to develop an appropriate sample 




Chapter 4 : Sample preparation and effect of carrier proteins 
4.1 Overview 
In the previous chapter we highlighted the need to separate HSA (and other serum 
proteins) from P-III-NP in blood prior to trypsin digestion so as to analyse by LC-MS. 
Similarity in size, but vast difference in concentration of P-III-NP (42 kDa, 1-5 ng/mL) 
and HSA (66 kDa, 35-50 mg/mL) make separation difficult. Here the potential of 
common proteomic separation techniques (i.e. protein precipitation, molecular weight 
cut-off filtration, and immunocapture) are assessed for separating P-III-NP from serum 
proteins. The efficiency of HSA removal and P-III-NP recovery of these approaches 
have also been determined. 
4.2 Introduction 
Circulating intact P-III-NP related to GH administration is obtained from blood. The 
incomplete definition of the blood proteome results from its abundance in albumin 
(55 %), wide dynamic range in protein concentrations (in the region of 10-12 orders, 
g/L- pg/L) and the presence of glycoproteins [159]. The complexity and dynamic range 
of proteins presented in this matrix complicates MS detection; and current MS 
instruments cannot analyse over this range without pre-fractionation of the sample 
[160]. As a result of the presence of albumin (see Figure 4-1), significant MS 
interference has been observed in the analyses of low abundant proteins like P-III-NP 
from serum [161-164]. Hence, for our purpose, the separation of HSA from P-III-NP is 
the primary aim of sample preparation. To achieve this and to simplify the serum 




Figure 4.2-1: Illustrative iceberg model to show the dynamic range of plasma proteins in serum 
where the concentrations of the classes of proteins shown are summarised from [159]. HSA and 
GH biomaker proteins, IGF-I and P-III-NP, are highlighted to demonstrate their basal 
concentration range against the human blood proteome. 
 
4.2.1 Disulphide bonds 
In Chapter 2 some of the structural properties of P-III-NP are discussed. Here the 
tropocollagen or "collagen-like" nature of the protein is further discussed, with specific 
focus on the disulphide bonds, to investigate whether this function can be used to 
achieve a mass separation from albumin that would potentially enable the physical 
separation of the two proteins in serum. Disulphide covalent bonds are chemical bonds 
that occur between two sulfhydryl or thiol groups. In proteins these bonds occur 
between cysteine residues, which have a thiol group on its side chain that is easily 
oxidised to form a sulfhydryl (-S-S-) bridge, shown in Figure 4-2 below. The formation 
of disulphide bonds between the correct pairs of cysteine residues is essential for the 
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Figure 4.2-2: Disulphide bond formation due to the oxidation of two cysteine residues to for a 
cystine residue. 
 
4.2.1.1 P-III-NP disulphide bonds 
In the Col 1 domain of P-III-NP, five intra-chain disulphide bridges on each of the pro 
α1-chains give a globular structure to this region making it hydrophilic [129]. In this 
conformation, the hydrophobic amino acid residues are folded into the protein exposing 
the more polar residues outward where they can have dipole-dipole solvent 
interactions, thus attributing solubility to the protein. Whilst in the Col 2 domain six 
inter-chain disulphide bonds between the three pro α1-chains exist. These bonds act 
as a nucleus for the left-handed twisting of the collagen-like region in the Col 3 domain 
[166] and stabilises the protein structure. 
 
Figure 4.2-3: Schematic illustration of the trimeric P-III-NP protein. Disulphide bonds that 
connect the three identical pro α-1 chains in the Col1 and Col2 domain are shown using a ball 
and stick, two are highlighted with blue circles. (Image adapted with permission from [70]). 
 
These disulphide bonds can be reduced in P-III-NP with the application of heat 
(> 55 °C) which denatures the protein; however, upon cooling the protein to 
approximately 20 °C, complete renaturation is seen to occur if these inter-chain 
disulphide bonds are not subsequently blocked [66]. With reduction and blocking of the 



























of the protein is permanently destroyed to generate three identical partial pro-collagen 
α1 (III) chains, each consisting of 130 aa with a ~14 kDa MW. 
 
Figure 4.2-4: Reduction of a cystine disulphide bond with dithiothreitol (DTT) following the 
blocking of sulfhydryl group by alkylating with iodoacetamide (IDA) to form a carbamidomethyl 
cysteine IDA derivative. 
 
4.2.1.2 Albumin disulphide bonds 
HSA is a 585 aa protein with an α-helix heart structure divided into three homologous 
domains, shown in Figure 4-5 below. Containing thirty-five cysteine residues, 
seventeen disulphide bonds exist in HSA to leave a free C residue. This free thiol 
(C-34) can potentially form inter-molecular disulphide bridges with other HSA 
molecules or thiol-containing substances in plasma. However, due to steric hindrance 
affecting the accessibility of C-34, the majority of serum HSA in vivo remains as 
HSA-SH [167]. 
Of the 17 disulphide bonds in HSA formed by the other 34 cysteine residues, 16 are 
"double S-S bonds" in that they exist between residues located beside each other 
within the molecule. Reduction and alkylation of HSA results in the unfolding of the 
protein's tertiary structure to leave most of the secondary structure intact except for a 

















































considering that all disulphide bonds are intra-molecular, the MW of HSA remains 
> 66 kDa after reduction. 
 
Figure 4.2-5: Schematic of HSA showing its three homologous domains (I, II and III). Disuphide 
bonds (e.g. highlighted with purple box)between cysteine residues (yellow). A single cysteine 
group (C-34) that remains free or does not form a disuphide bond is highlighted by the green 
circle. (Figure reprinted with permission from [168]). 
 
4.2.2 Depletion methods 
High abundant proteins (e.g. albumin and IgG) account for 90 % of the total protein 
count in serum [159]. With the achievable differences obtained in the MW and 
isoelectric point (pI) of HSA and P-III-NP (after disruption of their tertiary structure) 
investigation into the application of classical proteomic depletion approaches to reduce 
the complexity of the serum are considered. These include organic solvent protein 
precipitation (ppt) [57, 169], ultrafiltration [91, 162], albumin immunodepletion (or 
affinity capture) [161, 170, 171]. 
4.2.2.1 Protein precipitation 
Precipitation of proteins in solution results from the change in solubility due to a change 
in the chemical environment that decreases the solvation potential. Polar interactions 
with solvent, ionic interactions with salts and the repulsion of like electrostatic forces 
within the protein leads to solubility of the protein [90]. Hence, at the isoelectric point 
(pI) of a protein where there is no net charge, proteins are insoluble in solution and will 
precipitate. At a pH above a protein's pI there is a net negative charge; below the pI a 
net positive charge exists. 
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The addition of organic solvent (e.g. acetonitrile, acetone or ethanol) to serum 
precipitates HMW (high molecular weight) proteins to leave the more soluble low MW 
(LMW) fraction in solution. Addition of organic solvents displaces the water molecules 
around the hydrophobic regions of the proteins and lowers the dielectric constant of the 
solution resulting in an increase in the attraction of charged molecules which promotes 
electrostatic interactions within the protein to result in precipitation. Acetonitrile (ACN) 
has been found to be the most reproducible and effective at removing HSA [90]. During 
precipitation the tertiary structure of a proteins is removed , as it is in a denatured state, 
hence association with other proteins (e.g. binding proteins) will be lost. At 
concentrations > 20 %, ACN has been shown to disrupt the association of proteins to 
HSA [160]. Hence, as a relatively cheap approach to fractionation it is not surprising 
that ACN depletion is often used in proteomics [57, 169]. 
Alternatively salts (e.g. ammonium sulfate), metal ions (e.g. zinc sulfate), or acids (e.g. 
trichloroacetic acid) can be used to precipitate proteins. Like organic solvents the 
addition of salts to protein solutions removes water molecules from the protein surface 
by preferential binding to result in ppt as a result of aggregation due to hydrophobic 
interactions. Metal ions compete with solution protons for coordination of binding sites 
on the protein to effectively lower both the solution pH and protein's pI to result in ppt. 
Acids form insoluble salts with positively charged aa groups within the protein, thus 
increasing interaction with solvent to increase insolubility and result in ppt. Although 
capable of ppt these approaches are less frequently used compared with organic 
solvents, due to their lack of ease in compatibility with LC-MS where they affect 
ionisation efficiencies. 
4.2.2.2 Ultrafiltration 
A gentler approach to protein fractionation is ultrafiltration, which uses a size exclusion 
mechanism to separate LMW proteins from HMW proteins with a molecular sieve. 
Some users claim that separation of proteins with ultrafiltration is only observed when 
the MW difference to be separated is > 10 fold, however this is rarely the case [172]. 
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Primarily, separation is achieved by difference in MW, however, solute-solute 
interactions, solvent-membrane interactions, mode of solute transport (connective or 
diffusive) and concentration also need to be considered.  
Serum samples are often denatured to eliminate solute-solute interactions especially 
for albumin and the LMW proteins it potentially transports [160]. Membrane-solute 
interactions can be minimised by either passivating the membrane to eliminate 
exposed non-specific binding sites, or by changing the solution composition with the 
addition of proteins (e.g. albumin), salts (e.g. sodium dodecyl sulfate) or surfactants 
(e.g. Tween-20) [173]. Clogged membranes can result from loading too concentrated 
samples like serum onto the filter; hence, samples are to be diluted. Slower speed and 
longer centrifugal spin times (than those recommended by manufacturers) can 
potentially increase the recovery of LMW proteins, however, the passage of HMW 
proteins through the membrane also increases [174].  
4.2.2.3 HSA depletion columns 
High selectivity of HSA depletion using affinity capture columns has resulted in the 
common use of depletion columns in the sample preparation of serum for the analysis 
of low abundance proteins (LAPs) [161, 171]. Several mechanisms for binding exist, 
these include Cibacron Blue F3GA [175] or specific antibodies [176].  
It is not surprising that the use of monoclonal antibodies to capture HSA from serum is 
highly specific. However, the efficiency of this approach is limited in the volume of 
sample that can be applied to this system as a result of the low binding capacity of 
antibodies [161]. To overcome this, samples can be split into several aliquots for HSA 
depletion and pooled after separation, however the expense associated with these 
systems (especially in culturing the antibodies) does not make this feasible. Cibacron 
blue on the other hand is a cheaper approach to albumin depletion in that it mimics 
nicotinamide adenine and purine dinucleotides by binding proteins containing a 
dinucleotide fold with high affinity interaction [177]. Lollo et al. [170] state that non-
selective binding of proteins can occur through a complex combination of electrostatic, 
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hydrophobic and hydrogen bonding interactions with the planar ring structure of 
Cibacron Blue or its negatively charged sulfate groups. Despite this approach, having a 
relatively high load capacity (compared with antibody based systems), lack of 
selectivity of its secondary binding results in the unpredictable loss of proteins which 
can eliminate its advantage of use for LAPs in serum.  
4.2.3 Immunocapture 
Contrary to albumin depletion, the enrichment of target proteins (or corresponding 
proteolytic peptide) is an alternative approach to simplify serum samples to enable the 
analysis of LAPs. Using an antibody-based sample clean-up approach like 
immunocapture or immunoaffinity enrichment has enabled the sensitive analysis of 
serum LAPs by LC-MS [93, 178]. This is mainly due to the affinity of the antibody used 
to target the desired protein during sample clean-up. Although some degree of 
specificity for the antibody is required, unlike immunoassays, polyclonal antibodies are 
appropriate for immunocapture coupled to bottom-up LC-MS, since the specificity of 
LC-MS analysis is dependent on the appropriate selection of proteolytic peptides with 
unique SRM transitions. Antibody targets can be proteins or peptides, although 
proteins are preferred as they have stronger affinity [94]. The availability and cost to 
culture such antibodies is the main limitation to this approach, thus matrix clean-up in 




Figure 4.2-6: Schematic to show the possible sample preparation workflows that should simplify 
the serum proteome to enable analysis of low abundant proteins such as P-III-NP. 
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4.3 Materials and Methods 
The source of materials where unmentioned can be found in section 2.3 and section 
3.3. Acetic acid glacial (Analytical Reagent grade) and ammonium acetate (Certified 
AR for Analysis) were purchased from Fisher Scientific (Loughborough, UK). 
Trifluoroacetic acid (99 %, Reagent Plus®) and Tween-20 were purchased from Sigma 
Aldrich (St. Louis, MO, USA). 
4.3.1 Separation of HSA and P-III-NP by protein precipitation 
Acetic acid (1 %, 200 μL) was added to bovine P-III-NP (10 μg/mL in 50 mg/mL HSA, 
100 μL) and HSA (50 mg/mL, 100 μL) samples and vortexed (10 sec). To each sample 
acetonitrile (400 μL) was added before gently mixing for 10 min at 25 °C at 900 rpm. 
Samples were then centrifuged for 7 min at 13,000 g, before transferring the 
supernatant to a clean Lobind® tube. The supernatants were evaporated at 45 °C for 
approximately 2 h. Samples were reconstituted in ammonium bicarbonate 
(100 mM, 50 μL) before digesting with trypsin (2 µg) using the protocol described in 
section 2.3.4. Samples were analysed by conventional-flow LC-MS using the LC 
parameters described in section 3.3.2 whilst monitoring the SRM transitions listed in 
Table 4-1 below. 
Table 4-1: Collision energies for SRM (selected reaction monitoring) transitions monitored for 
bP-III-NP, developed in the absence of synthesized bT1 peptide developed using a Waters 










688 539 13 
688 704 10 
688 761 10 
T5 
534 363 20 
534 448 13 
534 628 27 
 
4.3.1.1 Monomeric single stranded P-III-NP 
To convert intact bovine P-III-NP (10 μg/mL in 0.1 % HSA, 100 μL) to its monomeric 
single-stranded form, disulphide bonds were removed by reduction (DTT) and 
alkylation (IDA) using the protocol described in section 2.3.2.1. Once derivatised, the 
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monomeric P-III-NP was added to carbamidomethylated HSA (50 mg/mL, 100 μL). The 
sample was then precipitated using the protocol described above, before analysing by 
conventional-flow LC-MS. 
To determine whether losses of P-III-NP could be due to the protein being trapped by 
the high concentration of HSA normally found in matrix, the experiment was repeated 
with a smaller volume of HSA (50 mg/mL, 10 μL). Separation of P-III-NP peptides and 
serum peptides were increased by decreasing the gradient slope of the LC method 
using the conditions described in Table 4-2 below. 
Table 4-2: Extended LC gradient conditions used to achieve additional separation of P-III-NP 
peptides from serum peptides using conventional-flow LC. 
Time (min) Flow (mL/min) % A % B 
0.00 0.3 95 5 
3.00 0.3 93 7 
23.00 0.3 92 8 
24.00 0.3 89 11 
44.00 0.3 88 12 
45.00 0.3 10 90 
45.01 0.3 95 5 
47.00 0.3 95 5 
 
4.3.1.2 Monomeric single stranded P-III-NP at pH 5.97 
To a sample of monomeric bovine P-III-NP (10 μg/mL in 50 mg/mL 
carbamidomethylated HSA, 10 μL), ammonium acetate (100 mM, 90 μL) was added. 
The pH of the sample was adjusted to 5.97 with acetic acid (1 %), whilst measuring 
with a Benchtop pH meter (Orion™ 3star, Thermo Scientific), before adding acetonitrile 
(300 μL) and vortexing for 5 sec and incubating at 25 °C for 10 min to facilitate protein 
precipitation. The supernatant was removed, to the remaining pellet acetonitrile 
(300 µL) was added before vortexing (5 sec) and centrifuging at 4 °C for 10 min at 
16,100 g. Supernatants were pooled and evaporated for approximately 3 h at 45 °C in 
a Speedvac, before reconstituting in ammonium bicarbonate (100 mM, 50 μL) and 
digesting with trypsin (2 µg) using the protocol described in section 2.3.4. Samples 




4.3.2 Separation of HSA and P-III-NP using molecular weight cut-off 
filtration 
To reduce losses resulting from non-specific binding to molecular weight cut-off 
(MWCO) centrifugal filters (Merck Millipore; Cork, Ireland), columns were passivated 
with Tween-20 as follows. Tween-20 (5 %, 500 µL) was loaded into each MWCO filter 
and incubated for 1 h at room temperature (approx. 25 °C) before removing with a 
pipette. The filter was washed with sterile distilled water (500 µL) to remove residual 
Tween-20 and centrifuged for 10 min at 14,000 g. This washing step was repeated 
twice more. Once passivated, MWCO filters were either used immediately or stored at 
4 °C. For storage, sterile distilled water (100 µL) was loaded into the filter to retard 
bacterial growth. 
Intact bovine P-III-NP (10 μg/mL in 50 mg/mL HSA, 100 μL) and HSA (50 mg/mL, 
100 μL) were reduced (DTT) and alkylated (IDA) using the protocol described in 
section 2.3.2.1. To each sample, ammonium bicarbonate (100 mM, 200 μL) was added 
before loading into a passivated 30 kDa MWCO centrifugal filter. Samples were 
centrifuged for 10 min at 14,000 g, before collecting the filtrate and evaporating to 
dryness at 45 °C for ~4 h. Samples were then reconstituted in ammonium bicarbonate 
(100 mM, 50 μL) and digested with trypsin (2 µg) at 37 °C overnight whilst shaking at 
1,400 rpm. To each sample, formic acid (2 %, 10 μL) was added before transferring to 
an autosampler vial and for analysis by conventional-flow LC-MS, using the extended 
LC gradient conditions shown in Table 4-2. 
4.3.2.1 Efficiency of Albumin depletion 
Carbamidomethylated HSA samples (50 mg/mL, 100 µL) were albumin depleted using 
protein precipitation and MWCO (10 and 30 kDa ) filtration protocols (sections 4.3.1 
and 4.3.2). Depleted samples and a HSA standard (500 µg/mL, 100 µL) were digested 
with trypsin (2 µg) overnight at 37 °C with shaking at 1,400 rpm. To stop trypsin activity, 
formic acid (2 %, 10 µL) was added to each sample before evaporating to dryness at 
45 °C for approx. 6 h. Samples were then reconstituted in formic acid (0.3 %) and 
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acetonitrile (5 %) solution (50 µL) containing Substance P (37 nM). Samples were 
analysed by conventional-flow LC-MS using targeted SRM methods for HSA tryptic 
peptide, VFDEFKPLEEPQNLIK (with Substance P as reference) to assess the 
efficiency of HSA depletion. 
Analysis was done on a Waters Acquity® UPLC® coupled to a Waters Xevo®  TQ-S MS 
interfaced with a conventional ESI ion source using the MS tune parameters listed in 
section 3.3.1. Gradient LC separation of digested HSA (10 µL) was achieved on an 
Acquity® UPLC® BEH 130Å (C18, 1.7 µm, 2.1 x 100 mm) column with mobile phase A, 
0.3 % formic acid in water, and B, 0.3 % formic acid in acetonitrile and a flow rate of 
300 µL/min. Mobile phase B was held at 20 % for 3 min before increasing to 50 % in 
7 min, then to 95 % in 2 min and held for a further minute. Mobile Phase B was then 
immediately returned to 20 % and held for 2 min to re-equilibrate the column. The SRM 
transitions monitored for the selected HSA peptide and substance P are shown in 
Table 4-3 below. 
Table 4-3: Collision energies for SRM transitions acquired for trypsin generated HSA peptide, 
VFDEFKPLEEPQNLIK, and substance P for conventional-flow LC-MS methods developed 
using a Waters Xevo® TQ-S MS. 








682 219 25 
682 247 17 
682 900 20 
Substance P 
449 253 15 
449 543 15 
449 600 10 
 
4.3.2.2 Depletion of albumin from pooled serum samples 
Albumin was depleted from  serum samples (100 µL) in triplicate using protein 
precipitation, MWCO filtration (30 kDa), combined protein precipitation then MWCO 
(30 kDa) filtration and double MWCO (30 kDa) procedures. Once depleted, samples 
were digested with trypsin (2 µg/mL) and evaporated using the conditions described 
above. One sample from each triplicate was reconstituted in formic acid (0.3 %) and 
acetonitrile (5 %) solution (50 µL) containing Substance P (37 nM), and analysed for 
the targeted HSA peptide by conventional-flow LC-MS. The second sample was 
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reconstituted in formic acid (0.3 %) and acetonitrile (5 %) solution (50 µL) containing 
100 pM hT1 and T5 peptides, and analysed for the targeted P-III-NP peptides by nano- 
flow LC-MS using the conditions described in sections 3.3.1 and 3.3.2.3. The remaining 
sample was reconstituted in formic acid (0.3 %) and acetonitrile (5 %) solution (50 µL) 
and analysed using the data-dependent method detailed in section 2.3.3.2.3 to identify 
proteins (with a threshold > 80 %) remaining in depleted matrix. 
4.3.3 Recovery of P-III-NP from double MWCO filtration 
Bovine P-III-NP (~100 ng/mL, 100 µL) in HSA (50 mg/mL) and without HSA, and HSA 
(50 mg/mL, 100 µL) samples were reduced and alkylated using the protocol described 
in section 2.3.2.1. The samples containing HSA were then filtered with a 30 kDa 
MWCO filter twice, using the protocol described in section 4.3.2 above. All samples 
were then evaporated to dryness at 45 °C for approximately 6h, before reconstituting in 
ammonium bicarbonate (100 mM). Samples were then digested overnight with trypsin 
(2 µg) at 37 °C whilst shaking at 1,400 rpm. To stop trypsin activity formic acid (2 %, 
10 µL) was added before transferring samples to an autosampler vial and analysed by 
nano-flow LC-MS using the conditions described in sections 3.3.1 and 3.3.2.3 to 
assess the recovery of P-III-NP from MWCO filtration. 
4.3.3.1 Effect of potential carrier proteins on P-III-NP analysis 
To improve recovery of P-III-NP from double MWCO filtration, the ability of abundant 
proteins tetracosatide (ACTH 1-24; Sigma Aldrich, St. Louis USA), Substance P, and 
recombinant human insulin (Sigma Aldrich, Buchs, Switzerland) to act as a "carrier" for 
hT1 and T5 during sample preparation, was investigated. 
Tetrocosactide, substance P and insulin samples (each at 150 ng/mL, 100 μL) were 
digested with trypsin using the protocol described in section 2.3.4, except at 
reconstitution stage formic acid (0.3 %) and acetonitrile (5 %) solution (50 µL) 
containing 100 pM hT1 and T5 peptides was added to the tubes. Samples were 
analysed by nano-flow LC-MS using the conditions described in sections 3.3.1 and 
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3.3.2.3. The action of insulin as a carrier for P-III-NP was further investigated using the 
double MWCO filtration. 
To a carbamidomethylated sample of bP-III-NP (100 ng/mL in 50 mg/mL HSA) insulin 
(150 ng/mL, 200 μL) was added before transferring to a MWCO (30 kDa) filter for 
separation. Once double MWCO filtered and digested with trypsin (2 μg), samples were 
analysed by nano- flow LC-MS. This experiment was repeated, however, insulin 
(150 ng/mL) was used to passivate MWCO filters instead of Tween-20. Samples were 
analysed by nano-flow LC-MS using the conditions described in sections 3.3.1 and 
3.3.2.3 with modified bT1 SRM transition listed in Table 4-4 below. To assess whether 
insulin improves the recovery of P-III-NP (compared to digested bP-III-NP (100 ng/mL 
in 0.1% HSA) standard) bT1 and T5 signals were compared to those obtained without 
a “carrier”. 
Table 4-4: Initial collision energies for SRM (selected reaction monitoring) transitions monitored 











688 761 15 
688 440 20 
688 369 20 
688 240 20 
 
4.3.4 Separation of HSA and P-III-NP using immunocapture 
For the following protocol both anti-P-III-NP monoclonal antibodies and Cal 0 (buffered 
solution containing bovine proteins, preservatives and yellow-orange dyes) were 
sourced from a P3NP-EL-US immunoassay kit (CisBio Bioassays, Codolet, France). 
Bovine P-III-NP (100 ng/mL in 50 mg/mL HSA), HSA (50 mg/mL) and Cal 0 were 
brought to room temperature (18-25 °C). In duplicate, each sample (100 µL) was 
pipetted into appropriate microtitre wells containing immobilised anti-P-III-NP mouse 
monoclonal antibody. A second mouse monoclonal anti-P-III-NP antibody (linked to 
horseradish peroxidase, mouse immunoglobulins, stabilisers and preservative, 100 µL) 
was added to each well before covering with adhesive film and incubating overnight at 
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4 °C whilst shaking at 700 rpm. The adhesive film was removed and the contents of the 
wells were dispelled before washing with PBS buffer containing 0.3 % Tween-20 
(300 µL) three times. To each well elution solution (200 µL), containing tetracosactide 
(ACTH 1-24, 15 mg/mL), acetonitrile (33 %) and trifluoroacetic acid (0.4 %) was added 
before incubating at 60 °C for 5 min whilst shaking at 900 rpm. Samples were then 
transferred into labelled LoBind Eppendorf® tubes and digested with trypsin (2 µg) as 
described in section 2.3.4. Samples were analysed with nano- and micro-flow LC-MS 
using the conditions described in sections 3.3.1 and 3.3.2.  
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4.4 Results and Discussion 
Using the developed conventional LC method described in section 3.3.2.1, a potential 
interfering early eluting peak at ~tR 4.5 min (Figure 4-7) can be seen close to the 
expected region for the P-III-NP T5 peptide (tR 5 min). In the data dependent results for 
trypsin digested HSA, numerous peptides were observed in the eluting region of T5 
hence to better separate and eliminate potential ion suppression of our P-III-NP 
peptides the slope of the LC gradient in this region was decreased in future 
experiments. At the time of analysis, a synthesised standard for the bT1 peptide was 
not available, hence the SRM transitions used were inferred from the fragmentation 
pattern of hT1 with the incorporation of aa sequence differences. A tryptic digest of 
bP-III-NP analysed by LC-MS using these transitions gave two characteristic peaks for 
bT1 (approximately 1 min apart), this doublet peak was used to identify the bT1 
peptide. 
4.4.1 Separation of HSA and P-III-NP by protein precipitation 
Separation of P-III-NP and HSA was not achieved by protein precipitation. In all the ppt 
experiments P-III-NP was observed in the precipitation fraction. This observation is 
most likely due to insolubility of the protein in acetonitrile, however it could also be due 
to the very abundant HSA, which is expected to precipitate, trapping the P-III-NP in its 
clusters during the precipitation process. 
In attempted separation of P-III-NP (10 µg/mL) from HSA (50 mg/mL) a small amount 
of P-III-NP was observed in the acetonitrile supernatant (see Figure 4-7), however, 
most of the protein is in the precipitate along with HSA. The efficiency of ppt is not 
expected to be 100 % [90], hence observance of P-III-NP in the supernatant is likely to 
be a result of the incomplete precipitation of the protein. With a reduction in the 
concentration of P-III-NP and HSA (diluted 1 in 10 ) no P-III-NP was observed in the 
supernatant fraction after ppt. The precipitate contained a small amount of P-III-NP T5 
peptide. No bT1 peptide was observed in either fraction. Absence of P-III-NP in the 
supernatant of the diluted sample (Figure 4-8) suggests that P-III-NP is in fact 
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precipitated by acetonitrile and not trapped by HSA; the low concentration of the 
recovered analyte in the precipitate is probably due to loss during sample handling, or 
ion suppression by HSA peptides. 
The effect of the size and tertiary structure of P-III-NP on precipitation was investigated 
with the attempted ppt separation of trimeric and monomeric bP-III-NP (both 10 µg/mL) 
from HSA (50 mg/mL). Unfortunately, both P-III-NP variants were insoluble in 
acetonitrile and precipitated, clearly demonstrating that these variables do not have an 
effect on ppt. 
Based on amino acid composition, the pI was calculated for P-III-NP (3.97) and HSA 
(5.67). Where the pH of a solution equates to a protein's pI, proteins are less soluble 
due to there being a net zero charge on the functional groups, which should readily 
facilitate precipitation. With this in mind, selective precipitation of HSA was attempted 
at pH 5.97. At this pH albumin should remain uncharged and thus insoluble in the 
aqueous solution (supernatant), whilst P-III-NP should be charged and interact with the 
solvent. Unfortunately, the proteins co-precipitated, thus separation was not achieved. 
The unexpected precipitation of P-III-NP at pH 5.97, which should have a net negative 
charge and interact with the solvent, could be due to the incorrect assignment of pI as 
a result of the incomplete characterisation of the protein as the presence of PTMs will 




Figure 4.4-1: Chromatograms of a bP-III-NP sample (10 µg/mL) without HSA (a), and the acetonitrile and precipitate fractions collected from an ACN ppt of bP-III-NP 
(10 µg/mL) in 50 mg/mL human serum albumin (b and c, respectively), analysed by conventional-flow LC-MS after digesting overnight with trypsin. Retention time, 















































































a) 10 µg/mL bovine P-III-NP b) 10 µg/mL  bovine P-III-NP_ ACN supernatant c) 10 µg/mL bovine P-III-NP_ precipitate
m/z 534 → 628 
m/z 534 → 448 
m/z 534 → 363 
m/z 688 → 761 
m/z 688 → 704 
m/z 688 → 539 
m/z 534 → 628 
m/z 534 → 448 
m/z 534 → 363 
m/z 688 → 761 
m/z 688 → 704 
m/z 688 → 539 
m/z 534 → 628 
m/z 534 → 448 
m/z 534 → 363 
m/z 688 → 761 
m/z 688 → 704 








Figure 4.4-2: Chromatograms of a bP-III-NP sample (10 µg/mL) without HSA (a), and the acetonitrile and precipitate fractions collected from an acetonitrile protein 
precipitation (at pH 5.97) of diluted bP-III-NP (10 µg/mL) in 50 mg/mL human serum albumin (b and c, respectively), analysed by conventional-flow LC-MS after 
digesting overnight with trypsin. Retention time, peak height and peak area (in bold) are shown for each peak. The eluting region for bT1 and T5 peptides have been 
























































b) 10 µg/mL  bovine P-III-NP_ dil. ACN supernatant c) 10 µg/mL bovine P-III-NP_ dil. precipitate
m/z 534 → 628 
m/z 534 → 448 
m/z 534 → 363 
m/z 688 → 761 
m/z 688 → 704 
m/z 688 → 539 
m/z 534 → 628 
m/z 534 → 448 
m/z 534 → 363 
m/z 688 → 761 
m/z 688 → 704 
m/z 688 → 539 
m/z 534 → 628 
m/z 534 → 448 
m/z 534 → 363 
m/z 688 → 761 
m/z 688 → 704 







4.4.2 Separation of HSA and P-III-NP by MWCO filtration 
Separation of P-III-NP (42 kDa) and HSA (69 kDa) was achieved using MWCO filtration 
despite their similarity in size. Removal of the tertiary structure of P-III-NP by reduction 
and alkylation of the cysteine disulphide bond generates a monomeric protein 
(~14 kDa), that is one-third the size of its trimeric precursor. Similar treatment of HSA 
however, only results in the elongation of the protein which retains its MW of ~66 kDa. 
Thus, through the cleavage of the disuphide bonds in these proteins, a sufficient 
difference in MW is created that allows for their separation with a 30 kDA MWCO filter 
as is shown in Figure 4-9 (c) below, where the bT1 and T5 P-III-NP peptides were 
observed after a trypsin digestion of the filtrate. 
Approximately 50 % of the bP-III-NP was recovered in the filtrate, compared to the 
control sample (a). Like ppt experiments, the recovery of proteins from MWCO filtration 
is not expected to be 100 %. Non-specific binding of proteins to the filter can occur. To 
reduce this the filter columns were passivated with a surfactant, Tween-20 (5 %), prior 
to use so as to block the non-specific binding sites. Loss of P-III-NP could also be due 
to protein being trapped within the HSA in the filter; to reduce this samples are diluted 
with solvent (ammonium bicarbonate solution) prior to loading on to the column. 
With a reduction of bP-III-NP (100 ng/mL) in a similar matrix (50 mg/mL HSA), no bT1 
and T5 peptides were observed in the filtrate. This lack in observation of the peptides 
could be due to ion suppression caused by HSA peptides, as demonstrated in section 
3.4.3, where the presence of HSA > 20 µg/mL suppresses the MS signal of the 
P-III-NP peptides. To enable analysis of serum P-III-NP in matrix (50 mg/mL HSA, 
equivalent to the highest expected serum basal concentration) it is essential that a 




Figure 4.4-3: Chromatograms of a) bP-III-NP sample (10 µg/mL), b) MWCO filtered human serum albumin (50 mg/mL) and c) bP-III-NP (10 µg/mL) in 
50 mg/mL human serum albumin, analysed by conventional-flow LC-MS after digesting overnight with trypsin. Retention time, peak height and peak 























































a) 10 µg/mL bovine P-III-NP b) 50 mg/mL albumin_MWCO c) 10 µg/mL bovine P-III-NP in 50 mg/mL albumin_MWCO
m/z 534 → 628 
m/z 534 → 448 
m/z 534 → 363 
m/z 688 → 761 
m/z 688 → 704 
m/z 688 → 539 
m/z 534 → 628 
m/z 534 → 448 
m/z 534 → 363 
m/z 688 → 761 
m/z 688 → 704 
m/z 688 → 539 
m/z 534 → 628 
m/z 534 → 448 
m/z 534 → 363 
m/z 688 → 761 
m/z 688 → 704 








Figure 4.4-4: Chromatograms of P-III-NP hT1 and T5 peptides (100 pM, 10 µL) spiked in HSA depleted serum sample using acetonitrile protein precipitation (ACN 
























































m/z 534 → 628 
m/z 534 → 448 
m/z 534 → 363 
m/z 1038 → 440 
m/z 1038 → 240 
m/z 692→ 768 
m/z 534 → 628 
m/z 534 → 448 
m/z 534 → 363 
m/z 1038 → 440
m/z 1038→ 240 
m/z 692 → 768 
m/z 534 → 628 
m/z 534 → 448 
m/z 534 → 363 
m/z 1038 → 440 
m/z 1038 → 240
m/z 692 → 768
m/z 534 → 628 
m/z 534 → 448 
m/z 534 → 363 
m/z 1038 → 440 
m/z 1038 → 240 
m/z 692 → 768 
a) ACN ppt b) MWCO filtration
d) Double MWCO filtrationc) ACN ppt + MWCO filtration
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4.4.3 Efficiency of albumin depletion by ACN ppt and MWCO filtration 
So far we have established that separation of P-III-NP and HSA is necessary to 
analyse serum P-III-NP by LC-MS. Protein precipitation is unable to carry out this 
function, however, at high P-III-NP concentration (10 µg/mL) separation using MWCO 
filtration is possible. At lower concentrations (e.g. 100 ng/mL) P-III-NP peptides were 
not detectable in the MWCO filtrate of a HSA (50 mg/mL, 100 μL) sample. This is 
thought to be due to insufficient HSA removal that would cause ion suppression of the 
T1 and T5 peptides in the MS. 
Table 4-5 shows the concentration of HSA remaining after MWCO and ppt of HSA 
(50 mg/mL) and serum (pooled) samples. MWCO and ppt on their own are insufficient 
in its removal of HSA. However, when combined (as either ppt then MWCO or double 
MWCO) the depletion efficiency of these techniques for HSA is drastically improved. 
Some of the proteins found in the depleted matrix are listed in Table 4-5 with a 
complete list shown in Appendix I. Data dependent analysis of the depleted serum 
samples show ALBU_H (HSA) present in all matrices, except the combined ppt and 
MWCO filtered sample. This observation does not correlate with that of the sample 
used to determine HSA concentrations by our targeted LC-MS methods. This, 
highlights the lack of reproducibility of the ppt and MWCO combination. Although 
sufficient depletion is achieved by this approach, the co-precipitation of P-III-NP and 
HSA limits its use for our analysis. This sample however is useful for determining the 
effects of other serum proteins on P-III-NP LC-MS analysis. 
Spiked into depleted serum samples, hT1 and T5 (10 pM) peptides were observed in 
all matrices except that obtained by ppt (see Figure 4-10 below). Table 4-5 shows a 
large quantity of HSA remaining in the ppt depleted samples, which would result in the 
complete suppression of the P-III-NP peptides. Absence of other serum proteins in the 
HSA sample drastically improves the efficiency of depletion by this approach. This 
highlights the lack of specificity and completeness of acetonitrile precipitation. Post ppt 
of serum the residual proteins are sufficient to completely suppress hT1 and T5 in the 
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MS. Unfortunately the insufficient HSA depletion achieved by this method does not 
allow us to assess the effect of the other serum proteins. When combined with MWCO, 
the serum proteins remaining in the matrix do not affect the analysis of P-III-NP by 
LC-MS. 
Table 4-5: Efficiency of HSA removal achieved by acetonitrile protein precipitation (ACN ppt) 
and molecular weight cut off (MWCO) filtration using a 30 kDa sieve. Some of the more 
abundant proteins remaining in depleted serum matrix (with a threshold > 80 %), identified 
using Mascot algorithm version 2.2.06 searching against the UniProt Swiss-Prot protein 
database are listed. 
 Depleted serum albumin (µg/mL) Proteins identified in 
depleted serum matrix 
(peptide threshold > 80 %) 50 mg/mL HSA 
Pooled human 
serum 
ACN ppt 40 1149 
ALBU_H, APOA1, APOA2, 
HBA1, HBB, TRFE, CXCL7, 
APOA4 
MWCO filter 30 80 ALBU_H, APOA1, APOA4 
ACN ppt  
+ MWCO filter - 22 
APOA1, APOA2, HBB, 
TRFE, CXCL7 
Double 
MWCO filter - 4 APO2, ALBU_H, APOA4 
 
It is surprising to observe the hT1 and T5 peptides (10 pM) in the single MWCO 
depleted serum sample with signal intensities similar to the other matrices. Considering 
the early failure to separate bP-III-NP (100 ng/mL, 2.5 nM) from HSA (50 mg/mL) lack 
of complementarity of these observations could be due to insufficient reproducibility of 
MWCO filters, trapping of bP-III-NP in the HSA that is cut-off by the filter, or losses 
caused by sample handling and non-specific binding. Like ppt, MWCO separation 
appears to be more efficient in the HSA sample than serum, however for this approach 
the levels of depletion of the two matrices are more comparable. The MWCO filter 
should trap all proteins > 30 kDa; nevertheless ALUB_H (66 kDa) and ALPOA1 
(45 kDa) are among the proteins observed in the filtrate. The observance of these 
proteins could be due to the capacity of the filter being exceeded. However, this is 
unlikely as with double MWCO filtration HSA remains in the filtrate. Thus, irrespective 
of size, some proteins (> 30 kDa) will escape the filter and the efficiency of MWCO will 
always be < 100 %. Sufficient depletion is achieved using double MWCO filtration, 
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which is capable of separating P-III-NP and HSA, thus this approach is further 
investigated for use in the preparation of serum for P-III-NP LC-MS analysis. 
4.4.4 Recovery of P-III-NP from double MWCO filtration 
With double MWCO separation of bP-III-NP in 50 mg/mL HSA (100 ng/mL, 100 µL) a 
12 % recovery of P-III-NP was observed (n > 10). Sporadically recoveries > 50 % have 
been observed; this could be due to a lack in reproducibility of albumin depletion 
achieved by the MWCO filter column. MWCO filters are designed to capture higher MW 
proteins than the filter cut-off; hence, in its current use we are inverting its primary 
function for which the efficiency of this approach is not defined by the manufacturer. To 
improve recovery from the filter, potential MWCO carrier proteins (tetracosactide, 
substance P and recombinant human insulin) which should limit non-specific binding of 
P-III-NP to the filter to allow for passage into the filtrate were investigated. 
4.4.4.1 Carrier proteins 
Based on the size of P-III-NP (42 kDa) it is not expected to bind to HSA (66 kDa) in 
serum; hence, HSA is not a carrier for P-III-NP. At low concentrations, similar to that of 
basal serum P-III-NP (5 ng/mL, 125 pM), proteins are prone to sample handling losses 
especially by non-specific binding. Thus, the removal of albumin during MWCO 
filtration can increase the loss of P-III-NP during sample handling. To avoid this, the 
presence of small but highly concentrated proteins (peptides) able to pass through the 
filter and bind to non-specific sites within the filter and also bind the sample capture 
vessels were investigated. This was determined in terms of their effect on minimising 
P-III-NP loss. 
Substance P, a 1346 Da neurotransmitter protein, has the aa sequence 
RPKPQQFFGLM. This peptide contains two potential cleavage sites for trypsin  
(highlighted in bold), however due to the close proximity of Pro to these sites there is 
likely to be very little or no cleavage from the endoprotease. Interference from a trypsin 
digest of the peptide was investigated with hT1 and T5 peptides (10 pM); 
chromatograms are shown below in Figure 4-11. For T5 some suppression is observed 
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in the m/z 534 to 448 and 363 transitions, however no interference was observed for 
the hT1 peaks. In full scan mode, Substance P was seen to elute at the end of the run, 
hence, it should not be the cause of the suppression observed. 
Tetracosactide (adrenocorticotropic hormone (ACTH) 1-24) is a 2933 Da protein with 
the aa sequence SYSMEHFRWGKPVGKKRRPVKVYP. Several potential tryptic 
cleavage points exists in this peptide, however, due to the close proximity of Pro or 
multiple neighbouring cleavage sites the probability of cleavage is affected. Analysis of 
P-III-NP peptides with carrier show some interference for T5 and none for hT1. Like 
substance P, the intact protein elutes at the end of the gradient in full scan; however, 
no investigation into the tR for potential tryptic peptides was done. 
Human insulin, a 6 kDa protein, has two potential tryptic cleavage sites within its 
b-chain which has the aa sequence FVNQHLCGDHLVEALYLVCGERGFFYTPKT. The 
cleavage closer to the c-terminus of the protein is unlikely, due to the neighbouring Pro 
in the P2 secondary trypsin binding site (relative to K), hence cleavage should yield 
peptides FVNQHLCGDHLVEALYLVCGER and GFFYTPKT. Like the other proteins, 
some suppression of T5 is observed, despite the intact insulin protein and its tryptic 
peptides eluting at the end of the LC gradient. Insulin shows the least (although 
insignificant) interference for the hT1 and T5 peptides, hence, it is selected as our 




Figure 4.4-5: Chromatograms of P-III-NP hT1 and T5 peptides (10 pM, 5 µL) analysed by nano-flow LC-MS with and without potential carrier proteins tetracosactide 









































































a) P-III-NP hT1 and T5 peptides (10 pM) b) P-III-NP hT1 and T5 peptides (10 pM) in tetracosactide (150 ng/mL)
d) P-III-NP hT1 and T5 peptides (10 pM) in insulin (150 ng/mL)c) P-III-NP hT1 and T5 peptides (10 pM) in Substance P(150 ng/mL)
m/z 534 → 628 
m/z 534 → 448 
m/z 534 → 363 
m/z 1038 → 440 
m/z 1038 → 240
m/z 692 → 768
m/z 534 → 628 
m/z 534 → 448 
m/z 534 → 363 
m/z 1038 → 440 
m/z 1038 → 240
m/z 692 → 768
m/z 534 → 628 
m/z 534 → 448 
m/z 534 → 363 
m/z 1038 → 440 
m/z 1038 → 240
m/z 692 → 768
m/z 534 → 628 
m/z 534 → 448 
m/z 534 → 363 
m/z 1038 → 440 
m/z 1038 → 240
m/z 692 → 768
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4.4.4.2 Assessment of recovery using a carrier protein 
Overall, no improvement in the recovery of P-III-NP separated from HSA by double 
MWCO filtration was achieved with insulin acting as a carrier (see Table 4-6 below). 
Compared to the control sample (Tween-20 passivated), no improvement in the MS 
signal for the T5 peptide was observed for the Tween-20 passivated and insulin (in-
solution) sample. For bT1, the observed recovery is misleading, as observed signals 
are likely from interferences. Extensive suppression in one of the replicates was 
observed for bT1 and the %RSD for T5 peak was significantly high (> 51 %). 
For the insulin passivated MWCO filter sample, complete suppression of bT1 was 
observed in both samples. A small decrease in T5 recovery was observed with similar 
%RSD, compared to the control sample. For the insulin passivated and insulin (in-
solution) sample, a decrease in recovery was observed for the T5 and bT1 peptides. Of 
the systems investigated, this combination gave the lowest recovery for P-III-NP, 
especially for the T5 peptide. 
The %RSD for the duplicate samples are sporadic in all MWCO filtered combinations, 
which is not surprising as the reproducibility of ultrafiltration has been reported as being 
poor [179, 180]. This is likely associated with interferences in the matrix. Despite 
double MWCO filtration being capable of separating HSA from P-III-NP, interferences 
from the matrix and low recovery makes this system difficult to work with, as such this 
approach is not further investigated. 
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Table 4-6: Recovery (peak area) of trypsin digested bP-III-NP (100 ng/mL, 100 µL) separated from HSA (50 mg/mL) using double MWCO filtration. The effect of 
insulin as potential carrier protein is included. Values are displayed as an average (n=2) except for those in blue, where n=1. 























































Area m/z                            
T5 
534 -> 628 103 314 15 254 15 0.9 5 490 5 76.0 11 746 11 13.1 3642 4 9.9 
534 -> 448  639 927 99 880 16 5.4 30 479 5 70.2 72 858 11 6.4 24 144 4 18.4 
534 -> 363 470 229 72 211 15 10.3 28 066 6 51.6 52 297 11 12.1 15 177 3 5.5 
bT1 
688 -> 761 256 979 7 202 3 2.9 4 781 2 - - - - 2 085 1 33.3 
688 -> 440 93 832 5 179 6 33.0 - - - - - - 6 363 7 9.1 
688 -> 369 72 594 4 698 6 0.5 6 004 8 - - - - 3 339 5 16.7 




            
T5 
534 -> 628 404 054 51 029 13 5.1 17 585 4 71.9 33 973 8 10.4 12 048 3 4.7 
534 -> 448  2 514 786 333 595 13 5.9 99 235 4 94.6 217 821 9 9.1 74 027 3 4.0 
534 -> 363 1 834 109 244 522 13 6.0 85 146 5 69.7 158 873 9 9.9 51 796 3 3.6 
bT1 
688 -> 761 621 173 15 770 3 6.9 8 920 1 - - - - 5 423 1 24.6 
688 -> 440 93 832 7 689 8 26.4 4 207 4 - - - - 8 968 10 34.6 
688 -> 369 72 594 5 559 8 22.3 12 098 17 - - - - 5 741 8 9.2 
688 -> 240 18 8134 6 349 3 14.6 26 820 14 - - - - 7 638 4 7.5 
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4.4.5 Immunocapture of P-III-NP 
Separation of P-III-NP and HSA was achieved using immunocapture with mouse 
monoclonal P-III-NP antibody (CisBio Bioassays). Table 4-7 shows the recovery of 
bP-III-NP for 5 ng/mL and 500 ng/mL samples, which was > 70 % for all peptide MS 
transitions. The %RSD for all sample pairs was ≤ 25; a drastic improvement to that 
observed using MWCO filters. The calculated albumin depletion of this method using 
HSA (50 mg/mL, 100 µL) was 99.99 %; with ~60 ng/mL HSA remaining in the sample 
after depletion. 
Table 4-7: Recovery (peak area) of bP-III-NP separated from HSA (50 mg/mL) by 










































534 -> 628 8 585 20 261 236 18 126 529 139 329 110 7 
534 -> 448  45 120 133 603 296 10 716 010 933 004 130 8 
534 -> 363 35 456 91 133 257 13 521 067 640 381 123 8 
bT1 
687 -> 761 24 778 22 670 91 15 294 541 217 183 74 22 
687 -> 440 8 895 8 349 94 10 97 713 72 513 74 23 
687 -> 369 6 014 7 599 126 1 74 059 60 332 81 23 
687 -> 240 6 631 7 803 118 11 84 634 73 096 86 25 
 
For the pseudo-serum basal bP-III-NP sample (5 ng/mL) recoveries much greater than 
100 % for the T5 peptide was observed despite the identical volumes (100 µL) being 
analysed. This disparity in the results could be due to non-specific binding loss 
occurring in the control sample which was analysed in 0.01 % HSA to circumvent 
matrix effects. In the sample separated by immunocapture, a significantly higher 
concentration of HSA is present that would reduce this loss. For the bT1 peptide 
~100 % recovery is observed; in reality however, this will be much decreased following 
the pattern of T5 (the more MS sensitive of the two peptides). Like the 5 ng/mL sample, 
the recovery for bT1 is < T5, as expected. The degree of loss is expected to be less 
between standard and sample, thus should be more realistic in its estimation of loss. 
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For the 50 ng/mL bP-III-NP sample the recoveries are slightly greater than 100 % for 
the T5 peptide. At higher protein concentration the loss is expected to be reduced, as 
has been observed. However in the absence of high HSA concentrations, loss is still 
expected. The better correlation of data at this concentration is more likely a reflection 
of similarity in the analyte loss to non-specific binding in the control to the losses in the 
capture of P-III-NP by the antibody for the pseudo-serum sample. 
The observed recovery and albumin depletion of this approach sufficiently satisfies the 
criteria required for the sample preparation of serum containing hP-III-NP (at basal 
concentrations) for LC-MS analysis using the developed methods. Application to a 
pooled serum sample, analysed by micro-flow and nano-flow LC-MS after trypsin 
digestion are shown in Figure 4-12, Figure 4-13, respectively. The hT1 and T5 peptides 
are qualitatively identified in the sample by both analytical methods. Interference (from 
HSA) for the hT1 peptide is observed (see Figure 4-14 below) as the ion ratio and peak 
intensity of this peptide is anomalous compared to the standard. A peak corresponding 
to hT1 is seen in the immunocapture HSA sample; samples fortified with pure hT1 
peptide show an increase in the peak area. Hence, further development of the LC-MS 
for hT1 is required, especially if it is to be used quantitatively to determine P-III-NP. For 
the T5 peptide, however, the ion ratios (tolerance window of relative abundance 
± 20 %) and peak intensity (signal to noise > 3:1) are within the expected range for a 
basal serum sample [181]. Also, no interference is observed in the immunocaptured 
HSA sample (Figure 4-14). Targeting the T5 peptide a semi-quantitative approach was 
used to estimate a P-III-NP concentration of 2 ng/mL (50 pM) using a 200 µL volume 
for this pooled serum sample. By immunoassay (Orion Diagnostica) this sample was 




Figure 4.4-6: Chromatograms of P-III-NP hT1 and T5 peptides (100 pM) (a) and immunocaptured P-III-NP from Cal 0 (containing bovine proteins, preservatives and 
a yellow orange dye, CisBio Bioassays) a pooled human serum samples (200 µL) (b and c, respectively), analysed by micro-flow LC-MS after digesting overnight 





































a) P-III-NP peptides hT1 and T5 (200 pM) b) Cal 0 (negative control) c) Pooled human serum 
m/z 534 → 628 
m/z 534 → 448 
m/z 534 → 363 
m/z 1038 → 440 
m/z 1038 → 240
m/z 692 → 768
m/z 534 → 628 
m/z 534 → 448 
m/z 534 → 363 
m/z 1038 → 440 
m/z 1038 → 240
m/z 692 → 768
m/z 534 → 628 
m/z 534 → 448 
m/z 534 → 363 
m/z 1038 → 440 
m/z 1038 → 240








Figure 4.4-7: Chromatograms of P-III-NP hT1 and T5 peptides (100 pM) (a) and trypsin digested immunocaptured P-III-NP from Cal 0 (containing bovine proteins, 
preservatives and a yellow orange dye, 200 µL, CisBio Bioassays) and a pooled human serum sample (200 µL) (b and c, respectively), analysed by nano-flow LC-
MS after digesting overnight with trypsin. Retention time, peak height and peak area (in bold) are shown for each peak. The eluting region for hT1 and T5 peptides 





































a) P-III-NP peptides hT1 and T5 (200 pM) b) Cal 0 (negative control) c) Pooled human serum 
m/z 534 → 628 
m/z 534 → 448 
m/z 534 → 363 
m/z 1038 → 440 
m/z 1038 → 240
m/z 692 → 768
m/z 534 → 628 
m/z 534 → 448 
m/z 534 → 363 
m/z 1038 → 440 
m/z 1038 → 240
m/z 692 → 768
m/z 534 → 628 
m/z 534 → 448 
m/z 534 → 363 
m/z 1038 → 440 
m/z 1038 → 240








Figure 4.4-8: Chromatograms of trypsin digested immunocaptured HSA (50 mg/mL, 200 µL) and fortified hT1 samples analysed by micro-flow (a and c, respectively) 
and nano-flow (b and d, respectively) LC-MS. Retention time, peak height and peak area (in bold) are shown for each peak. The eluting region for hT1is highlighted. 
a) HSA, micro-flow LC-MS b) HSA, nano-flow LC-MS










m/z 534 → 628 
m/z 534 → 448 
m/z 534 → 363 
m/z 1038 → 440 
m/z 1038 → 240




























m/z 534 → 628 
m/z 534 → 448 
m/z 534 → 363 
m/z 1038 → 440 
m/z 1038 → 240
m/z 692 → 768
m/z 534 → 628 
m/z 534 → 448 
m/z 534 → 363 
m/z 1038 → 440 
m/z 1038 → 240
m/z 692 → 768
m/z 534 → 628 
m/z 534 → 448 
m/z 534 → 363 
m/z 1038 → 440 
m/z 1038 → 240




P-III-NP can be separated from HSA in serum using double MWCO filtration or 
targeted P-III-NP immunocapture methods with albumin depletion efficiencies 
> 99.6 %. Resulting from co-precipitation of the two proteins, separation cannot be 
achieved using protein precipitation. Double MWCO filtration gives a low recovery of 
P-III-NP (even in the presence of a carrier protein) and the reproducibility of the filter is 
questionable, hence this approach was not further investigated. Immunocapture gives 
a reproducible recovery of P-III-NP > 70 %. Application of this method to a pooled 
human serum sample containing P-III-NP at basal concentrations gave an estimated 
concentration of 2 ng/mL (50 pM) when analysed by the developed micro- and 
nano-flow LC-MS methods. So far suitable sample preparation and LC-MS methods 
have been developed which enable the detection of serum hP-III-NP. However to 
associate traceability to these methods and eventually enable their use for absolute 
quantification, suitable reference material for hT1 and T5 or intact hP-III-NP is needed. 





Chapter 5 : An approach to obtaining peptide standards for the 
quantification of P-III-NP 
5.1 Overview of the chapter 
In the previous chapter, hP-III-NP was extracted and analysed by LC-MS from human 
serum to give an approximate concentration of 2 ng/mL (50 pM) against the T5 peptide 
standard. For absolute quantification of P-III-NP, suitable reference peptides or intact 
protein are needed. In the absence of reference material for hP-III-NP, synthesis of 13C 
and 15N isotopically labelled and unlabelled peptides for hT1 and T5 was initiated. 
Once synthesised, absolute quantification of the acid hydrolysed aa subunits of each 
peptide is to be quantified by targeted LC-MS approaches. With sufficient synthesis 
and quantification, these peptides are to be used as internal reference standards for 
the absolute quantification of serum hP-III-NP, using the developed digest P-III-NP LC-
MS approach described in Chapter 3. 
5.2 Introduction 
In MS-based quantitative analysis, the unknown concentration of a target sample 
analyte is determined by comparison with the absolute MS signals of a set of known 
standards. To achieve accurate concentrations, reproducible analyte measurements 
are necessary; this is achieved with minimum variance in sample extraction, 
preparation, and analytical methods. Stable-isotopic standards (with similar chemical 
properties to the target analyte) can be incorporated in the sample workflow to 
normalise these variances, however the earlier they are included the more effective 
they are at improving the reproducibility of methods [182, 183]. 
The absence of reference material for hP-III-NP makes application of protein labelling 
impossible. However, if the proposed digest approach to measurement is adopted, 
peptide labelling becomes appropriate and heavy isotope labelled (typically 13C and/or 
15N) variants of target surrogate peptides, hT1 and T5, can be incorporated into the 
sample workflow. Ideally both the labelled and unlabelled peptide variants should co-
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elute and display similar MS/MS fragmentation patterns, despite the presence of the 
isotopic labelling on the heavy-variant; which will associate a difference in mass to the 
precursor and product ions. With the incorporation of these heavy labelled standards in 
the sample workflow directly after protein digestion, the co-analysis of both analytes 
should correct any analytical variances associated with LC-MS methods as well as 
protect against false bias originating from matrix interference. 
5.2.1 Peptide synthesis 
Peptides fragments of P-III-NP are not commercially available hence they require 
synthesis. Mimicking in vivo protein production, peptides (and proteins) can be 
chemically synthesised by the sequential coupling of the respective amino acids in its 
sequence. Solution and solid phase approaches have been used for peptide and 
protein synthesis, though the latter approach is preferred based on its simplicity, speed, 
efficiency and amenability to automation [184, 185]. 
During synthesis, peptides are elongated from their carboxyl- to amino-terminus to 
facilitate the control of sequence variation with the sequential addition of 
reversibly-protected α-amino group residues. To control the location of peptide bond 
formation during synthesis, aa residues containing additional reactive side groups are 
also reversibly blocked. In solid-phase peptide synthesis (SPPS), insoluble porous 
resins (normally containing polystyrene) are used to anchor the growing peptide. The 
associated insolubility of the peptide, as a result of its attachment to the resin, 
facilitates the continuous removal of the impurities and excess aa in the sample mixture 
throughout peptide synthesis. For the coupling of amino- and carboxyl-ends of two aa 
residues to occur, the carbonyl- group needs to be activated, this is achieved with the 
inclusion of coupling agents such as DIC, HATU and DIPEA (refer to list of 
abbreviations or materials and methods below for full compound names) in the reaction 
mixture. 
For the α-amino group, the most commonly used protecting groups are 
tert-butoxy-carbonyl (Boc) and fluoren-9-ylmethyloxycarbonyl (Fmoc). Boc protecting 
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groups are sensitive to acids such as TFA, whilst Fmoc groups are sensitive to bases 
like piperidine. Thus, based on their reactivity and effective removal from aa residues, 
Fmoc strategies are preferred in routine peptide synthesis. The milder conditions 
required for Fmoc removal allows orthogonal deprotection of aa residues during 
synthesis, without disruption of neither the peptide-solid support link nor any side chain 
protecting groups (e.g. Trt, Pbf, OtBu and Boc), which are normally acid sensitive. 
Fmoc decoupling can be monitored by UV spectroscopy, where the absorbance of 
dibenzoflulvene-piperidine complexes (formed between piperidine and the cleaved 
Fmoc group) at 301 nm are used to indicate successful cleavage of the Fmoc 
protecting group during synthesis [185]. Alternatively decoupling of α-amino protecting 
groups can be monitored using several qualitative tests (e.g. Kaiser and picrylsulphonic 
acid tests) that are sensitive to primary amino groups [186, 187]. 
For SPPS, the core of the resin used is normally made of polystyrene (with 1-2 % 
divinylbenzene), and are usually small and spherical in shape. The swelling of the 
polystyrene resins is important for synthesis, in that expansion of the polymer affects 
the diffusion and accessibility of reagents to the core. These resins are ideally swelled 
to their maximum in organic solvents, such as dimethylformamide (DMF) ethanol or 
acetonitrile, before commencing synthesis. Attachment of peptides to the polystyrene 
core of resins is achieved through linkers on their surface. The density of linkers 
attached dictates the loading capacity of the resin, which defines the quantity of peptide 
that can be synthesised. Manufacturers normally express loading capacities in mmol/g, 
where values represent the concentration of linker per gram of resin. A variety of 
linkers have been developed for polystyrene based resins; some are listed in Table 5-1 
with their final cleavage conditions and synthesised peptide carboxyl-terminal 
functional groups [185]. Most linkers are cleaved in acidic conditions and produce 
peptides with either an acid (COOH) or amide (CONH2) functional group at the peptide 
carboxyl-terminus. Resins that are preloaded with the first aa are also available. Use of 
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these resins for SPPS will increase the efficiency of yield, where the first aa coupling is 
a limiting factor. 
5.2.2 Validation of peptide standards 
For use as standards in analytical methods, peptides need to possess chemical purity 
of > 95 % and be accurately quantified, to ensure the quality of their measurements 
meets the specification of the assay (i.e. specificity, precision, bias, lower limits of 
quantification) [182, 188]. Purification is achieved by the fractionation of crude peptide 
samples, and can be monitored by elemental analysis, Karl Fisher analysis (for water 
content), LC-UV or NMR spectroscopy. Without purification, quantification of peptides 
is impossible, as measurements will most certainly include impurities. Whilst 
gravimetric methods are applicable, aa analysis of acid hydrolysed peptides by LC-MS 
is a better approach to peptide quantification. Here single aa concentrations of a known 
amount (accurately measured weight) of hydrolysed peptide is used to determine the 
net peptide content. By the multiplexed analysis of different aa residues within the 
peptide sequence, cross-comparison of determined concentrations can also be used to 
support the purity of the peptide sequences, which in addition to peptide sequence, MS 




Table 5-1: List of some of the resins available for SPPS, for which the cleavage conditions and 
the carboxyl-terminus functional group of the synthesised peptide are given.  
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5.3 Materials and Methods 
The source of materials where unmentioned can be found in section 2.3, section 3.3 
and section 4.3. Fmoc-Hyp(OtBu)-OH, Fmoc-Gly-OH, Fmoc-Ile-OH, Fmoc-Asp(OtBu)-
OH, Fmoc-Ser(tBu)-OH, Fmoc-Glu(OtBu)-OH, L-pyroglutamatic acid, amino acid 
standard mix (analytical reagent, cat. no. AAS18, containing all natural aa except Asn 
and Gln), ethyl (hydroxyimino)cyanoacetate (97 %. Oxyma), 2,2′-(ethylenedioxy) 
diethanethiol (95 %. EDT), N,N′-Diisopropylcarbodiimide (98 %. DIC), 
1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluoro-
phosphate (97 %. HATU), dimethylformamide (99.8 %, anhydrous. DMF) and 
piperidine (99 %, reagent plus®) were purchased from Sigma Aldrich (St. Louis, MO, 
USA). Fmoc-L-ala-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Gln(trt)-OH, Fmoc-Leu-OH, 
Fmoc-His(trt)-OH, Fmoc-Cys(trt)-OH, and Fmoc-Val-OH were purchased from Hong 
Kong PE Biosciences Ltd (Shanghai, China). L-Ile-N-Fmoc (13C6, 97-99 %; 
15N 97-99 %), L-Arg:HCL (13C6, 99%) and L-Leu (13C6, 99%) were purchased from 
Cambridge Isotope Laboratories, Inc. ( Andover, MA, USA). Picrylsulfonic acid was 
purchased from Tokyo Chemical Industry Company Ltd. (Tokyo, Japan). Methanol, 
dichloromethane (DCM) and diethyl ether were purchased from Fisher Scientific 
(Loughborough, UK). N,N-Diisopropylethylamine trihydrofluoride (95 %) was purchased 
from Acros Organics™ (DIPEA. Fisher Scientific, Loughborough, UK). Phenol (ACS, 
Reag. Ph Eur) was purchased from Merck Millipore (Darmstadt, Germany). 
Triisopropylsilane, (98 %. TIPs) and thioanisole (99 %) were purchased from Alfa 
Aesar™ (Heysham, England). 
5.3.1 Heavy labelled peptide development 
Using the optimised hT1 and T5 SRM transitions detailed in section 3.3.1.1, heavy 
labelled peptide variants were designed for each peptide to ensure that in all the 
monitored transition-fragments an isotopic 13C/15N aa residue was incorporated. The 
designed isotopic-labelled heavy peptide sequences are shown below: 
Heavy hT1: Q-NH3-[13C/15N-Q]-EAVEGGCSHLG-[13C/15N-Q]-SYADR 
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Heavy T5: GD(P+OH)GP(P+OH)G-[13C/15N-I]-(P+OH)GR 
 
5.3.1.1 F-moc peptide synthesis 
Peptides for hT1, T5 and heavy T5 were manually synthesised by Fmoc-solid phase 
peptide synthesis (SPPS). For the T5 peptides a Fmoc-Arg(Boc)-Wang resin (100-200 
mesh) with a load capacity of 0.6 mmol/g (Bachem, Bubendorf, Switzerland) was used. 
For hT1 a Fmoc-Arg(Pbf)-NovaSyn®TGA resin with a load capacity of 0.18 mmol/g 
(Merck Millipore) was used. Each peptide was prepared using the following protocol. 
1. The resin (200 mg) was swollen in DMF in a fritted polypropylene tube for 
30 min. The resin was then washed with DMF, methanol and DCM before 
removing a small amount (< 0.1 mg) to which picrylsulphonic acid (20 μL) was 
added to check for Fmoc protection of the linked Arg with the observance of a 
negative amine reaction (no colour change to resin). 
2. The Fmoc protecting group was removed by treating the resin with piperidine in 
DMF (20 % v/v) for 30 min. Subsequently, the piperidine was removed by 
filtering under vacuum before washing the resin with DMF, methanol and DCM, 
to remove impurities and excess reagent. Once washed, a small amount of 
resin (< 0.1 mg) was removed and tested with picrylsulphonic acid for a positive 
amine reaction (orange colour change in resin) to ensure Fmoc removal. 
3. For each aa coupling (except 13C/15N aa and pyroE residues), a four equivalent 
(excess) mixture of the Fmoc-aa, DIC and oxyma (1:1:1 molar ratio) in DMF 
was prepared using the weights and volumes shown in Table 5-1, Table 5-2 
and Table 5-3 below. For 13C/15N-Ile a three equivalent mixture was prepared. 
For pyroE a ten equivalent mixture of Fmoc-aa, HATU and DIPEA (1:1:1 molar 
ratio) in DMF was prepared. (Coupling mixtures were made no more than 2 min 
before adding to the resin). 
4. After Fmoc removal, the resin was washed with DMF before adding the 
coupling mixture of the first aa of the peptide being synthesised. The resin was 
left to react with the coupling mixture for 2 h, after which excess reagents and 
160 
 
impurities (including by-products) were removed by washing with DMF, 
methanol and DCM. A small amount of resin (< 0.1 mg) was removed and 
tested with picrylsulphonic acid to check for Fmoc protection (indicative of 
successful aa coupling). 
5. The Fmoc protecting group was then removed by repeating step 2. 
6. Subsequent aa were added to the sequence by repeating steps 3-5, until the 
sequence was complete. Samples were dried overnight under vacuum before 
decoupling. 
Once the peptides were synthesised, they were removed from the resin by incubating 
(3 h) in a cleavage solution (4 mL) containing TFA, water, phenol, TIPs, thioanisole and 
EDT (90:5:5:2.5:5:2.5 molar ratio). The cleaved peptide was then filtered into a clean 
Falcon tube under vacuum (residual peptide was washed off the beads with TFA 
(~1 mL)). The filtrate was then concentrated to a volume < 500 μL by heating (~40 °C) 
under nitrogen before precipitating the peptide with ice-cold diethyl ether (~4 °C). 
Samples were then centrifuged at 4000 rpm for 10 min and the supernatant discarded. 
The precipitate was washed 2-3 times with diethyl ether to remove impurities, before 




























AA (mg) 142.7 196.5 169.6 142.7 196.6 161.9 142.7 196.6 197.5 142.7 
Oxyma (mg) 70.0 70.0 70.0 70.0 70.0 70.0 70.0 70.0 70.0 70.0 
DMF (mL) 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 
DIC (µL) 74.0 74.0 74.0 74.0 74.0 74.0 74.0 74.0 74.0 74.0 
 























AA (mg) 142.7 196.5  142.7 196.6 161.9 142.7 196.6 197.5 142.7 
Oxyma (mg) 70.0 70.0 52.5 70.0 70.0 70.0 70.0 70.0 70.0 70.0 
DMF (mL) 1.6 1.6 1.2 1.6 1.6 1.6 1.6 1.6 1.6 1.6 
DIC (µL) 74.0 74.0 55.5 74.0 74.0 74.0 74.0 74.0 74.0 74.0 
 







































AA (mg) 59.2 44.8 66.1 55.2 88.9 42.8 50.9 89.2 55.2 84.3 42.8 42.8 61.3 48.9 44.8 61.3 88.9 46.5 
Oxyma (mg) 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 - 
DMF (mL) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 1.6 
DIC (µL) 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 - 
HATU (g) - - - - - - - - - - - - - - - - - 130.0 





5.3.1.2 LC-UV analysis  
To monitor the presence of impurities produced in the peptide product, a sample of the 
crude product (~100 μg/mL, 5 μL) in HCOOH (0.3 %) and CH3CN (5 %) solution was 
analysed by LC—UV using a Hewlett Packard (Agilent Technologies. Santa Clara, CA, 
USA) series 1050 HPLC coupled to a Hewlett Packard 1046A programmable 
fluorescence detector (Waldbronn, Germany). Gradient LC separation was achieved on 
an Agilent Technologies Zorbax SB-C-18 (3.5 μm, 2.1 x 100 mm) column with mobile 
phase A, 0.1 % trifluroacetic acid in water, and B, 0.1 % trifluroacetic acid in acetonitrile 
and a flow rate of 300 μL/min. At the start of the gradient mobile phase B was 0 % and 
increased to 90 % over 20 min, where it was held for a further 3 min. Mobile phase B 
was then decreased to 0 % over 2 min and held for 6 min to re-equilibrate the column. 
UV absorbance at 254, 230, 214, 220 and 281 nM were monitored (with 550 nM as a 
reference) for all signals. 
5.3.1.3 LC-MS/HRMS 
To ensure the desired peptides were within their synthesised product, full and the 
[M+2H]2+ product ion scan spectra of each product (~1 μg/mL, 5 μL) in formic acid 
(0.3 %) and acetonitrile (5 %) solution were collected (where possible) by 
LC-MS/HRMS using the conditions detailed in section 2.3.3 and section 2.3.4. For the 
heavy T5 peptide the [M+2H]2+ precursor ion corresponds to m/z 538. 
5.3.1.4  Purification of synthesised peptide product 
Fractionation of the crude peptide product in formic acid (0.3 %) and acetonitrile (5 %) 
solution (5mg/mL, 8mL, injected at a flow of 1 mL/min) was achieved on a Waters® 
HPLC system (515 HPLC pump equipped with a binary gradient module 2545, 267 
sample manager and solvent flow operator) coupled to a Waters® Micromass ZQ and 
Waters® 2996 Photodiode array detector. Separation was achieved on a Waters® 
XTerra™ MS C18 (3.5 µm, 4.6 x 150mm) column with mobile phase A, 0.1 % formic 
acid, 5 % acetonitrile in water, and B, 0.1 % formic acid in acetonitrile and a flow rate of 
10 mL/min. Gradient elution was achieved over 30 min, where the % B was changed 
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from 0 to 70 %, and then decreased to 10 % in 5 min, where it was held for 3 min 
before decreasing to 0 % in 2 min before equilibrating the column for a further 8 min. 
For MS analysis the instrument was operated in positive ESI mode with a capillary and 
cone voltage were 2.7 kV and 30 V, respectively. The source and desolvation 
temperatures were 150 and 300 °C. The cone and desolvation gas flows were 50 and 
500 L/H. Fractionation of sample was triggered at selected m/z (± 1 amu) whilst 
scanning over a range of m/z 300 to 1100, and UV at 214 nM with a diode array 
detecting wavelength between 210 to 500nM. 
5.3.2 Quantification of peptide by aa analysis 
In duplicate, the purified T5 peptide product (956 µg/mL, 500 µL) was hydrolysed in 
hydrochloric acid (6M) at 110 °C for 24 h using pressurised glass vessels. The 
hydrolysed sample was diluted 1 in 100 with acetonitrile containing 5 nM 13C-Arg and 
13C-Leu. The sample was analysed by LC-MS using the targeted aa LC-MS method 
described below, and compared to aa standards for quantification. The experiment was 
repeated in a glass test tube for comparison. 
5.3.2.1 Amino acid analysis 
Separation of the amino acid standard mix (500 pM - 50 nM, 10 µL) and the hydrolysed 
peptide sample solution (both in acetonitrile containing 5 nM 13C-Arg and 13C-Leu) was 
achieved on a Waters Acquity® UPLC® coupled to a Xevo® TQ-S MS interfaced with a 
conventional ESI ion source using the chromatographic separation described by 
Hubertus et al. [189]. Gradient LC separation of the aa standard (10 µL) was achieved 
using an Acquity® UPLC® BEH Amide (1.7 µm, 2.1 x 150  mm) column at 35 °C with a 
flow of 400 µL/min. Mobile phase A (10 mM ammonium formate in 85 % acetonitrile 
containing 0.2 % formic acid) and B (10 mM ammonium formate in water containing 
0.2 % formic acid) were used. Mobile phase A was held at 100 % for 6 min, after a 
which a gradient was started and mobile phase decreased to 94.1 % in 0.1 min, before 
decreasing to 82.4 % in 3.9 min and then to 70.6 % in 2 min. Mobile phase A was then 
returned to 100 % in 0.1 min, and the column re-equilibrated for 4 min. 
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For MS analysis the instrument was operated in positive mode with a capillary voltage 
of 2.8 kV. The source and desolvation temperatures were 150 and 200 °C. The cone 
flow 150 L/h and desolvation gas flow 0.15 mL/min. SRM transitions monitored for the 
respective aa residues are shown in Table 5-5 below. 
Table 5-5: Initial cone voltages and collision energies for the SRM (selected reaction 












132 44 32 16 
132 69 32 14 
132 86 32 8 
Heavy Ile 138 91 32 12 
Arg 
175 60 8 12 
175 70 8 18 
175 116 8 12 
Heavy Arg 181 74 8 20 
Asp 134 74 32 10 134 88 32 15 




5.4 Results and Discussion 
The preliminary results are presented for the peptide synthesis of the isotopic heavy-
labelled (13C/15N) and unlabelled P-III-NP hT1 and T5 peptides analogues. To assess 
the applicability of the chosen resin for synthesis unlabelled peptide analogues were 
synthesised first. For T5, both analogues were synthesised and have been purified, 
however they await quantification by aa LC-MS analysis. For T1, however, only 
synthesis of the unlabelled analogue has been achieved so far. Though the aa 
quantification methodology is incomplete, the process of development of this method is 
presented and discussed. 
5.4.1 Synthesised T5 peptide product 
5.4.1.1 Purity 
Using the absorbance of peptide bonds at a wavelength of 214 nM, absorbance 
readings for the peptide product can be used to detect the number of components in a 
peptide mixture after LC separation, thus providing a purity profile. Using this approach, 
chromatograms representative of the purity of the crude and fractionated (purified) 
peptide product have been attained by LC-UV analysis and are presented in Figure 5-1 
and Figure 5-2 below. 
In the crude peptide product, several peptides are detected along with the peptide 
product (tR 7.5 min, Figure 5-1). These additional products most likely originate from 
deleted, truncated or incompletely de-protected peptide sequences produced during 
synthesis. To remove and purify for the desired product, fractionation of the LC 
separated product was performed, for which a combined UV (214 nM) and MS (m/z 
534 ± 1 amu) trigger were employed. Purity analysis of the purified peptide product, 






Figure 5.4-1: Chromatogram of the crude T5 peptide product obtained by LC-UV analysis 




Figure 5.4-2: Chromatogram of the purified T5 peptide product obtained by LC-UV analysis 
monitoring absorbance at 214 nM. 
 
5.4.1.2  Sequence verification 
In SPPS, the Wang-linked resin was used for synthesis, hence the cleaved peptide 
product should have a carboxyl and amino group at the respective ends of the peptide. 










synthesised T5 peptide (214 nM)












synthesised T5 peptide (purified, 214 nM)
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Analysed by LC-MS/HRMS the crude and purified peptide products give the full and 
product ion scan spectra shown in Figure 5-3 and Figure 5-4. In the MS full scan, the 
singly- and doubly-charged T5 peptide ions were observed within the spectrum of the 
peak eluting at tR 4.25 min, with a m/z 1067.5096 (theoretical m/z 1067.5116) and 
m/z 534.2596 (theoretical m/z 534.2594), respectively. The b- and y-ions observed in 
the product scan spectrum of the doubly-charged peptide ion (534.26 ±0.2 amu) 
correspond with the aa sequence GDP+OHGPP+OHGIP+OHGR, which is the desired 
sequence for T5. 
 
 
Figure 5.4-3: Total ion chromatogram of the synthesised T5 peptide product showing the full 





Figure 5.4-4: Extracted ion chromatogram at m/z 534.2594 ±5 ppm and corresponding product scan spectrum of the T5 doubly-charged peptide ion using a 
normalised collision energy of 20 %. The most abundant b- and y-ions are annotated, where no charged is indicated the ions are singly-charged. (Refer to Table 
2-10 for theoretical m/z values). 
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5.4.2 Synthesised heavy T5 peptide product 
5.4.2.1 Purity 
 
Figure 5.4-5: Chromatogram of the crude heavy T5 peptide product obtained by LC-UV analysis 





Figure 5.4-6: Chromatogram of the purified heavy T5 peptide product obtained by LC-UV 
analysis monitoring absorbance at 214 nM. 
 













synthesised heavy_T5 peptide (214 nM)












synthesised heavy_T5 peptide (purified, 214 nM)
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Chromatograms representative of the purity profile for the crude and purified heavy T5 
products are presented in Figure 5-5 and Figure 5-6 above. Compared to the crude 
product of T5, a small amount of peptide impurity was observed in the heavy T5 
product, nevertheless, fractionation of the sample was performed using LC with 
combined UV (214 nM) and MS (m/z 538 ± 1 amu) triggered separation. Re-analysed 
by LC-UV, a single peptide is observed at tR 7.5 min (Figure 5-6). 
5.4.2.2  Sequence verification 
Analysed by LC-MS/HRMS the crude and purified peptide product give the full and 
product ion scan spectra shown in Figure 5-7 and Figure 5-8 below. In the MS full 
scan, the expected singly- and doubly-charged heavy T5 peptide ions were observed 
within the spectrum of the peak eluting at tR 4.25 min, at m/z 1074.5275 (theoretical 
m/z 1074.5288) and m/z 537.7680 (theoretical m/z 537.7680), respectively. The b- and 
y-ions observed in the product scan spectrum of the doubly-charged peptide ion 
(534.26 ±0.2 amu) correspond with the aa sequence GDP+OHGPP+OHG13C6/15N-IP+OHG; 
which is the desired sequence for heavy T5. 
Co-elution of the T5 (Figure 5-3) and heavy T5 (Figure 5-7) peptides was observed at 
tR 4.25 min. This is expected as both peptides have similar aa sequence, hence they 
show comparable affinities for the C-18 chemistry of the LC column. Differentiation of 
the two peptides is achieved by MS where the presence of the isotopic 13C6/15N-Ile 
residue replaces the Ile residue in T5. This associates a +7 Da shift in the peptide 
mass of heavy T5 and is evidenced with the observation of the [M+H]+ ion at m/z 
1074.5274 for (compared to T5, [M+H]+ m/z 1067.5116). Based on the location of the 
isotopic residue in the heavy T5 peptide, conservation of the appropriate mass shift (+7 
and +3.5 Da for the singly- and doubly-charged peptide ions) is expected for all the 
SRM transitions monitored in the nano-and micro-flow LC-MS targeted P-III-NP 
methods (Section 3.3.1.1, Table 3-3). For heavy T5, the y72+, y92+ and y6+ fragment 
peptide ions are observed at m/z 366.7089, 451.7435 and 635.3576 (compared to T5 




Figure 5.4-7: Total ion chromatogram of the synthesised heavy T5 peptide product showing the 
full scan MS spectrum at tR 4.25 min where the [M+H]+ and [M+2H]2+ heavy T5 peptide ions are 
annotated. 
 
Table 5-6: Theoretical m/z of the b- and y-ions of heavy T5 peptide ion. 















- - 1 G 11 - - 
173.0557 - 2 D 10 1017.5073 509.2573 
286.1034 - 3 P+OH 9 902.4804 451.7438 
343.1248 - 4 G 8 789.4327 395.2200 
440.1776 - 5 P 7 732.4112 366.7093 
553.2253 - 6 P+OH 6 635.3585 318.1829 
610.2467 - 7 G 5 522.3108 261.6590 
730.3480 - 8 13C6/15N-I 4 465.2893 233.1483 
843.3956 - 9 P+OH 3 345.1881 173.0977 
900.4171 - 10 G 2 232.1404 116.5738 





Figure 5.4-8: Extracted ion chromatogram at m/z 537.7680 ±5 ppm and corresponding product scan spectrum of the heavy T5 doubly-charged peptide ion using a 
normalised collision energy of 20 %. The most abundant b- and y-ions are annotated, where no charged is indicated the ions are singly-charged. (Refer to Table 
5-6for theoretical m/z values). 
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5.4.3 hT1 peptide 
5.4.3.1 Purity 
 
Figure 5.4-9: Chromatogram of the crude hT1 peptide product obtained by LC-UV analysis 
monitoring absorbance at 214 nM. 
 
The chromatogram of the crude synthesised hT1 peptide product obtained by LC-UV is 
shown in Figure 5-9, where two eluting peaks with low resolution are observed at tR 8.7 
and 8.8 min. Unlike the T5 peptides, hT1 contains a Cys residue that is readily oxidised 
to form a disulphide bond to result in the formation of a peptide dimer. Thus, these 
closely eluting peaks may originate from the same peptide in different oxidative states, 
as opposed to being present as a result of being a synthesis impurity. 
In the purification of this peptide, differences in m/z of the reduced and oxidised peptide 
forms need to be considered so as to maximise on the recovery of the peptide product. 
Complete reduction and alkylation of the hT1 peptide will simplify the purification of the 
peptide with the production of a single MS target (corresponding to the derivatised 
peptide), however, the stability of the alkylated peptide is unknown. Hence, purification 
of the underivatised peptide product is recommended. hT1 peptide synthesis is used as 
a model for the heavy variant, hence once optimisation of purification methods are 
complete, synthesis of the heavy hT1 will commence. 















synthesised T1 peptide (214 nM)
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5.4.3.2 Sequence verification 
In the full scan spectrum (Figure 5-10) of the crude synthesised product only the 
reduced hT1 peptide was observed. The [M+2H]2+ ion at m/z 1009.4353 (theoretical 
m/z 1009.4373) is present in the spectrum although dominated by a more abundant 
isotope at m/z 1009.9367. Also the [M+3H]3+ ion at m/z 673.2925 (theoretical m/z 
673.2941) is observed in the spectrum. The absence of the oxidised peptide could be 
due to low concentration of injected sample, which has been diluted 100-fold compared 
to that analysed by LC-UV. Thus the analysis of a more concentrated sample is to be 
undertaken. Using the reduced doubly-charged peptide ion as precursor, the product 
ion spectrum (Figure 5-11) obtained using an nCE of 20 % although showing a 
dominant peak for the precursor ion, the b- and y-peptide ions shown corresponds with 
that of the desired hT1 aa sequence Q-NH3QEAVEGGCSHLGQSYADR. It is expected 
that if the collision energy is increased, the intensity of the observed peptide fragments 
ions will also increase, however this still to be confirmed. 
 
Figure 5.4-10: Total ion chromatogram of the crude synthesised hT1 peptide product showing 






Table 5-7: Calculated m/z of the b- and y-ions of reduced hT1 peptide ion. 















- - 1 Q-NH3 19 - - 
240.0979 - 2 Q 18 1906.8348 953.9210 
369.1405 - 3 E 17 1778.7762 889.8918 
440.1776 - 4 A 16 1649.7336 825.3705 
539.2460 - 5 V 15 1578.6965 789.8519 
654.2729 - 6 D 14 1479.6281 740.3177 
711.2944 - 7 G 13 1350.5855 675.7964 
768.3159 - 8 G 12 1293.5641 647.2857 
884.3407 - 9 C 11 1236.5426 618.7749 
972.3727 - 10 S 10 1133.5334 567.2703 
1109.4316 555.2195 11 H 9 1046.5014 523.7543 
1221.5317 611.7615 12 L 8 909.4425 455.2249 
1279.5372 640.2722 13 G 7 796.3584 398.6828 
1407.5958 704.3015 14 Q 6 739.3369 370.1721 
1561.6700 747.8175 15 S 5 611.2784 306.1428 
1632.7071 829.3492 16 Y 4 524.2463 262.6268 
1728.7282 864.8678 17 A 3 361.1830 181.0951 
1843.7552 922.3812 18 D 2 290.1459 145.5766 




Figure 5.4-11: Extracted ion chromatogram at m/z 1009.4373 ±5 ppm and corresponding product scan spectrum of the reduced hT1 doubly-charged peptide ion 
using a normalised collision energy of 20 %. Some b- and y-ions are annotated, where no charged is indicated the ions are singly-charged. (Refer to Table 5-7 for 
theoretical m/z values). 
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5.4.4 Protein quantification by aa analysis 
 
Figure 5.4-12: Standard curve of Arg (nM) using absolute peak area and height obtained by LC-




Figure 5.4-13: Standard curve of Leu (nM) using absolute peak area and height values by LC-
MS analysis. The equation and regression of each curve is shown. 
 
 
y = 1.33x + 0.24
R² = 0.999
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y = 3.57x - 4.17
R² = 0.994































Using the standard curves for Arg and Leu (shown in Figure 5-12 and Figure 5-13, 
respectively) the concentration of the acid hydrolysed purified synthesised T5 product 
(theoretical concentration 4.48 nM) was determined. The concentration of each sample 
is shown in Table 5-8 below. Of the aa chosen for quantification, Ile seems to be more 
precise, and produces an average peptide concentration of 4.24 nM (using peak 
height). For Arg, less precision is observed within the replicates, and a lower 
concentration than expected was obtained from the samples hydrolysed in the 
pressurised glass container, as opposed to the test tube. This could be due to loss of 
analyte to the surface of the vessel, or incomplete hydrolysis of the sample. The 
concentration of Arg obtained from the peptide prepared in the test tube is 4.66 nM 
(using peak area). This vessel is thinner than the pressurised glass, hence the 
efficiency of heat conduction could be greater. Based on the location of each residue in 
the sequence, it would be expected that Arg is cleaved first. As a free aa in the reaction 
mixture, adsorption losses are a more likely cause of the reported low Arg 
concentration. Hence investigation into the degree of loss and methods to correct or 
avoid this are needed. In addition the use of other aa (e.g. Gly) for quantification should 
be investigated. 
Table 5-8: Absolute concentration values of synthesised T5 peptides using aa analysis. Where 
(PG) and (G) represents pressurised glass or test tube, respectively, to indicate the vessel in 






 Area Height Area Height 
Sample 1 (PG) 3.49 3.32 4.78 4.10 
Sample 2 (PG) 2.08 2.03 5.35 4.33 
Sample 3 (G) 4.66 7.10 4.94 4.31 
 
5.5 Summary 
Peptides for T5, heavy T5 and hT1 have been produced by solid phase protein 
synthesis. The de novo peptide sequence obtained from the LC-MS/HRMS analysis of 
each product verifies that the aa sequence is that of the desired peptide. Purification of 
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the T5 and heavy T5 peptides was successful and methods are being developed for 
quantification. Possessing a more complex chemistry due to its vulnerability to 
oxidation, purification methods for the hT1 peptide still requires optimisation. Once 




Chapter 6 : Conclusions and future work 
6.1 Conclusions 
As an initial step towards developing a quantitative method based on mass 
spectrometry for analysing P-III-NP, the amino acid sequence of the protein needs to 
be fully characterised. Proteins often incorporate structural elements associated with 
the post-translational modifications (PTMs) of some of the genetically encoded aa in 
their sequence. These PTMs are challenging to replicate in synthesis (e.g. specific 
Cys-Cys disulphide bridges or glycosylated units), hence, even with knowledge of the 
aa sequence synthetic protein synthesis is impossible. Recombinant DNA technologies 
may be considered for synthesis where an appropriate cell line has been selected to 
support PTMs and correct topological formation of the expressed protein. 
Based on the size of the P-III-NP, full characterisation is difficult by MS. However with 
the removal of the protein’s disulphide bonds (especially the intra-chain bonds at the 
carboxyl-terminal end) to yield three identical pro α-1 chains that can be further 
digested with trypsin to yield reproducible peptides suitable for MS analysis partial 
protein characterisation has been possible. By this simplification, peptide sequences 
with PTMs are produced that lack the structural characteristics of the intact protein, 
which are less complicated to synthesise. This enables the production of reference 
material for unique P-III-NP peptides. Both as normal and heavy labelled variants, in 
quantities that allow for certification as quantitative standards usually required for 
doping control purposes. 
Identification of P-III-NP peptide fragments T1 and T5 by HRMS was obtained for the 
first time and is presented here, helping advance the characterisation of P-III-NP. 
Based on the structure of P-III-NP, some PTMs can be predicted. The data presented 
in Chapter 2 highlights the importance of including PTMs in protein MS identification, 
as sole dependence on generated in silico digest fragments can lead to the non-
detection of peptide fragments. 
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Once selected, specific P-III-NP peptides hT1 and T5, were used to develop sensitive 
micro- and nano-flow LC-MS analytical methods, for which an LOD as low as 5 pM 
(5 µL) was achieved and is presented in Chapter 3. However, without extraction from 
serum, the analysis of P-III-NP by LC-MS was unachievable, as a result of ion 
suppression from the abundant albumin concentration in the matrix. Thus the 
applicability of use of some common proteomic sample preparation approaches (e.g. 
protein precipitation, filtration and immunocapture) for separation of P-III-NP and 
albumin were investigated as described in Chapter 4. Here successful immunocapture 
of P-III-NP from a pooled normal human serum sample enabled the identification of 
hT1 and T5 peptides by LC-MS analysis after tryptic digestion, for the first time. 
To determine P-III-NP concentrations from LC-MS measurement, parallel quantification 
of hT1 and T5 peptides is desired. Using this comparative evaluation of the peptide 
concentrations increases the accuracy of P-III-NP measurements. Unfortunately, 
further optimisation of the assay selectivity for hT1 is needed before hT1 
measurements can be considered for quantification. In the absence of this, T5 semi-
quantification of the analysed serum sample gave a protein concentration of 2 ng/mL 
(50 pM), which is within the expected basal serum range of P-III-NP (1-5 ng/mL, 25-
125 pM). 
To develop commutable quantitative LC-MS methods, standardised international 
reference material for P-III-NP (as peptides or intact protein) as well as heavy-labelled 
“internal standards” are needed. In chapter 5 the initial steps that have been taken 
towards the "in-house" synthesis of labelled and unlabelled hT1 and T5 peptides are 
described. Here, high standards for purification and qualification of these standards 
have been adopted to ensure reliability in their intended use for quantification. With the 
completed synthesis of these peptide standards, full quantification of P-III-NP by 
LC-MS will be possible, which will allow for the comparison of measurements with 
those determined by immunoassay approaches. 
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6.2 Future work 
The work presented within this thesis clearly demonstrates the promises of LC-MS for 
P-III-NP analysis. To deliver accurate measurements, the comparative quantification of 
unique tryptic peptides hT1 and T5 is intended, however further optimisation of hT1 
analysis to improve its separation from HSA and investigate the completion of 
derivatisation to increase sensitivity, is needed before this approach can be used. For 
protein quantification, measurement of two peptides is not necessary hence in the 
absence of assay specificity for hT1, T5 based measurements should be assessed. For 
quantitative peptide analysis, however, the completed synthesis and qualification of 
reference standards is imperative to assay development. Hence, as the next step 
towards quantification, continuation of the peptide synthesis already initiated (see 
Chapter 5) is necessary. 
Once quantification of serum P-III-NP is achieved by the developed LC-MS approach, 
comparison of assay results with those determined by immunoassay should be used to 
validate assay measurements. Within this study a comprehensive statistical analysis of 
LC-MS based measurements should be conducted to facilitate the determination of 
assay performance. Once a viable assay has been produced, the re-calculation of GH 
biomarker scores based on the LC-MS measurements of P-III-NP should be 
considered. This will for the first time produce scores independent of immunoassay 
measurements and allow for full comparison of the discriminatory factor of the two 
approaches. 
As a digest approach for quantification has been adopted, the use of more readily 
synthesised peptide standards is applicable in the absence of authentic intact protein. 
To improve the sensitivity of MS measurements, incorporation of intact protein 
standard in the sample flow will normalise sample preparation losses to improve assay 
results. Hence, as a way forward, the production of an intact P-III-NP standard, as 
labelled and unlabelled protein, is valuable. To achieve this by SPPS, full 
characterisation of the protein is necessary so that all PTMs may be considered. In 
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addition to the incorporation of PTMs, unlike the peptide synthesis, the correct cross-
linking of the pro-α1 chains is necessary post SPPS to complete synthesis. This is a 
challenging and complicated step, which will produce several isomers and affect the 
purity of the protein product to result in a low production yield. As discussed in Chapter 
1, recombinant procollagen III can be produced where rhP-III-NP is a waste by-product 
of the target collagen III. Unfortunately current synthesis excludes the P-III-NP unit 
from the recombinant product to increase the yield of the target protein. If intact P-III-
NP becomes available, it is recommended that the peptide sequences of hT1 and T5 
are checked using the developed methods, to ensure compatible sequence with the 
endogenous P-III-NP protein. 
Similar to immunoassays, the immunocapture method currently used for sample 
preparation, is vulnerable to antibody modification or withdrawal by manufacturers. To 
overcome this threat and enable method viability, alternative sample preparation 
techniques should be developed. Applicability of peptide or protein specific aptamers 
(single stranded nucleic acid) should be assessed for this purpose, along with other 
albumin depletion methods.   
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Figure 4: Proteins identified in protein precipitation depleted serum by Mascot 
 
